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Abstract 
In the recent past, the human gut microbiota has gained increasing interest as a target for the 
delivery of substances due to the observed interaction between the microbiome, nutrition and 
health. The water-soluble vitamin niacin showed first effects on the composition of the gut 
microbiota. In order to enhance the availability of niacin in the ileocolonic region, where most 
of the microorganism are located, an early systemic absorption of niacin in the stomach and 
small intestine must be prevented. Therefore, two active forms of niacin (nicotinic acid (NA) 
and nicotinamide (NAM)) were encapsulated by a protective shellac coating applied via 
fluidized bed coating. The modulation of the release profile of niacin was assisted by a newly 
designed in vitro dissolution test and verified by a human bioavailability study with 10 
healthy volunteers for each group. Different intrinsic effects on the release profile such as 
derived from the properties of the encapsulated compound were investigated. The active 
substance core was produced by a one-step spray granulation and a two-step process 
(extrusion with subsequent spheronisation). The latter method achieved a higher particle yield 
and required a lower use of shellac in relation to the mass of active substance. As an 
alternative to shellac coated microcapsules, the incorporation of niacin into pectin-zein 
hydrogel beads was characterized. A precise targeted release of niacin into the ileocolonic 
region in vitro and in vivo was reached by using a shellac based coating with adapted 
intermediate subcoatings consisting of either citric acid for NAM or sodium bicarbonate of 
NA. The subcoatings were able to control the effect of the physico-chemical properties of the 
encapsulated compound and to influence the pH-dependent dissolution of the surrounding 
shellac coatings. The water-solubility in combination with the aqueous pH value and the 
surface characteristics of the compound were factors influencing the release profile. On the 
other hand, premature release from the pectin-zein hydrogel beads could not be prevented due 
to the high water solubility and low molecular weight of NAM. Consequently, the 
enhancement of the availability of niacin was reached using a shellac based coating 
formulation adapted to the compounds properties, which are predominantly determining the 
encapsulation technique and materials. The designed in vitro dissolution test for the targeting 
provided a precise instrument to predict the release behavior in humans. 
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1 Motivation and objectives 
Nowadays, the focus has increasingly shifted from disease cure and therapy to disease 
prevention. Therefore, nutraceuticals are of growing interest. The term nutraceutical was 
coined by Stephen DeFelice and is a portmanteau of the words nutrition and pharmaceutical. 
On the one hand, a nutraceutical consists of a food or a part of a food; on the other hand, it 
provides medical or health benefits, including the prevention and treatment of diseases 
(DeFelice, 1995; Santini et al., 2017). If a nutraceutical is proven for safety, bioavailability 
and clinically beneficial health properties, it can be used to prevent the onset of pathological 
conditions, to conserve the well-being, to avoid or delay the need of pharmaceuticals, to 
reduce the costs of chronic therapies and to become a proactive medicine approach (Santini et 
al., 2017). Obesity and its comorbidities are an increasing problem in industrialized and 
developing countries (Friedman, 2009). Recent studies showed an association between the 
composition of the gut microbiome and obesity (Bäckhed et al., 2004; Le Chatelier et al., 
2013; Ley et al., 2006; Turnbaugh et al., 2006). Bacteroidetes, beside Firmicutes, one group 
of the dominant beneficial bacteria in the human gut, is decreased in obese people compared 
to lean people (Ley et al., 2006), which has an influence on the metabolic potential of the gut 
microbiota (Turnbaugh et al., 2006). Therefore, a positive effect on the microbiome would be 
desirable with regard to the prevention of obesity and the co-morbidities such as insulin 
resistance and diabetes.  
Niacin is a water-soluble vitamin, which is also known as vitamin B3. The two active forms 
are nicotinic acid (NA) and nicotinamide (NAM) (Friedrich, 1987; Kirkland, 2007). In a 
mouse model, the administration of tryptophan as well as NAM led to an altered composition 
of the intestinal microbiota, which is concluded to be a result of induced expression of 
antimicrobial peptides from epithelial cells (Hashimoto et al., 2012; Waetzig and Seegert, 
2012). Singh et al. also supported a beneficial effect of niacin, that suppressed colitis and 
colon cancer by mediating the colon receptor Gpr109a (Singh et al., 2014). Thus, the 
tryptophan metabolites NA and NAM can act as protective substances by beneficially 
influencing the gut microbiome (Schreiber et al., 2014). 
However, simply increasing the content of NA and NAM in food would lead to a nearly total 
absorption in the upper intestine. Therefore, niacin need to be protected until it reaches the 
site of action (Yang et al., 2017), in this case the ileocolonic region, where most of the 
microorganisms are located (Sekirov et al., 2010). Microencapsulation is one opportunity to 
create a nutraceutical with a targeted delivery (Kunz et al., 2003). In many cases, a coating is 
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applied that allows gastric resistance and that dissolves in the colon due to colon specific 
conditions (Czarnocka and Alhnan, 2015; Maroni et al., 2013). Regarding a legislation as 
nutraceuticals, the used materials must be approved as a food additive or GRAS-deemed, 
which are still scarce. Therefore, the encapsulation of niacin is challenging due to a limited 
number of food-grade materials, which are suitable for an (ileo)colon targeted delivery. 
Furthermore, previous in vitro dissolution tests for colon-targeted delivery systems are not 
prescribed and are dependent on the desired formulation. Thus, it is sophisticated to develop a 
precise instrument to predict the release behavior in humans, which is needed for the adaption 
of the encapsulation formulation. In addition, physico-chemical properties of encapsulated 
compounds can influence the resulting release profile (Menge, 2016; Ozturk et al., 1988; 
Ragnarsson et al., 1992; Sousa et al., 2002), which is a technological challenge for the 
different compounds NA and NAM. 
The aim of the present thesis is thus to develop and evaluate a new niacin nutraceutical with a 
targeted delivery in the ileocolonic region using food-grade materials. The systemic 
resorption should be minimal, whereby the availability for the gut microbiome is ensured. 
Therefore, in vitro tests of different formulations were developed and considered before the 
release behaviour of two formulations was characterized in vivo in cooperation with the 
Department of Internal Medicine 1, Nutrition and Metabolic Medicine, UKSH Kiel, Germany.  
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Hypothesis 1: pH-sensitive food-grade film and gel forming materials are suitable for a 
colon-targeted delivery of niacin. 
a) Due to the high pka, a coating using the ammonium salt of shellac enables gastric 
and small intestine resistance and a pH-dependent release of niacin in the 
(ileo)colonic region. (Paper I and Manuscript II) 
Background 
The choice of colon-targeted coating materials for food use is rather limited compared to 
pharmaceutical materials. Shellac is a food-grade material and is legislated as a food additive 
with the E-number E904. Due to its acidic character and a high pka value of 6.9 – 7.5, it is 
insoluble in the acidic gastric milieu and could lead to a delayed and/or colon targeted release 
in the human lower intestine with higher pH values (Al-Gousous et al., 2015; Pearnchob et al., 
2003a; Roda, 2007). 
Experimental approach 
Food-grade niacin microcapsules coated with shellac will be developed by fluidized bed 
coating. In vitro dissolution tests will be conducted to predict the release of niacin under 
simulated gastrointestinal conditions. 
 
b) Due to its molecular structure and low digestibility, pectin in combination with 
zein features crucial properties for retarded release formulations. Morphology of 
the pectin-zein particles determines the coating properties and the resulting 
release profile. (Manuscript V) 
Background 
Low methoxylated pectins can form gels in the presence of calcium ions by cross-linking of 
free carboxyl groups with the calcium ions. The resulting calcium pectinate is described to act 
as colon-targeting material due to its insolubility and the enzymatic degradation by gut 
microbiota (Liu et al., 2003; Sriamornsak, 2011; Willats et al., 2006). Zein is used as water 
barrier (Liu et al., 2006), which is suitable especially for the encapsulation of water soluble 
substances like niacin. Furthermore, the production process parameters for hydrogel beads can 
influence the morphology (Smrdel, 2008), which also can affect the coating properties and the 
resulting release profile (Guo and Kaletunç, 2016; Harvestine et al., 2014).  
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Experimental approach 
For the encapsulation of niacin, the process of ionotropic gelation will be examined using 
pectin and zein as core and coating materials. To study the effect of the process parameters on 
the morphology, two different processes with varying conditions will be conducted: a one-
step gelation and coating process and a two-step process, which will separate the gelation and 
coating procedure. The resulting encapsulation efficiency and the gastrointestinal release 
profile will be determined by in vitro digestion.  
 
Hypothesis 2: The use of a triple shellac coating enables a robust targeted release of 
niacin despite the influence of extrinsic factors such as the production process, storage 
conditions and pH values of simulated gastrointestinal fluids. (Manuscript II) 
Background 
Process parameters during coating can influence the resulting release profile (Buch et al., 
2009; Farag and Leopold, 2009; Farag and Leopold, 2011b; Farag and Leopold, 2011c; 
Thoma and Bechtold, 1999). Shellac undergoes ageing, which influences the release profile 
and can result in a lower gastric resistance and a lower solubility at higher pH values (Farag 
and Leopold, 2009; Penning, 1996), whereby the use of the ammonium salt form reduces this 
ageing effect (Limmatvapirat et al., 2007). Furthermore, residence times and pH values in the 
gut can vary due to inter- and intraindividual differences (Dressman et al., 1998; Ibekwe et al., 
2008; Russell et al., 1993; Shani-Levi et al., 2017), that mainly affects the dissociation of 
shellac and therefore the release of the encapsulated compound. This could lead to premature 
or insufficient release. 
Experimental approach 
The robustness of shellac coated pellets will be evaluated based on the resulting in vitro 
release profile and scanning electron microscope pictures. Therefore, several coating 
processes will be replicated and compared. Furthermore, the pellets will be exposed to various 
storage conditions over a period of 24 months. Different possible physiological conditions of 
residence time or pH values will be simulated in vitro. 
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Hypothesis 3: Adjustment of shellac coating for niacin by in vitro assay enables targeted 
release in the ileocolonic region in vivo. (Paper I and Manuscript II)  
Background 
To achieve a sufficient delivery of niacin into the ileocolonic region, the absorption in the 
upper gastrointestinal tract must be prevented (Schreiber et al., 2014). Using in vitro assays to 
simulate digestion fluids and anticipating residence times in the gastrointestinal tract allows 
the development of a target delivery system (Jorgensen and Bhagwat, 1998; Zahirul and 
Khan, 1996). 
Experimental approach 
An in vitro assay will be designed based on transit times for pellets (Abrahamsson et al., 
1996; Clarke et al., 1993; Davis et al., 1987) and pH values in the gut segments (Dressman et 
al., 1990; Evans et al., 1988; Ibekwe et al., 2008; Russell et al., 1993). The bioavailability will 
be confirmed in an in vivo study with 10 healthy subjects in each group (nicotinic acid and 
nicotinamide), conducted by the research group of Prof. Dr. Matthias Laudes, University 
Hospital in Kiel. The study will comprise the free vitamin as well as the microencapsulated 
form using various dosages. The serum level of nicotinic acid and nicotinamide will be 
quantified. 
 
Hypothesis 4: A precise targeting can be achieved by modulating simultaneously the 
influencing intrinsic factors of release. 
a) Physico-chemical properties of the encapsulated compound such as intrinsic pH 
value, water solubility and surface structure influence the coating properties and 
the resulting release profile. (Manuscript III) 
b) Different subcoatings will precisely modulate the release profile of the 
microencapsulated compounds with varying physico-chemical characteristics. 
(Manuscript III) 
Background 
Due to small amounts of water penetrating the shellac coat during the digestion process, the 
encapsulated compounds will be partly solubilized and thereby influencing the pH-value in 
the surrounding shellac layer (Menge, 2016; Ozturk et al., 1988; Ragnarsson et al., 1992; 
Motivation and objectives 
6 
 
Sousa et al., 2002). Furthermore, the water solubility can also affect the water penetration and 
solubilisation of the compounds (Ragnarsson et al., 1992; Sousa et al., 2002). These processes 
will influence the pH-dependent dissociation of shellac and the diffusion of the encapsulated 
compound. Subcoatings may counteract the effect of solubilized compounds and affect the 
release profile (Farag and Leopold, 2011a). 
Experimental approach 
Different compounds with different physico-chemical characteristics will be optimized for 
their release in the ileocolonic region by individual coating formulations that control the effect 
of the encapsulated compounds. Riboflavin 5’-monophosphate sodium salt hydrate will be 
used as reference substance. Further, the effect of NA and NAM will be compared. In vitro 
dissolution tests will give information about the release profile after the application of 
different subcoatings. 
 
Hypothesis 5: The wet extrusion and spheronisation process is superior compared to 
spray granulation in order to obtain high yield of spherical NAM pellets requiring lower 
addition of shellac. (Manuscript IV) 
Background 
The formation of spray granulated NAM pellets resulted in spherical and compact particles, 
which were suitable for a uniform and functional coating. However, due to the high amount of 
unsuitable particles, only a narrow range could be subjected to coating, which led to a rather 
low yield. Further, a high amount of shellac was required to achieve an ileocolon-targeted 
release, which is related to the high specific surface area. Wet extrusion followed by 
spheronisation is known as a method to prepare pellets of  higher and uniform particle size 
(Knop and Kleinebudde, 2005).  
Experimental approach 
For the wet extrusion/spheronisation process, a twin-screw extruder will be used. To calculate 
the effects of the process parameters on the resulting properties of NAM pellets, a Design of 
Experiment approach will be examined. Finally, the release profile of coated NAM extrudates 
will be compared with coated NAM spray granulates. 
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2 Theoretical background 
2.1 Niacin  
The collective term niacin, also known as vitamin PP (pellagra preventing) or vitamin B3, 
refers to all forms with vitamin activity of nicotinic acid (NA) (pyridine-3-carboxylic acid; 
Figure 2.1A), nicotinamide (NAM) (pyridine-3-carboxamide; Figure 2.1B) and pyridine 
nucleotide structures like nicotinamide adenine dinucletides (Friedrich, 1987; Kirkland, 
2007). Pyridine nucleotides are soluble coenzymes, which are consisting of adenosine 
monophosphate and nicotinamide mononucleotide. They are present as oxidized or reduced 
nicotinamide adenine dinucleotides either in their unphosphorylated (NAD+ (Figure 2.1C) 
and NADH) or phosphorylated (NADP+ (Figure 2.1D) and NADPH) forms (Nakamura et al., 
2012). NA as well as NAM can be transformed to the biologically active forms of niacin, 
NAD+ and NADP+. NAD+ and NADP+ are describing the total pool of all four forms as 
mentioned above (Kirkland, 2007). 
 
                       
 
 
 
 
 
 
 
 
 
 
A 
B 
C D 
Figure 2.1: Chemical structures of niacin compounds. (A) nicotinic acid, (B) nicotinamide, (C) 
nicotinamide adenine dinucleotide, (D) nicotinamide adenine dinucleotide phosphate 
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2.1.1 Chemical and physical characteristics 
The chemical and physical characteristics of NA and NAM are summarized in Table 2.1. 
Both, NA and NAM, are crystalline and colourless/white substances with a low molecular 
weight of 123.11 and 122.12 g/mol. They are water-soluble, whereby NAM is highly (1000 
g/l) and NA moderately soluble in water (16 g/l). NA has a melting point of 236 – 237°C with 
sublimation. NAM is melting at a temperature of 129 – 132°C. The pH value of a saturated 
aqueous NA solution is 3 and the pka is 4.8 (25°C). NAM leads to an aqueous solution with a 
pH value of 6. The pka of NAM is 3.3 (20°C). The maximum UV absorbance of NA or NAM 
in water is at 260 – 263 nm, the absorption intensity is pH dependent. The free vitamin does 
not fluoresce. The reduced forms of the coenzymes (NADH and NADPH) have a strong UV 
absorption at 340 nm. The oxidized forms have a weaker absorption at 260 nm (Ball, 2006; 
Eitenmiller et al., 2008; Friedrich, 1987; Kirkland, 2007). 
 
Table 2.1: Chemical and physical characteristics of nicotinic acid and nicotinamide (Ball, 
2006; Eitenmiller et al., 2008; Friedrich, 1987; Kirkland, 2007) 
 Nicotinic acid (NA) Nicotinamide (NAM) 
Appearance Crystalline powder Crystalline powder 
Colour White White 
Molecular weight  123.11 g/mol 122.12 g/mol 
Water solubility 16 g/l  620 – 1000 g/l 
Melting point 236 – 237°C 129 – 132°C 
pH value ≈ 3 (in H2O) ≈ 6 (in H2O) 
pka value 4.8 (25°C) 3.3 (20°C) 
Max. UV absorbance 260 – 263 nm 260 – 263 nm 
 
Generally, niacin is known as a very stable vitamin: it is resistant to air, heat, light, acids and 
alkalis. NAM can be partially hydrolysed to NA by acid and alkali, but it does not lose its 
biological activity (Ball, 2006; EFSA, 2012; Harris, 1988). It is also stable during food 
processing, storage and cooking of foods, except of leaching losses (Ball, 2006). Furthermore, 
it was found that nicotinic acid powder was stable in 0.1 N HCl, HCl medium with a pH value 
of 2.2 and in a phosphate buffer with a pH value of 6.8 for a period of up to 76 hours (Chuong 
et al., 2010). The EFSA concluded from technical dossiers that the shelf life of NA and NAM 
is 36 months at 25°C. Under accelerated conditions (40°C) the shelf life is reduced to 12 and 
24 months, respectively (EFSA, 2012). 
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Niacin powders are almost white and odourless. NAM, however, generates a bitter taste (Ball, 
2006; EFSA, 2012; Friedrich, 1987).  
NA shows poor flowability properties (Chuong et al., 2010), whereby NAM powder has a 
high electrostatic charge, which is disadvantageous for handling (Hojgaard and Wittendorff, 
2013).  
 
2.1.2 Food content, food supplementation 
Niacin is available in plant, as well as in animal products, whereas NA is mainly present in 
plant products. However, much of NA exists in poorly understood bound forms of 
heterogeneous mixtures of polysaccharides and glycopeptides esterification. The consumption 
of products with high levels of bound NA results in low bioavailability, which could finally 
lead to niacin deficiency and the development of pellagra. Especially the consumption of corn 
products was associated with pellagra. For an effective absorption of NA from corn, an 
alkaline treatment is necessary to release NA and to achieve a higher bioavailability 
(Friedrich, 1987; Kirkland, 2007). 
Animal products mainly offer niacin in form of the coenzymes NAD/H and NADP/H. During 
aging and cooking of meat, as well as during intestinal digestion, NAM will be released from 
the coenzyme form. Beside the niacin content of human foods, the content of the amino acid 
tryptophan plays an important role in the supply of niacin. 60 mg tryptophan can be converted 
to 1 mg NA. Therefore, the niacin content in food is expressed as niacin equivalents (NE) and 
is defined as niacin content (mg) + 1/60 tryptophan content (mg) (Friedrich, 1987; Kirkland, 
2007). Recommended daily allowances (RDA) of niacin are varying depending on the target 
group: the RDA is ranging from 2 mg preformed niacin per day (infants) to 16 - 18 NE/day 
(during pregnancy) (Kirkland, 2007; Strohm et al., 2016). Niacin is not assigned to vitamins 
with a critical intake. German data show that the median intake of niacin is within or even 
higher than the range of reference (NVSII, 2008; Strohm et al., 2016). To ensure a diet rich in 
niacin equivalents, a consumption of protein containing foods such as fish, meat, beans, 
peanuts and mushrooms is recommended. A supplemental intake of niacin is not necessary for 
healthy people with a healthy lifestyle (Strohm et al., 2016). However, niacin is supplemented 
beside other vitamins (NVSII, 2008). Both, NA and NAM are authorised for the use in food 
and food supplements and for addition to foods for specific nutritional purposes and particular 
nutritional uses, to processed cereal-based foods and baby foods for infants and young 
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children and to infant formulae and follow-on formulae. Furthermore, niacin is listed as 
pharmacologically active substance (EFSA, 2012).   
 
2.1.3 Synthesis, absorption, distribution and metabolism of niacin in humans 
Synthesis 
Beside the nutritional intake of NA, NAM and pyridine nucleotides, the amino acid 
tryptophan can act as precursor for the synthesis of niacin in mammals (Figure 2.2). 
However, the majority of tryptophan is catabolized through kynurenine and 2-amino-3-
carboxymuconic-6-semialdehyde (ACMS) to Acetyl-CoA. If ACMS accumulates, some of it 
reacts spontaneously to quinolinic acid, which can be enzymatically transformed to NAMN, 
predominantly in the kidney and liver. Via Preiss-Handler pathway, NAD+ can be synthesized 
from NAMN. Both, NA and NAM can also be transformed to NAD+: NA via Preiss-Handler 
and NAM via Dietrich pathway (Figure 2.2) (Kirkland, 2007).  
The utilization of tryptophan for niacin synthesis is affected by individual variations because 
of genetics, disease state and dietary components. Additionally, hormones and the energy, 
protein, pyridoxine and riboflavin status can influence the tryptophan-niacin-conversion. The 
niacin status is less incorporated into the regulation. First, dietary tryptophan is used to restore 
the nitrogen balance, afterwards, to restore blood pyridine nucleotides and last, to be excreted 
as niacin metabolite (Kirkland, 2007; McDowell, 2000). 
 
Absorption 
NAM and NA can be absorbed in stomach and small intestine, whereby the absorption in the 
small intestine is more rapid. Intact nucleotides (NADP/H) can be prior converted into NAM 
by pyrophosphatase in the upper small intestine (Kirkland, 2007). It is described that both 
vitamin forms are absorbed via a carrier-dependent (Nabokina et al., 2005) and/or sodium 
dependent mechanism (Evered et al., 1980). At higher concentrations, the absorption is 
triggered by passive diffusion (Kirkland, 2007). After entering the enterocytes, either NAM or 
NA are converted via Dietrich or Preiss-Handler pathway into NAD+ to be stored or they can 
be released in their native forms into the portal circulation, whereby only minor amounts of 
native NA are circulating. Most of NA is converted through NAD+ to NAM. The principal 
circulating form of niacin is NAM (Kirkland, 2007; McDowell, 2000).  
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Additionally, some microorganisms of the gut microbiota are capable to synthesize niacin, 
which is absorbed to colonocytes. The transport is a carrier-mediated mechanism. However, 
no data is available regarding the influence on the systemic niacin status (Biesalski, 2016; 
Kumar et al., 2013).   
 
Distribution and metabolism 
First, the circulating niacin compounds are either internalized by erythrocytes or transported 
to the liver, whereby the latter is the central processing organ for niacin.  Both organs receive 
NA and NAM and can convert them into the nucleotides for storage (Kirkland, 2007). The 
storage of NAD+ is used to supply other tissues with niacin, although most tissues can utilize 
NAM and sometimes NA to synthesize their own NAD+. The most circulating form is NAM, 
which is released of NAD+ via NAD glycohydrolases (Dietrich pathway) (Henderson, 1983; 
McDowell, 2000). Compounds for urinary excretion are metabolized in the liver, depending 
on the niacin status of the organism (Kirkland, 2007). NAM is primarily methylated to N1-
methylnicotinamide (Friedrich, 1987; Kirkland, 2007), which can be further oxidized to N1-
methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-3-carboxamide (Felsted and 
Chaykin, 1967). A second enzymatic system is suggested to oxidize NAM to NAM-N-oxide 
(Real et al., 2013). NA is conjugated with glycine to nicotinuric acid.  High intake of dietary 
niacin can increase the levels of untransformed niacin in the urine (Kirkland, 2007). N1-
methylnicotinamide is an often used metabolite of the urine to assess the niacin status 
(Friedrich, 1987).  
 
2.1.4 Physiological, pharmacological and toxicological effects 
The main function of niacin is that of the coenzyme form NAD/H and NADP/H. Enzymes 
containing NAD/H and NADP/H are important for biological oxidation-reduction systems 
because of their capacity to act as hydrogen-transfer agent. NAD+ is reduced to NADH in 
several reactions of glycolysis, citric acid cycle, β-oxidation of fatty acids and other cellular 
oxidation reactions. Afterwards, the formed NADH functions as hydrogen donor to the 
respiratory chain for ATP production. Therefore, NAD(H) plays a central role in catabolic 
reactions, whereas NADP(H) is present in biosynthetic (anabolic) reactions. NADP+ can be 
synthetized from NAD+ via NAD kinase. The reduction of NADP+ during the pentose 
phosphate pathway or during the malate-pyruvate shuttle across the mitochondrial membrane 
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results in NADPH, which serves as reducing agent for fatty acid production, cholesterol 
synthesis, manufacture of desoxyribonucleotides and several other cellular macromolecules 
(Kirkland, 2007; McDowell, 2000). 
Furthermore, both NAD/H and NADP/H are integrated in the synthesis and degradation of 
amino acids. NAD+ plays a role in ADP-ribosylation of proteins and poly(ADP)ribose. These 
poly ADP-ribolysated proteins are important for mechanisms like DNA-repair, DNA-
replication and cell differentiation (McDowell, 2000).  
Beside the essential physiological effects of niacin, several pharmacological functions of 
niacin are described. NA is associated with the treatment of hyperlipidaemia. The effect is 
related to a decrease of lipolysis in adipose tissue due to the binding of NA to a G-protein 
receptor (GPR109A) and a resulting inhibition of the activity of the enzyme adenylate 
cyclase. This leads to decreased cAMP (cyclic adenosine monophosphate) levels, which 
results in decreased mobilization of fatty acids. Therefore, VLDL (very low-density 
lipoprotein) formation in the liver is supressed and LDL (low-density lipoprotein) levels are 
decreasing. Furthermore, the positive HDL (high density lipoprotein) can be increased due to 
NA treatments (Gille et al., 2008; Kirkland, 2007). As a result, NA is an effective agent to 
reduce risk factors for atherosclerosis. However, high doses of orally administered NA causes 
unwanted side effects such as flushing, nausea and diarrhoea. A dose of 50 – 100 mg NA 
leads to a flush of the face and the upper body. Increasing the dose to 500 – 1000 mg the rest 
of the body is also affected by strong flushes. Flushing is explained by induced vasodilation. 
Typical symptoms are burning or stinging sensations, similar to sunburn but for shorter 
lasting (30 – 90 minutes). Although the flushing decreases after several weeks of continuous 
treatment, intolerable flushing is one reason of discontinuing the NA treatment. Doses up to 
2000 mg NA could result in gastrointestinal side effects, whereby doses up to 3000 mg can 
lead to effects with liver toxicity and damage, a reduction of glucose tolerance and an increase 
in plasma uric acid (BfR, 2012; Domke et al., 2004; Gille et al., 2008; Kirkland, 2007). 
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Figure 2.2: De novo biosynthesis and metabolism of NAD(P)+ . (Friedrich 1987; Favennec et al. 
2015; Chen und Guillemin 2009; Pissios 2017; Kirkland 2007; Berdanier und Adkins 1998). 
Abbreviations: 2py: N1-methyl-2-pyridone-5-carboxamide; 4py: N1-methyl-4-pyridone-3-
carboxamide; ACMS: 2-amino-3-carboxy-muconate semialdehyde; ACMSD: ACMS-decarboxylase; 
ADP: adenosindiphosphate; ADPR: ADP ribolysation reactions; ATP: adenosintriphosphate; Aox: 
aldehyde oxidase; Gln: glutamine; Glu: glutamic acid; HAAO: 3-hydroxyanthranilate; IDO1: 
indoleamine 2,3-dioxygenase I; IDO2: indoleamine 2,3-dioxygenase II; KF: kynurenine formylase; 
KMO: kynurenine 3-monooxygenase; KYNU: kynureninase; NA: nicotinic acid; NAM: nicotinamide; 
NAD: nicotinamide adenine dinucleotide; NNMT: NAM-N-methyltransferase; NMNAT: NA-
mononucleotide-adenylyltransferase; NAMNAT: NAM-mononucleotide-adenylyltransferase; NADG: 
NAD-glycohydrolases; NADK: NAD-kinase; NADS: NAD-synthetase; NAPRT: NA-
phosphoribosyltransferase; NAMPRT: NAM-phosphoribosyltransferase; NAMDA: NAM-deamidase; 
NRK: NAM-riboside-kinase; PRPP: phosphoribosylpyrophosphate; PPi: pyrophosphate; SAM: S-
adenosylmethionine; SAH: S-adenosylhomocysteine; TDO2: tryptophan 2,3-dioxygenase; QPRT: 
quinolinate phosphoribosyltransferase 
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Therefore, the SCF (Scientific Committee on Food) defined a LOAEL (Lowest Observed 
Adverse Effect Level) of 30 mg NA per day. The UL (Tolerable Upper Intake Level) was set 
to 10 mg NA per day for adults (except for pregnant and nursing women) (Domke et al., 
2004). Slow-release formulations (e.g. Niaspan®) were developed to suppress peak plasma 
levels and to achieve a continuous NA absorption over time (Gille et al., 2008; Knopp et al., 
1998). However, some slow-release formulations could lead to constitutional or 
gastrointestinal symptoms (Knopp et al., 1985). Liver damages were already detected after 
doses of 1000 – 2000 mg NA per day (BfR, 2012). The colon targeted encapsulation of niacin 
of the present thesis, which aimed a minimal systemic exposure, is innovative and new. 
In contrast to NA, NAM is under discussion regarding the prevention or delay of the onset of 
IDDM (Insulin-Dependent Diabetes Mellitus) (Kirkland, 2007). Furthermore, a recent study 
showed in a mouse model, that the topical administration of NAM influenced the gut 
microbiota and showed anti-inflammatory effects in the colon. It is suspected that NAM or 
tryptophan are transported on the luminal surface of epithelial cells, where mTOR is 
activated. Antimicrobial peptides are expressed and can affect the composition of the gut 
microbiota (Hashimoto et al., 2012). Despite the fact, that some gut microorganisms are also 
capable to synthesize niacin coenzymes (NAD/H) de novo or from the vitamin precursors 
(NA, NAM or nicotinamide riboside), further effects on systemic processes are unknown 
(Biesalski, 2016; Gazzaniga et al., 2009). Additionally, it was hypothesized that microbial 
produced niacin could bind to the colon receptor Gpr109a, which leads to a beneficial effect 
on colitis and colon cancer (Singh et al., 2014). The present thesis gives new approaches for a 
topical application of niacin in the colon.  
With regard to toxicological effects of NAM, no adverse side effects on an acute basis are 
known (Domke et al., 2004; Kirkland, 2007). Larger doses (up to 10 g/day) can lead to 
gastrointestinal disorders and liver injuries. No flush symptoms are related to NAM. The SCF 
did not define a LOAEL for NAM, whereby the NOAEL (No Observed Adverse Effect 
Level) was set to 25 mg/kg/day and the UL to 900 mg/day for adults. Due to lower adverse 
side effect of NAM, compared to NA, it is often used for fortification and supplementation 
formulations (Domke et al., 2004).  
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2.1.5 Quantification 
A wide range of chemical or microbiological assay techniques are available to detect niacin in 
food. Analytical methods can be based on official methods of USP/BP, AOAC or 
ISO/CEN/BS. Regarding AOAC methods, NA and NAM can be determined using 
colorimetric or microbiological assays. The colorimetric method is based on the Koenig 
reaction with cyanogen bromide. The coupling of the derivates (pyridinium compound, the 
result of the reaction of niacin and cyanogen bromide) to aromatic amines forms coloured 
compound, which is proportional to the niacin content, and can be measured 
spectophotometrically at an absorption maximum of 463 nm (Eitenmiller et al., 2008; 
Lawrence, 2015). This assay has been criticized because of its lack in specificity and 
sensitivity and the high toxicity of the reagent cyanogen bromide (Kim et al., 2011; Rose-
Sallin et al., 2001).  For microbiological assays, Lactobacillus plantarum is used. Niacin 
enables the proportional growth of Lactobacillus plantarum in a supporting medium. 
However, this method requires considerable laboratory set-up and maintenance time. 
Additionally, it can be subject to contamination. The most common methods are based on the 
UV absorbance of NA and NAM. Therefore, a UV/VIS-spectrophotometer (McLaren et al., 
1973; Sheen et al., 1992) or a high performance liquid chromatography (HPLC) combined 
with a diode array detector (DAD) was used (Kirchmeier and Upton, 1978; Sood et al., 1977; 
Walker et al., 1981). The absorption maximum is measured at 261 or 262 nm. If niacin is 
determined simultaneously with other vitamins like pyridoxine, riboflavin and thiamine, a 
wavelength of 254 nm is chosen (Walker et al., 1981). However, due to the low specificity in 
the UV region of interest, interference with other food ingredients could lead to a low 
specificity and sensitivity (Kim et al., 2011; Lawrence, 2015). For determination of niacin in 
pure substance, injectable solutions and vitamin tablets and capsules, spectrophotometric and 
HPLC methods are suitable, as recommended by USP/BP (Lawrence, 2015). Further HPLC 
methods with fluorimetric detection after a post-column derivatisation with UV irradiation 
were developed to quantify niacin in food, although the pure niacin does not fluoresce (Lahély 
et al., 1999; Lawrence, 2015; Rose-Sallin et al., 2001). The combination of HPLC and mass 
spectrometry (MS) is also used for the determination of niacin. However, to overcome matrix 
effects, stable isotope-labelled compounds were used as internal standard e.g. deuterated 
niacin compounds (Goldschmidt and Wolf, 2007; Lawrence, 2015).  
Depending on the food matrix and the type of niacin to be determined, different extraction 
processes are needed to determine the niacin content. Determining the total niacin content, 
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usually an alkaline hydrolysis is used. During the alkaline hydrolysis, bound niacin (NAD/H 
and NADP/H) is released from food matrix, whereby NAM is converted to NA. As a result, 
the total niacin content, independent from bioavailability for humans, can be determined. If 
only the free or added niacin needs to be quantified, an aqueous or acid hydrolysis is required, 
which can lead to a conversion from NA to NAM (Lawrence, 2015).  
 
2.2 Microencapsulation  
Microencapsulation is defined as a process, to encapsulate solid, liquid or gaseous substances, 
which can be released under specific conditions in controlled rates (Kunz et al., 2003). The 
size of the resulting microcapsules is ranging from 0.1 to 999 µm (Jackson and Lee, 1991). 
Encapsulation processes are commonly used by the pharmaceutical and food industry. The 
compound is protected towards external environmental influences like moisture, temperature, 
light, oxygen and interaction with incompatible substances. The reduced interaction leads to 
an improved product stability and shelf life (Bule et al., 2010; Champagne and Fustier, 2007; 
Gibbs et al., 2009; Heinzelmann and Franke, 1999; Kunz et al., 2003; Nedovic et al., 2011). 
Furthermore, microencapsulated products are mostly common as solids (powders or pellets), 
which are more stable and easier to handle than fluids, especially for slightly soluble 
substances (Gibbs et al., 2009). Microencapsulation techniques can also be used to mask 
unpleasant odours and tastes (Favaro-Trindade et al., 2010; Nedovic et al., 2011; Sohi et al., 
2004) and to achieve a targeted release in the human gut to enhance the bioavailability or to 
influence the microbiota (Anal and Singh, 2007; Champagne and Fustier, 2007; Desai and Jin 
Park, 2005; Takahashi et al., 2009). The microencapsulation procedures are various (Arshady, 
1993; Jackson and Lee, 1991; Kunz et al., 2003) e.g. physicochemical processes such as 
coacervation and liposomic entrapment (Frenzel et al., 2015), chemical processes such as 
interfacial polymerisation and physical processes such as extrusion, spray drying (Serfert et 
al., 2013) and fluidized bed coating (Berg et al., 2012; Schell and Beermann, 2014). Latter 
techniques are more common in food industry (Kunz et al., 2003). The following techniques 
are used for the experiments of the present thesis. 
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2.2.1 Fluidized bed coating  
The application of a coating layer is one opportunity to cover and protect a compound and to 
influence the surface properties of the covered particles with regard to aesthetic or protective 
purposes. The coating should uniformly cover the surface of every single particle. 
Agglomerates should be avoided. Fluidized bed coating is used for smaller particles (100 µm 
to a few millimetres) (Gouin, 2004; Kumpugdee-Vollrath and Krause, 2011; Sandadi et al., 
2004; Teunou and Poncelet, 2002). The coating process is based on suspended solid particles 
and the drying of the atomized liquid coating material around them (Kumpugdee-Vollrath and 
Krause, 2011; Nedovic et al., 2011).  
The detailed process during the fluidized bed coating is shown in Figure 2.3. Small solid 
particles are suspended and maintained in a fluidising bed by a temperature (and humidity) 
controlled air stream. The fluidising air is flowing bottom-up. Depending on air velocity and 
particle flow properties, the state of the fluid bed is varying (Teunou and Poncelet, 2002). The 
coating material, which is dissolved in an acceptable solvent for food (e.g. water or ethanol), 
is transferred by a peristaltic pump to the nozzle, where it is atomized using compressed air. 
The atomized coating droplets are sprayed onto the particles. After reaching the top of the 
chamber, the wetted particles move downwards, while the solvent of the coating is 
evaporating. The coating material solidifies and distributes on the particles. Due to the 
fluidized bed, this wetting and drying process will be repeated several times, until a uniform 
film with the desired thickness is reached (Arshady, 1993; Desai and Jin Park, 2005; 
Kumpugdee-Vollrath and Krause, 2011). 
Depending on the nozzle position, three spray modes are differentiated: bottom spray, top 
spray and tangential spray. The bottom spray mode is demonstrated in Figure 2.3. The nozzle 
is placed in the middle of the gas distributer plate and the coating solution is sprayed from the 
bottom to the top in parallel flow with the fluidization air. Processing chambers with a narrow 
diameter, like laboratory size equipment, lead to a well-organized particle flow, which results 
in reproducible coating successes. For upscaling processes with a larger diameter, a 
cylindrical Wurster insert is employed, which is a special form of the bottom spray mode. The 
Wurster process facilitates efficient separation between spraying and drying zone. The 
Wurster cylinder is inserted around the nozzle in a small distance to the distributor plate. The 
distributor plate for a Wurster process is characterised by larger holes in the cylinder and 
nozzle zone compared to the outer parts. This constellation leads to a more organized flow of 
the particles. The fluidized particles are horizontally transported through the gap between the 
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Wurster insert and the distributor plate into the spraying zone. Afterwards, they are moved 
with high velocity into the expansion zone. The particles decelerate and fall into the area 
around the Wurster cylinder, where the drying process is continued. After that, the process 
starts from the beginning (Kumpugdee-Vollrath and Krause, 2011; Teunou and Poncelet, 
2002; Werner et al., 2007; Yang et al., 1992).  Problems could occur if the fluidized particles 
tend to adhere to the walls due to electrostatic charge or remaining solvent. Especially, in case 
of a Wurster insert, the fluidized bed could finally break down, which makes an optimal 
adjustment of temperature and spraying rate indispensable (Fukumori et al., 1991). 
 
In the top spray mode, the nozzle is placed in the expansion chamber. The fluidization air and 
the sprayed coating liquid are arranged in a counterflow (Yang et al., 1992). During the top 
spray configuration, coating imperfection is possibly caused by premature droplet evaporation 
before contacting the particles (Desai and Jin Park, 2005). The third spraying mode is the 
tangential-spray mode. The nozzle is located at the side of the product chamber. In contrast to 
top and bottom spray, for tangential spray an additional rotating disk is added to generate a 
centrifugal, gravitational and vertical particle flow in order to maximize the coating efficiency 
(Yang et al., 1992). The coating quality is comparable to a Wurster bottom spray apparatus, 
whereby the tangential spray is not suitable for friable materials, because of the high agitation 
(Teunou and Poncelet, 2002). Therefore, the bottom spray process, especially the Wurster 
configuration, is commonly used for coating processes.    
Figure 2.3: Schematic process of fluidized bed coating with bottom spray, modified according 
(Kumpugdee-Vollrath and Krause, 2011; Teunou and Poncelet, 2002) 
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Fluidized bed coating can be conducted as a batch or continuous process. The focus in the 
present thesis is on the batch process as shown and explained in Figure 2.3. Until now, the 
batch process is more common for coating processes, although a continuous process is 
desirable because of a time saving. During a single bed continuous process, particles with a 
pre-defined size are automatically discharged by a pipe at the bottom of the chamber that is 
determined by a controlled airflow. Due to gravity, coated particles are classified from 
uncoated particles. Dust and small particles are transferred back to the product chamber as 
well as crushed oversized particles. Additionally to the single bed continuous process, 
horizontal and multicell continuous fluid beds are existing with product chamber separated in 
smaller chambers. All continuous processes are prepared with the top spray configuration. As 
mentioned, the advantage of continuous processes are a higher flow rate and therefore lower 
production costs, which is important for the food industry. However, the coating quality can 
be imperfect, if the coating material is not covering the total surface. This would lead to a loss 
of protection. This could be a problem, especially, if the difference between the size of coated 
and uncoated particles is too small (Kumpugdee-Vollrath and Krause, 2011; Teunou and 
Poncelet, 2002).  
In order to achieve a uniform coating result and a high coating efficiency the adjustment of 
process parameters is important. Variables like inlet air temperature, inlet air velocity, spray 
rate, solution temperature and dry matter content, atomization pressure, ambient air 
temperature and relative humidity as well as outlet air temperature and relative humidity are 
influencing the fluidized bed operation. Especially the degree of agglomeration and premature 
drying are detrimental for the coating result (Arshady, 1993; Desai and Jin Park, 2005). 
Furthermore, agglomeration can result in a defluidisation that could lead to a process 
shutdown and product loss. To avoid agglomeration, the droplet size of the atomized coating 
material should be smaller than the particle size (Gouin, 2004; Werner et al., 2007). The 
droplet size is depending on process parameters such as the air and fluid velocity and material 
characteristics like viscosity, density and surface tension. A very small droplet size would 
lead to premature droplet evaporation, which results in a lower coating efficiency (Dewettinck 
and Huyghebaert, 1998).  
The application of a uniform coating is particularly important, when a targeted release profile 
is desired. The more spherical and regular the particle, the more uniform is the coating 
(Chopra et al., 2002). Additionally, different sizes and weights of particles lead to different 
coating thicknesses (Wesdyk et al., 1990). Therefore, a narrow size distribution of the 
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fluidized particles is important (Gibbs et al., 2009; Wesdyk et al., 1990). Methods such as 
pelletization disc, high shear granulator, fluid bed granulator and extrusion/spheronisation are 
commonly used for pelletization. In the present thesis, spray granulation and wet 
extrusion/spheronisation were used for producing spherical pellets and will be described in 
the following sections. 
 
2.2.2 Spray granulation 
Spray granulation can be defined as a particle-forming process by which a solid containing 
liquid is converted into solid granules by simultaneous drying (Link and Schlünder, 1997). 
Hot air is used to fluidize the produced particles. The temperature-controlled air also leads to 
an evaporation of the solvent, which is sprayed through an atomizing nozzle. The dissolved 
material will adhere on the surface of the seeding particle, which results in an increase of the 
granule diameter. External material or undersized particles of the previous batch, can be used 
as seeds or starting material. During the process, spray dried particles (drying prior to contact 
with fluidized particles), dust, abrasion and fragments are used for further granulation. In 
contrast to agglomeration, the particle growth proceeds by surface layering, comparable to the 
fluidized bed coating. For spray granulation the top spray mode is often used. The process is 
easy to handle in continuous process (as described in Chapter 2.2.1). The final granules 
(pellets) are consisting of the dry matter of the sprayed solution formed by spray granulation. 
Granules characteristically have a well-rounded and uniform “onion skin” layered structure, 
which is optimal for a further protecting coating step and a high particle strength (Link and 
Schlünder, 1997). The process parameters need to be adjusted to avoid agglomeration and to 
achieve spherical granules with a narrow particle size distribution. The particle size range can 
be controlled by regulating the air stream for classification (see Chapter 2.2.1) (Kumpugdee-
Vollrath and Krause, 2011; Teunou and Poncelet, 2002).  
 
2.2.3 Extrusion-spheronisation  
Formation of round and small pellets is achieved by extrusion and subsequently 
spheronisation. During extrusion, a wet mass is shaped into rods by passing an extruder 
screen. Four main extruder classes are existing: screw, sieve and basket, roll and ram 
extruder. In the present thesis, a twin-screw extruder was used. Two screws are mixing the 
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added powder (consisting of the drug and some pelletizations aids) and granulating liquid 
(e.g. water), while simultaneous transferring the wetted mass to the die at the end of the 
barrel, where cylindrical extrudates are formed (Figure 2.4A). The barrel can be tempered if 
necessary. After the extrusion process, the wet extrudates are transferred into a spheronizer. A 
spheronizer is equipped with a rotating cross-hatched friction plate, where the extrudates are 
broken up into smaller cylinders (Figure 2.4B). However, not every wetted mass can be 
successfully extruded and spheronized. Therefore, spheronization aids, in most cases 
microcrystalline cellulose (MCC), are used to form spherical pellets. Due to its high water 
absorption and retention property, a cohesive plastic mass is formed, which is brittle enough 
to be broken down but not to disintegrate completely and which is plastic enough to be rolled 
into spheres but not too wet to agglomerate (Dukić-Ott et al., 2009; Vervaet et al., 1995). 
 
 
 
            
 
 
2.2.4 Hydrogel bead production – ionotropic gelation 
Hydrogels are defined as three dimensional, hydrophilic networks. The incorporation of 
compounds is possible, whereby the release rate in the human gastrointestinal tract can be 
influenced. Hydrogel beads are often prepared by ionotropic gelation. This technique is based 
on the ability of some polymers to cross link in the presence of counter ions. Examples for 
natural polymers used for drug encapsulation via ionotropic gelation are alginates, gellan gum 
and pectin as anionic materials and chitosan as cationic material. To achieve a hydrogel bead, 
an aqueous solution of the polymer (and the desired compound to encapsulate) are added 
dropwise into a solution of the counter ions. The anions/cations of the polymer react with the 
cations/anions of the cross linking solution. For anionic polymers, calcium chloride is often 
A B 
Figure 2.4: Schematic demonstration of a twin-screw extruder (A) and a spheronizer (B) 
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used as cross-linking solution. Through electrostatic and ionic bonding a proper gel is formed. 
The polymers can also act as release rate retardant (Patil et al., 2010; Patil et al., 2012; 
Smrdel, 2008; Sriamornsak, 2011).  
 
2.2.5 Materials for colon targeted delivery  
Depending on the desired functionality of the formulation, different materials are suitable. 
Independently of the application as a coating or matrix material, the material is required to 
ensure that the formulation is delivered to the target site, where the encapsulated compound is 
released in adequate amounts. Regarding a colon targeted delivery, the active ingredients need 
to be protected during the entire gastric and small intestine transit. The site-specific release 
should be indicated by differences between the small and large bowel. These are more 
difficult to seize compared to the passage from stomach to the small intestine. However, 
differences in the composition of the microbiota, which is more abundant in the large intestine 
than in the small intestine, the intraluminal pressure, the total transit time, both increases from 
proximal to distal, and the differences in pH values of the fluids can trigger the release of the 
encapsulated substance (Maroni et al., 2013). 
For influencing the microbiota, a release in the distal ileum and proximal colon region, where 
most of the living microorganisms are located, is desirable (Sekirov et al., 2010). In the 
human gastrointestinal tract, the pH values are varying from stomach to proximal small 
intestine, distal small intestine and large intestine. Detailed information are listed in Chapter 
2.3. The pH value is increasing in the ileum and in the ascending colon the pH value is 
decreasing slightly (Evans et al., 1988; Ibekwe et al., 2008; Lesmes and McClements, 2009), 
due to microbial fermentation products (short-chain fatty acids (SCFA)) (MacFarlane et al., 
1992). Therefore, the application of pH-sensitive coatings an approach to achieve an        
(ileo-)colon targeted release e.g. shellac.  
The gastrointestinal tract (GIT) is the most heavily colonized organ in comparison to the 
human skin, genitourinary and pulmonary tract, which are inhabited by a number of 
microorganisms.  The number as well as the variety of microorganisms in the GIT is 
increasing from proximal to distal. In the stomach a number of 101 cells per gram are 
documented, which is increasing to 103, 104, 107 and 1012 cells per gram from duodenum, 
jejunum, ileum to colon. The dominating phyla of the human gut microbiota are Bacteroidetes 
and Firmicutes. Proteobacteria, Verrucomicrobia, Actinobacteria, Fusobacteria and 
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Cyanobacteria representing minor microorganisms (Sekirov et al., 2010). The inhabiting 
microbiota can catalyze many enzymatic reactions, which are not proceeded by enzymes of 
human digestion fluids. Therefore, materials, which are not susceptible to the digestion in the 
small intestine and which will be degraded by colonic bacteria, may serve as colon delivery 
aids e.g. pectin (Maroni et al., 2013; Rubinstein, 1990).  
 
2.2.5.1 Shellac  
Shellac is the refined form of the natural insect resin lac. The lac is secreted by insects Kerria 
lacca in India, Thailand or Southeast Asia, which are parasitic on certain trees. After the 
insects permeate the bark of the trees, they convert the sap internally to a polyester resin. 
Afterwards, they secrete the resin through their body surface. Thick encrustations of the resin 
are formed on the twigs. The resin should protect the brood from extreme temperatures and 
predators. After hatching, the encrustations are harvested (seedlac) and further processed to 
achieve the final refined product called shellac. Depending on the insect species, host trees 
and refining process, the chemical composition, color and the properties such as release 
behaviour of shellac is varying. Three different refining processes are used: melting process, 
bleaching process or solvent extraction process, whereby latter process does not change the 
chemical structure of shellac. The resulting shellac film is crushed to flakes or milled into a 
fine powder (Buch et al., 2009; Farag and Leopold, 2011b; Penning, 1996).  
Shellac consists of polyesters of mainly aleuritic acid, shellolic acid, jalaric acid, butolic acid 
and small amounts of free aliphatic acids (Christie et al., 1963; Wang et al., 1999). The soft 
fraction of shellac consist of single esters of a sesquiterpenoid acid and a hydroxyl fatty acid, 
whereby the hard fraction are single esters polymerized by ester linkages (Wang et al., 1999).  
Shellac is a food grade material and legislated as food additive under the E-Number E904. It 
is used in the food, food supplement, nutraceutical and pharmaceutical industry for different 
applications. Shellac is suitable as moisture barrier and gloss coat (Pearnchob et al., 2003b; 
Trezza and Krochta, 2001), therefore, it is often used as glazing agent for citrus fruits and 
confectionaries. In the nutraceutical or pharmaceutical industry, shellac is frequently used as 
enteric coating material for a delayed and/or colon targeted release in the human gut, due to 
its acidic character and the presence of carboxylic groups (Al-Gousous et al., 2015; Pearnchob 
et al., 2003a; Roda, 2007). The pka value of shellac is between 6.9 and 7.5, therefore shellac 
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dissolves at a pH value of about 7.0. In the acidic milieu of the stomach, shellac is still 
insoluble, because of protonated carboxylic groups (Limmatvapirat et al., 2007). These 
properties make shellac suitable for formulations with desired gastric resistance and delayed 
release in the ileocolonic region. 
Indeed, natural products are a potential source of batch-to-batch variations and alterations 
(Krause and Müller, 2001; Penning, 1996). Shellac, which is soluble in solvents like ethanol 
and methanol, is often described as an instable and hardening material over time. Aging of 
shellac leads to changes in the release characteristics like loss of gastric resistance and a 
decrease in intestinal fluid solubility, which is disadvantageous compared to synthetic 
materials (Farag and Leopold, 2009; Penning, 1996). During ageing, polymerization via 
esterification of the carboxylic and alcohol groups occurs, as shown in Figure 2.5. The 
aqueous shellac solution produced by addition of alkali salts, e.g. the volatile ammonium 
carbonate can hinder the polymerization reaction of the carboxylic and the alcoholic groups 
within the film (Figure 2.5) (Limmatvapirat et al., 2007; Penning, 1996). However, during 
coating, curing and storage a part of the present ammonium can evaporate as ammoniac, 
which results in protonated carboxyl groups and could be polymerized in further processes 
(Al-Gousous et al., 2015; Limmatvapirat et al., 2004; Schmidt and Teuber, 1991). Regarding 
the water vapour permeability and the water uptake, the aqueous ammonium shellac is more 
permeable than the native acid form of shellac (Hagenmaier and Shaw, 1991; Pearnchob et 
al., 2004). However, gastric resistance is also given. After exposition to gastric fluids, the 
carboxyl groups are protonated, which results in an insoluble and protecting outer layer 
(Henning et al., 2012; Penning, 1996). The water-soluble shellac is also used for the present 
studies. 
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Figure 2.5: Chemical structure of native shellac and its ammonium salt form and the effect of 
ageing (Limmatvapirat et al., 2007) 
 
The film formation of either the dissolved native shellac in organic solvents or the water-
soluble ammonium salt shellac solution occurred by evaporation of the solvent. The sprayed 
droplets coalesce on the surface, the polymer concentration and interaction is increasing, 
whereby an intermediate gel-like stage is reached. After further evaporation, a continuous 
solid polymeric film is obtained (Banker, 1966; Schmidt and Teuber, 1991). 
 
2.2.5.2 Pectin 
Pectin is a natural polysaccharide, which occurs in higher plants as cell wall structural 
carbohydrate. It is a heterogeneous molecule, which contains α-1,4-glycosidic bonded poly-
D-galacturonic acid. Neutral sugars, like L-rhamnose, can be inserted or attached to the main 
chain of pectin. The carboxyl groups of the pectin molecule are partially esterified with 
methanol. Depending on the degree of esterification (DE), low and high methoxylated (LM: 
DE < 50 %, HM: DE > 50 %) pectins are differentiated. Amidated pectins possess 
carboxamide groups instead of carboxylic groups, when ammonia was used for the de-
esterification process (Liu et al., 2003; Willats et al., 2006). Pectin is broadly used in the food 
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and pharmaceutical industry because of its gelling ability and known as E440. Depending on 
temperature, pectin type, DE, degree of amidation (DA), pH value, sugar, calcium and other 
solutes, gels with different physico-chemical properties can be formed. HM pectin is building 
a three-dimensional network by cross-linking of galacturonic acid via hydrogen bridges and 
hydrophobic forces to methoxyl groups. This reaction occurs in the presence of high sugar 
concentrations and low pH values. LM pectins form gels by cross-linking of free carboxyl 
groups with calcium ions, as described in Chapter 2.2.4. The formed complexes are also 
known as “egg box” complexes (Figure 2.6). Calcium pectinate shows a reduced solubility, 
which could lead to an inhibited release of the encapsulated compound. Furthermore, calcium 
pectinate is still suitable for enzymatic degradation in the colon. However, calcium pectinate 
matrices seem to be limited for lipophilic or extremely low water-soluble substances. For 
water-soluble compounds, the application of an additional coating layer or a combination with 
other polymers is proposed. Some combinations have already been studied (Liu et al., 2003; 
Willats et al., 2006). One option is the combination with an additional zein coating, which 
should enhance the water resistance (Chotiko and Sathivel, 2017; Liu et al., 2006). 
 
Figure 2.6: Egg box model for the gelation mechanism of low methoxylated pectin in the 
presence of calcium ions (Sriamornsak, 2011) 
 
2.2.5.3 Zein 
Zein is the major storage protein of corn. About 45 – 50 % of corn protein is zein. It is 
distributed as “zein-bodies” in the cytoplasm of the endosperm cells. The molecular weight of 
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zein is about 40 kDa and it belongs to the class of prolamins. Four classes of zein are known: 
α-, β-, γ- and δ-zein with different protein fractions. Zein is a natural biopolymer and 
approved by the FDA (Food and Drug Administration) (Patel and Velikov, 2014). Regarding 
its amino acid composition, zein has a deficiency in acid and basic amino acids, except of 
glutamic acid, and a high proportion of nonpolar amino acids (leucine, proline, alanine). This 
amino acid composition leads to a low solubility in water, alcohol and alkalis (pH value > 11). 
Due to its property to form tough, glossy, flexible and hydrophobic coatings, it is applicable 
for controlled release formulations and as moisture and water barrier (Paliwal and Palakurthi, 
2014; Shukla and Cheryan, 2001; Zhang et al., 2015). Liu et al., combined pectin and zein for 
the encapsulation of indomethacin and BSA into the hydrogel and achieved a colon-targeting 
(Liu et al., 2006).  
 
2.3 In vitro dissolution testing 
In vitro tests are conducted to evaluate the dissolution and release behaviour of dosage forms 
simulating the human gastrointestinal tract. Nevertheless, in vivo studies are still the “golden 
standard” for bioaccessibility, absorption, bioavailability, metabolism and excretion. 
However, in vitro dissolution methods are less labour and cost intensive, more rapid and have 
lower bioethical restrictions (Shani-Levi et al., 2017). Especially for early stages of 
formulation design and optimization, in vitro dissolution tests are feasible (Jorgensen and 
Bhagwat, 1998; Zahirul and Khan, 1996). 
Regarding European Pharmacopeia, the dissolution specification for a delayed release 
formulation has to be decided from case to case according to the formulation design. Due to 
prolonged gastrointestinal residence of the intact dosage form and variabilities in 
physiological conditions, the establishment of a proper dissolution test for controlled release 
oral dosage forms is very difficult, compared to immediate release formulations (Zahirul and 
Khan, 1996). To simulate the in vivo release for an (ileo-)colon targeted delivery, the in vitro 
dissolution tests need to be adjusted to the gastrointestinal conditions from stomach to colon 
and to the individual drug delivery system (pH-, time-, pressure- or microflora-activated 
system) (Yang et al., 2002). An overview of the human gastrointestinal conditions regarding 
pH value and transit time is given, which are the most important factors influencing the 
release from shellac coated particles. For pectin beads, microbial enzymes in the large bowel 
are considered. Nutraceuticals, which are supposed to be swallowed, are only validated 
simulating gastric and intestinal conditions. 
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Stomach 
The pH value of gastric fluid is low compared to the rest of the gastrointestinal tract. It was 
found that the pH value varies between fasted and fed state. In fasted state pH values of about 
1 – 3 were found (Dressman et al., 1990; Gruber et al., 1987; Ibekwe et al., 2008; Russell et 
al., 1993), whereby in fed state the pH value can increase to  pH 4 – 6 (Dressman et al., 1990; 
Russell et al., 1993). However, pH values higher than 6 are also documented (Dressman et al., 
1990; Lindahl et al., 1997; Russell et al., 1993). Within two or three hours, the pH value 
returns to fasted state values, depending on meal size (Dressman et al., 1998). The 
requirements of the Pharmacopeia for gastric resistance are fulfilled, if less than 10 % of the 
encapsulated drug is dissolved after two hours at pH value 1.2 (Tarcha, 1991). To simulate 
fed stomach conditions, higher pH values (pH 2 – 4) (Czarnocka and Alhnan, 2015) and more 
complex media compared to buffer solutions are used (Galia et al., 1998; Jantratid et al., 
2008; Klein et al., 2004).  
Regarding residence time in the stomach, a high variability from 15 – 420 min is described 
due to food composition, food structure and size, calorie content and biological factors 
(Clarke et al., 1993; Clarkston et al., 1997; Davis et al., 1987, 1987; Dressman et al., 1998; 
Guerra et al., 2012; Ibekwe et al., 2008). Pellets, which are smaller than 2 mm, are able to 
pass the pylorus independently of gastric emptying, which reduces the residence time (Davis 
et al., 1987).  
 
Small intestine 
The small intestine is compartmented in duodenum, jejunum and ileum from proximal to 
distal. Depending on fasted or fed state, the pH value in the small intestine can vary. Values 
for the pH are documented between 5.4 – 7.5 (Dressman et al., 1990; Guerra et al., 2012; 
Russell et al., 1993; Shani-Levi et al., 2017). An increasing pH value from proximal (6.2 – 
6.6) to mid (6.7 – 7.4) and distal (7.4 – 7.5) small bowel was found (Evans et al., 1988; 
Ibekwe et al., 2008). For in vitro dissolution tests a pH value between 6.5 and 6.8 is often 
used, which is representative for the complete small intestine (Czarnocka and Alhnan, 2015; 
Dressman et al., 1998; Farag and Leopold, 2011a; Galia et al., 1998; Klein, 2010; Marques, 
2004; U.S. Pharmacopeial Convention, 2005), whereby simulated fed state intestinal fluids 
can have a lower  pH value of about 5.0 (Klein, 2010; Marques, 2004; Marques et al., 2011).  
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The transit time in the small intestine was found to vary between 2 and 5 hours (Guerra et al., 
2012), depending on the combined food size, whereby the effect of the gastric emptying time 
is mostly responsible for this variability (Clarke et al., 1993; Davis et al., 1987; Dressman et 
al., 1998; Ibekwe et al., 2008; Malagelada et al., 1984). For pellets, a median small intestine 
transit time of 2.7 – 3.1 h (Clarke et al., 1993) and 1.5 – 5.7 h (Abrahamsson et al., 1996) is 
described.  
 
Large intestine 
From proximal to distal large intestine, the pH value increases from 6.37 to 6.61 and 7.04 
(Evans et al., 1988), whereby the pH value in the ascending colon is lower compared to the 
ileum (Gruber et al., 1987; Guerra et al., 2012; Lesmes and McClements, 2009; Shani-Levi et 
al., 2017). For in vitro simulations of the colon, phosphate buffers were used (Abraham and 
Srinath, 2007), sometimes with added enzymes like galactomannase (Singh et al., 2004) or 
pectinase (Liu et al., 2006). Added enzymes should simulate the enzymes produced by gut 
microbiota neglecting complexity as well as the anaerobic conditions. Therefore, adapted in 
vitro simulations were developed with added faeces inoculum, to mimic the fermentation in 
the lower gut (Barry et al., 1995; Glei et al., 2006; Stein et al., 2011). 
The transit time of the large intestine is characterized by a huge variability ranging from hours 
to days (Shani-Levi et al., 2017). Depending on the dosage form, different colon transit times 
were detected. Smaller pellets resulted in a longer transit time of 28.4 h, compared to tablets 
(15.2 h) (Abrahamsson et al., 1996). The longer residence time of smaller particles was 
explained due to a slower transport (Abrahamsson et al., 1996) and to the extensive mixing in 
the proximal colon (Dressman et al., 1998). The caecal arrival time (C50) of pellets is about 
3.6 – 7.9 h after oral intake, whereby the variability is affected due to the average gastric 
emptying and the small intestine residence (Clarke et al., 1993; Davis et al., 1987; Ibekwe et 
al., 2008). The ascending and transversal colon is of interest for further drug absorption. The 
distal parts of the colon only show small amounts of fluids to dissolve the encapsulated 
compound, because of its leading function to form faeces (Dressman et al., 1998; Schiller et 
al., 2005). 
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3.1 Abstract 
OBJECTIVE: Gut microbiota represent a potential novel target for future prediabetes and 
type 2 diabetes therapies. In that respect, niacin has been shown to beneficially affect the host-
microbiome interaction in rodent models. 
RESEARCH DESIGN AND METHODS: We characterized more than 500 human subjects 
with different metabolic phenotypes regarding their niacin (nicotinic acid (NA) and 
nicotinamide (NAM)) status and their gut microbiome. In addition, NA and NAM delayed-
release microcapsules were engineered and examined in vitro as well as in vivo in two human 
intervention studies (bioavailability study and proof-of-concept/safety study).  
RESULTS: We found a reduced α-diversity and Bacteroidetes abundance in the microbiome 
of obese human subjects associated with a low dietary niacin intake. Therefore, we developed 
delayed-release microcapsules targeting the ileo-colonic region to deliver increasing amounts 
of NA and NAM to the microbiome while preventing systemic resorption to avoid negative 
side effects (e.g. facial flushing). In vitro studies on these delayed-release microcapsules 
revealed stable conditions at pH 1.4, 4.5 and 6.8 followed by release of the compounds at pH 
7.4, simulating the ileo-colonic region. In humans in vivo, gut-targeted delayed-release NA 
but not NAM produced a significant increase of the Bacteroidetes abundance. In the absence 
of systemic side effects, these favorable microbiome changes induced by microencapsulated 
delayed-release NA were associated with an improvement of biomarkers for systemic insulin 
sensitivity and metabolic inflammation.  
CONCLUSION: Targeted microbiome intervention by delayed-release NA might represent a 
future therapeutic option for prediabetes and type 2 diabetes. 
 
Keywords: obesity, type 2 diabetes, microbiome, niacin, tryptophan, coating, delayed-release, 
microencapsulation 
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3.2 Introduction 
Rather than being viewed as simple commensals, the gut microbiome is now seen as playing 
an active role in the control of energy homeostasis and in the mediation of the adverse 
consequences of obesity (Turnbaugh et al., 2006). In the recent past several studies in humans 
and rodents revealed that obesity is associated with a reduction in Bacteroidetes (Ley et al., 
2005; Ley et al., 2006; Turnbaugh et al., 2009) as well as a lower diversity compared to 
healthy and lean subjects (Cotillard et al., 2013; Turnbaugh et al., 2009). Of physiological 
relevance, the composition of the gut microbiota can be altered by diet, as weight loss 
interventions have been reported to influence the abundance of Bacteroidetes (Ley et al., 
2006) and the overall microbial diversity (Cotillard et al., 2013; Heinsen et al., 2016). 
Administration of niacin (nicotinic acid (NA) and nicotinamide (NAM)) has been shown to 
beneficially effect the host-microbiome interaction in a mouse model (Hashimoto et al., 
2012). Nicotinamide adenine dinucleotide (NAD+) is the central co-factor of metabolism, 
mediating fuel oxidation, ATP generation, reactive oxygen species (ROS) detoxification, 
biosynthetic processes, DNA repair and nutritionally sensitive gene regulation (Belenky et al., 
2007). In vertebrates, NAD+ is synthesized de novo from tryptophan (Trp) and from three 
vitamin precursors. NAM and NA are the classical NAD+ precursor vitamins. Nicotinamide 
riboside (NR) was discovered to be a NAD+ precursor vitamin much more recently (Bogan 
and Brenner, 2008). The NAD+ metabolome has been shown to be dysregulated in obesity 
and type 2 diabetes (T2D) in mice (Trammell et al., 2016). Moreover, NR repletion has been 
shown to blunt weight gain on high fat diet (Cantó et al., 2012) and to oppose fatty liver on 
high fat high sucrose diet (Gariani et al., 2016), largely by increasing the activity of SIRT1, an 
NAD+-dependent protein lysine deacetylase.  
These data on the beneficial effects of niacin on both, the gut microbiome and the systemic 
glucose metabolism suggest this micronutrient to be an interesting candidate for future 
targeted microbiome interventions, e.g. to prevent manifestation of type 2 diabetes from 
prediabetes. However, because the upper gastrointestinal tract efficiently resorbs soluble 
micronutrients, simply increasing the NA and/or NAM nutritional load would not be expected 
to deliver these molecules into the ileo-colon region, where most of the microbiome is located 
(Sekirov et al., 2010). The aim of the present study was therefore (I) to examine NA and 
NAM in humans in relation to obesity and the gut phylogenome in a large human cohort of 
>500 well characterized individuals and (II) to use a microencapsulation procedure to develop 
a novel delayed-release system to deliver significant amounts of NA and NAM into the 
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human colon in order to beneficially affect the gut microbiome and the systemic metabolism 
while preventing systemic side effects. 
 
3.3 Research Design and Methods 
3.3.1 Study cohorts and study designs 
511 subjects of the Food Chain Plus (FoCus) cohort, which has been reported earlier (Müller 
et al., 2015), were included in the present investigation. Fasted serum samples and stool 
samples were collected and anthropometric measurements were performed within subjects of 
the FoCus cohort. Further, a 12-months retrospective food frequency questionnaire (EPIC) 
was completed by n=481 subjects (Kroke et al., 1999) in order to determine niacin 
(NA+NAM) nutritional intake. Baseline characteristics of the FoCus-subset are shown in 
Table 3.1. Two human intervention studies were performed to evaluate NA/NAM 
microcapsules in vivo: (I) a bioavailability study including 20 healthy subjects (mean age 
26.85±4.86a, 50% female, median BMI 22.78 kg/m2 (21.25; 25.57)) (Supplementary Table 
3.2) and (II) a proof-of-concept and safety study including 10 metabolically healthy subjects 
without manifest metabolic diseases and normal glucose and triglycerides levels (mean age 
44.80±11.06a, 80% female, BMI 26.67±3.68 kg/m2) (Supplementary Table 3.3). In those 
human interventions, NA- and NAM-effects observed under different dosages of 
microencapsulated NA (=”NA group”) or NAM (=”NAM group”) were compared with 
effects after ingestion of a reference dose of free NA (30 mg) or NAM (900 mg). During 
bioavailability study one subject of NA-group dropped out after two study days due to 
persistent difficulties in blood sample collection. Within the proof-of-concept and safety study 
one subject of NA-group had to be excluded after week 5 due to elevated aspartate 
transaminase (AST) levels, and one subject of NAM group dropped out in week 2 due to an 
accident not associated with the study. 
Subjects were recruited at the University Hospital Schleswig-Holstein (Kiel, Germany). 
Niacin interventions (D439/15) and FoCus study (A108/08) were approved by local ethic 
committee and written confirmed consent was obtained from each subject. 
 
3.3.2 Biochemical analysis 
Blood samples were subjected to routine laboratory analyses at the central laboratory of the 
University Hospital Schleswig-Holstein (Kiel, Germany). Homeostasis Model Assessment 
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(HOMA) index was calculated as glucose (mg/dl)*insulin (μU/ ml)/405. Serum was stored 
immediately at -80°C. NA and NAM serum levels were measured by liquid chromatography 
and mass spectrometry (LC-MS/MS; Agilent 1100 HPLC/CTC-PAL Autosampler/Sciex API 
4000 Triple Quadrupole) in an external specialized laboratory (Medizinisches Labor Bremen). 
Systemic metabolic parameters in the serum samples were measured by Enzyme-linked 
Immunosorbent Assay (ELISA) using myostatin test kit (SEB653Hu, Cloud-Clone Corp.), 
fetuin-A test kit (SEA178Hu, Cloud-Clone Corp.) and osteopontin test kit (SEA899Hu, 
Cloud-Clone Corp.), following manufacturer’s instructions. Gut microbiome analysis was 
performed by 16S rDNA amplicon sequencing as described by Heinsen et al. (Heinsen et al., 
2016). 
 
3.3.3 Production of NA and NAM microcapsules and in vitro evaluation 
Microcapsule cores, including NA or NAM (SternVitamin, Ahrensburg, Germany), were 
prepared. In order to achieve higher daily doses of NAM, NAM cores were prepared by a 
ProCell fluidized bed granulator with Vario 3 from an extern company (Glatt 
Ingenieurtechnik, Weimar, Germany). In contrast, NA was applied to Cellets350 in a Mini 
Glatt fluidized bed coater with bottom spray. In the next step, NA/NAM cores were both 
coated with an inner shellac (SSB Aquagold, Bremen, Germany) coating (2 % weight gain 
(w.g.)/50 % w.g.), an intermediate layer of a pH-modulating substance, sodium bicarbonate 
for NA (1 % w.g.) and citric acid for NAM (1 % w.g.) and at last an outer shellac coating 
(20 % w.g./10 % w.g.). Afterwards, microcapsules were dried at 50 °C in an oven for 1 h. For 
in vivo-studies NA and NAM microcapsules and NA- and NAM-powder (free niacin) were 
filled into standard size 0 gelatin capsules using a manual capsule filler. Differential dosing 
was achieved by administration of different amounts of full or partially filled capsules.  
Dissolution tests were performed in triplicate with 0.5 g of NA or NAM microcapsules in 
250 ml simulated gastric fluid (pH 1.4), citrate buffer (pH 4.5) and phosphate buffers (pH 
6.8&7.4) using a standard dissolution paddle apparatus at 100 rpm and 37 °C (DT 70, 
Pharmatest Group, Hainburg, Germany). The exposition to the release media was set to 1 h at 
pH 1.4, 0.5 h at pH 4.5, 2h at pH 6.8 and 1.5 h at pH 7.4. Niacin release was recorded every 
30 min by UV/vis spectrophotometer at 262 nm (Helios gamma. Thermo Fisher Scientific, 
Dreieich, Germany). 
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3.3.4 Scanning electron microscopy of microcapsules 
Microcapsules from stool samples were isolated, washed in demineralized water and dried 
overnight. Afterwards the isolated digested microcapsules, as well as undigested control 
microcapsules, were prepared on a holder with Leit-C conductive carbon cement. Before 
examination in a Hitachi S-4800 (Hitachi High Tech., Tokyo, Japan) scanning electron 
microscope (SEM) at an accelerating voltage of 3 kV, microcapsules were sputter-coated with 
a layer of 8-10 nm gold-palladium using a Leica EM SCD 500 (Leica Microsystems GmbH, 
Wetzlar, Germany) high-vacuum sputter coater. SEM pictures of the capsules isolated from 
stool samples were compared with SEM pictures of undigested microcapsules. 
 
3.3.5 Statistical Analyses 
Statistical analyses were carried out employing SPSS version 22.0 for windows (SPSS, 
Chicago, IL; USA) and graphic data analysis was performed using GraphPad Prism version 
5.0 (GraphPad Software, San Diego, CA, USA). Data were checked for normality by using 
Shapiro-Wilk-tests and presented as means ± SDs (normal distribution) or median and 
interquartile range (not normally distributed). Independent samples t-tests and Mann-
Whitney-U-tests were used to determine between group differences for continuous variables, 
and x2-test was used for categorical variables. To compare more than two groups Kruskal-
Wallis-test was used for non-parametric data. Welch-ANOVA with Games-Howell-Post-Hoc-
test was used for parametric data with heterogeneity of variances. According to distribution 
Spearman correlation analysis was performed. Area under the curves (AUCs) were calculated 
with GraphPad Prism. In case of serum levels after 12 h not matching baseline serum levels, 
the NAM-serum level curves were extrapolated. Extrapolation was performed by means of 
trend lines in Excel version 2010 (Excel, Microsoft Cooperation, Redmond, WA, USA). 
According to distribution Wilcoxon test or paired sample t-test were used to determine 
differences between AUCs of unformulated niacin and AUCs calculated under the application 
of microencapsulated niacin. Changes in systemic metabolic parameters during the study 
weeks were determined by Friedman-test and Wilcoxon test or paired t-test according to 
distribution. To determine significant changes in the microbial composition under niacin 
intervention GraphPad was used to perform over time repeated ANOVA and paired t-test. 
Statistical significance was set at p<0.05. 
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3.4 Results 
3.4.1 Niacin status in humans in relation to obesity, type 2 diabetes and the gut 
microbiome 
First, we examined the association of NA and NAM with the microbiome in relation to human 
obesity and type 2 diabetes in n=511 subjects from our FoCus cohort (Table 3.1). In 
agreement to earlier reports (Ley et al., 2005; Ley et al., 2006; Turnbaugh et al., 2009), the 
gut microbial composition of obese individuals showed significantly lower α-diversity 
measures of genera (p=0.036) and OTU (p<0.001) as well as significantly lower 
Bacteroidetes abundance on phylum level (p=0.027) compared to lean subjects. In obese 
subjects a low niacin intake was associated with both, a reduced α-diversity (rho=0.286, 
p=0.001) and a lower Bacteroidetes abundance (rs=0.191, p=0.026). This was further 
supported by a significant correlation of low NAM serum levels with a reduced α-diversity in 
obesity (rho=0.176, p=0.032). Of interest, these findings were only significant in insulin 
resistant obese subjects without clinical manifest type 2 diabetes (Figure 3.1), suggesting that 
a niacin related microbiome intervention might be most promising in the prevention rather the 
treatment of type 2 diabetes. In this respect, it has to be taken into account, that in the group 
of type 2 diabetic subjects several patients were treated with metformin which is known to 
influence the composition of the gut microbiome (Wu et al., 2017) and therefore might 
beneficially interfere with the niacin-microbiome interaction. 
 
3.4.2 Development of novel delayed-release niacin microcapsules and in vitro 
evaluation 
Having found an association of a low niacin intake with adverse microbiome changes we 
developed a microencapsulation procedure to deliver increasing amounts of NA or NAM into 
the ileo-colonic region where most of the gut bacteria are localized. In order to detect 
differential effects, two separate microcapsules were engineered, containing either NA or 
NAM (see material and methods). Subsequently, these microcapsules were compared to free 
NA and NAM in two human intervention studies: (I) a bioavailability study and (II) a proof-
of-concept and safety study (see below). After the coating process of the cores, both 
microcapsules, NA and NAM, were analysed by SEM for the verification of a homogenously 
distributed coating material. As shown in Figure 3.2A+B, the outer shellac coating formed a 
homogenous layer covering the complete capsule surface indicating a sufficient protection of 
the encapsulated compounds. To evaluate the in vitro dissolution profile, NA and NAM 
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microcapsules were subjected to simulated gastrointestinal fluids according to modified 
pharmaceutical standards (USP, 2011). The dissolution profiles in Figure 3.2C+D show 
gastric resistance of NA and NAM microcapsules for 1h at pH 1.4 and 0.5 h at pH 4.5 (release 
< 3%). Afterwards, the whole amount of encapsulated NA or NAM was released at pH 7.4. In 
contrast to NA microcapsules, NAM microcapsules already released about 35 % after 2 h at 
pH 6.8.  
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Table 3.1: Characteristics of the FoCus subset study cohort 
 
BMI < 20 
kg/m2 
BMI 20-
25 kg/m2 
BMI > 30 
kg/m2 
without 
T2D 
BMI > 30 
kg/m2 
with T2D 
ptotal p1 p2 p3 p4 p5 p6 
n= 66 n=149 n=148 n=148 
age (years) 45.53 ± 
15.58a 
52.90 ± 
10.82 
52.82 ± 
10.86 
52.93 ± 
10.83 
<0.001 <0.001 <0.001 <0.001 n.s n.s n.s. 
gender (% 
female) 
86.4 % 67.1 % 66.9 % 66.2 % <0.05 <0.01 <0.01 <0.01 n.s. n.s n.s 
height (m) 1.70b 1.72 1.70 1.70 n.s.       
(1.64; 
1.75) 
(1.68; 
1.79) 
(1.64; 
1.78) 
(1.64; 
1.80) 
weight (kg) 55.45 66.80 111.30 123.25 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
(50.38; 
58.43) 
(61.35; 
74.40) 
(95.73; 
132.20) 
(102.50; 
148.08) 
BMI 
(kg/m2) 
19.09 22.81 37.08 42.80 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
(18.18; 
19.73) 
(21.45; 
23.98) 
(32.40; 
45.13) 
(36.75; 
47.94) 
mmHg (sys) 120.00 120.00 130.00 140.00 <0.001 0.004 <0.001 <0.001 <0.001 <0.001 n.s. 
(110.00; 
130.00) 
(115.00; 
130.00) 
(130.00; 
140.00) 
(130.00; 
140.00) 
mmHg (dia) 80.00 80.00 80.00 80.00 <0.001 0.005 <0.001 <0.001 <0.001 <0.001 <0.001 
(70.00; 
80.00) 
(70.00; 
80.00) 
(80.00; 
90.00) 
(80.00; 
90.00) 
glucose 
(mg/dl) 
88.00 93.00 100.00 123.00 <0.001 n.s. <0.001 <0.001 <0.001 <0.001 <0.001 
(85.00; 
95.25) 
(87.00; 
99.00) 
(91.00; 
108.00) 
(104.25; 
162.00) 
insulin 
(mIU/l) 
5.25 6.50 17.20 25.50 <0.001 n.s. <0.001 <0.001 <0.001 <0.001 <0.001 
(3.90; 
8.30) 
(5.10; 
9.28) 
(11.00; 
24.23) 
(15.53; 
43.88) 
HOMA-IR 
index 
1.14 1.49 4.15 7.87 <0.001 0.005 <0.001 <0.001 <0.001 <0.001 <0.001 
(0.83; 
1.89) 
(1.08; 
2.26) 
(2.57; 
5.71) 
(4.18; 
16.94) 
trigylcerides 
(mg/dl) 
68.00 87.00 121.50 166.00 <0.001 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
(54.75; 
92.50) 
(64.00; 
112.50) 
(91.25; 
179.25) 
(122.00; 
237.75) 
Lp(a) (mg/l) 117.00 121.00 148.00 108.00 n.s.       
(95.00; 
361.00) 
(95.00; 
320.00) 
(95.00; 
378.50) 
(95.00; 
324.25) 
IL-6 (pg/ml) 2.15 2.50 4.00 5.20 <0.001  <0.001 <0.001 <0.001 <0.001 0.001 
(1.50; 
3.73) 
(1.50; 
4.20) 
(2.90; 
5.35) 
(3.33; 
7.08) 
CRP (mg/l) 0.90 0.90 4.35 5.85 <0.001 n.s. <0.001 <0.001 <0.001 <0.001 n.s. 
(0.90; 
1.13) 
(0.90; 
1.90) 
(1.75; 
8.65) 
(2.90; 
10.88) 
amean ± sd (all such values); bmedian; 25th, 75th percentiles in parentheses (all such values); ptotal = p-value for 
overall comparison, p1-6=pairwise comparison: p1=BMI < 20 kg/m2 vs. BMI 20-25 kg/m2; p2=BMI < 20 kg/m2 vs. 
BMI > 30 kg/m2 without T2D; p3= BMI < 20 kg/m2 vs. BMI > 30 kg/m2 with T2D; p4= BMI 20-25 kg/m2 vs. BMI 
> 30 kg/m2 without T2D; p5= BMI 20-25 kg/m2 vs. BMI > 30 kg/m2 with T2D; p6=BMI > 30 kg/m2 without T2D 
vs. BMI > 30 kg/m2 with T2D. Abbreviations: BMI= body mass index; mmHg=mm of mercury column; HOMA-
IR= Homeostasis Model Assessment insulin resistance index; Lp(a)= lipoprotein (a); IL-6= interleukin-6; 
CRP=C-reactive protein, T2D= type 2 diabetes; n.s.= not significant. 
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Figure 3.1: Niacin intake and serum levels in relation to the composition of the gut 
microbiome Scatterplots and spearman correlation analyses of (A) niacin nutritional intake 
and alpha-diversity, (B) niacin nutritional intake and Bacteroidetes abundance and (C) 
nicotinamide (NAM) serum levels and alpha-diversity of obese (without type 2 diabetes). 
 
 
Figure 3.2: In vitro evaluation of novel delayed-release niacin microcapsules 
Scanning electron microscope pictures of (A) undigested whole coated nicotinamide (NAM) 
microcapsule (left), cross section of an undigested nicotinamide microcapsules showing tight 
coating with nicotinamide core inside (right), (B) undigested whole coated nicotinic acid (NA) 
microcapsule (left) and higher magnified smooth coating surface of undigested microcapsules 
(right). (C) In vitro release of nicotinamide from nicotinamide microcapsules using pH 
change test. (D) In vitro release of nicotinic acid from nicotinic acid microcapsules using pH 
change test. In vitro results shown as mean ± SD (n=3). 
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3.4.3 Bioavailability study in healthy human subjects 
In the bioavailability study, 20 human volunteers received single doses of NA or NAM 
microcapsules followed by blood sampling in defined time intervals for 12 h (60 min intervals 
for 8 h after ingestion and two additional blood samples after 10 and 12 h). The procedure 
was repeated with increasing doses (NA=30, 150, 300 mg, NAM=900, 1500, 3000 mg) with 
washout phases of 6 days in between. The microcapsules showed open and empty coating 
shells after gastrointestinal passage, indicating release of the ingredients (Figure 3.3A). The 
NAM serum levels in the bioavailability study showed a delayed release 4h after oral 
ingestion suggesting opening of the capsules in the ileo-colonic region (Figure 3.3B). Due to 
the rapid metabolism of NA into NAM (Kirkland, 2007), in the NA-group only minimal 
fluctuations of NA serum levels could be observed, but no consistent and dose-dependent 
increase (data not shown). Of importance, for both NA and NAM, even under the highest 
dose of the microencapsulated compounds (NA= 300 mg, NAM=3000 mg) the serum 
concentrations were not significantly increased compared to the reference dose of 30 mg free 
NA or 900 mg free NAM. This finding clearly indicates that the delayed-release 
microcapsules deliver high amounts of NA or NAM to the microbiome without significant 
alterations in serum concentrations. This is of importance, since for NA high systemic levels 
are known to be associated with negative side effects like facial flushing and liver dysfunction 
(SCF, 2002).  
 
3.4.4 Proof-of-concept and safety study in healthy human subjects 
In the proof-of-concept and safety study we analyzed the microbiome and determined the 
systemic insulin sensitivity in n=10 metabolically healthy human volunteers receiving either 
NA or NAM microcapsules on a daily basis for a total of 6 weeks with a weekly increase in 
the dosage (NA=30 up to 300mg, NAM=900 up to 3000 mg). In the NA-group a significant 
increase in Bacteroidetes abundance over the time period of 6 weeks was observed 
(p=0.0025) (Figure 3.3C). In contrast, no significant change in the Bacteroidetes abundance 
could be observed in the NAM-group. This specificity of NA versus NAM is explained by the 
finding that Bacteroidetes are deficient in the enzymes nicotinamidase and nicotinamide 
phosphoribosyltransferase resulting in the inability to metabolize NAM (Gazzaniga et al., 
2009). Since obesity is associated with a reduction in Bacteroidetes abundance, these data 
suggest that NA is a stronger candidate for a targeted microbiome intervention compared to 
NAM. This is further supported by the findings on systemic insulin sensitivity: biomarkers for 
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insulin resistance were only significantly improved by microencapsulated NA, but not by 
microencapsulated NAM. For examples, microencapsulated NA in contrast to free NA or any 
NAM formulation induced a significant decrease in myostatin (1.78±0.67 to 1.55±0.48 ng/ml, 
p<0.05) and Fetuin-A levels (3.29±1.10 to 2.66±0.95 ng/ml, p<0.05), which serve as markers 
for skeletal muscle and liver insulin resistance. In addition, microencapsulated NA resulted in 
a significant reduction of circulating osteopontin levels (2.77±1.39 to 2.09±0.78 ng/ml, 
p<0.05), suggesting an improvement of metabolic inflammation which is often found in 
prediabetic and diabetic individuals. In terms of safety profile, one subject of the NA-group 
experienced a mild elevation of aspartate aminotransferase (AST)-levels at week 5, which 
returned to normal within 4 days. Apart from that, no safety signals or facial flushing 
occurred.  
 
3.5 Conclusions 
The impact of the nutritional load (Cotillard et al., 2013) and dietary patterns (Kong et al., 
2014) on the composition of the gut microbiome has been reported by several studies, 
however, to the best of our knowledge, our observation connecting niacin micro-nutrition and 
the human gut microbiome is novel. The positive correlations of niacin intake and niacin 
serum concentrations with alpha-diversity as well as the Bacteroidetes abundance suggest a 
favorable effect of niacin on the human gut microbial composition. To test this hypothesis, we 
developed delayed-release NA and NAM microcapsules to deliver increasing amounts of the 
micronutrients into the ileo-colonic region. In vitro analyses showed that NA and NAM 
microcapsule cores were protected by the coating layer (Figure 3.2). Because of the ability of 
microcapsules (< 2 mm) to pass the human pylorus independent of gastric emptying (Davis et 
al., 1986), the simulated gastric phase was reduced to 1 h. Both formulations released the 
whole amount of encapsulated niacin after reaching a pH of 7.4 (Figure 3.2) because of the 
exceeded dissolution pH of shellac (7.3) (Limmatvapirat et al., 2007). This dissolution pH is 
in agreement with the postulated pH of the human ileum (Evans et al., 1988). However, the 
pH in the desired ileo-colonic region can vary inter- and intra-individually and can be lower 
than the dissolution pH of shellac (Gruber et al., 1987). Furthermore, a decreasing pH in the 
colon is documented (Lesmes and McClements, 2009). Therefore, a partial release at pH 6.8 
is desirable as shown in Figure 3.2C.  
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Figure 3.3: In vivo evaluation of novel delayed-release niacin microcapsules 
Scanning electron microscope pictures of (A) whole opened nicotinamide (NAM) 
microcapsules (above, left), porous and spongy surface and profile of nicotinamide coating 
shell (above, right), whole opened nicotinic acid (NA) microcapsules with indigestible 
cellulose-core inside (bottom, left) and porous and spongy surface and profile of opened 
nicotinic acid microcapsules (bottom, right) after passage in the human volunteer. (B) 
Pharmacokinetic curves of free nicotinamide (NAM) and different doses of microencapsulated 
NAM. (C) Relative abundance of Bacteroidetes of NA-group in the course of proof-of-concept 
and safety study. 
 
Taking these information into account our results showed a sufficient release of NA and 
NAM from our microcapsules and indicate a targeted release in the ileo-colonic region, where 
the tested pH-values were found. As reviewed by Pišlar et al. (2015), median time of gastric 
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emptying after ingestion of non-disintegrating tablets accounts to approx. 35 min, the small 
intestinal transit time to 215 min (min/max: 60/544) and the colon arrival time to 254 min 
(min/max: 117,604) (Pišlar et al., 2015). Thus, our bioavailability curves with serum peak 
levels after 4−8 h indeed suggest a pH-dependent release of NA and NAM in the ileo-colonic 
region. We note, that the gastro-intestinal transit times reported by Pišlar et al. were examined 
in a group of subjects, receiving the first meal at 4 h post-dose whereas meals given earlier 
can increase the time of gastric emptying or shorten small intestine transit time (Pišlar et al., 
2015). During our bioavailability study, the first meal was given 3 h post dose. Nevertheless, 
the transit times still seem comparable to the ones reported by Pišlar et al. (2015), because 
pellets smaller than 2 mm are emptied from the stomach very rapidly and are unaffected from 
the digestive state of the subject (Davis et al., 1986). Comparison of AUCs under dosage with 
microencapsulated and free NAM proofed, that there is no significant increase in the total 
systemic niacin resorption. This finding clearly shows that our microencapsulation is able to 
deliver high amounts of NA/NAM into the colon without a significant increase in total 
systemic NA/NAM uptake in comparison to systemic uptake under application of the 
reference dose of free NA/NAM. 
Under dosage with our novel niacin formulations, no severe safety signals occurred according 
to laboratory parameters. Besides that no clinical symptoms or flush phenomenon was 
observed. In contrast, in the past, different niacin formulations to treat lipid disorders have 
been reported to induce several adverse side effects. For instance it is commonly known, that 
NA doses higher than 30−50 mg can induce facial flush, and doses of 300−2000 mg NA can 
cause gastrointestinal symptoms (BfR, 2012; SCF, 2002). Further, administration of high NA 
doses can lead to liver-disorders or even hepatitis and liver failure (BfR, 2012; SCF, 2002). 
Compared to NA, side effects of NAM are fewer and only appear under doses ≥3000 mg 
(BfR, 2012; Knip et al., 2000). Of importance, side effects like flush or liver-disorders also 
occurred under dosage with sustained- or extended-release formulations (Knopp et al., 1985; 
McKenney et al., 1994). However, these pharmacological niacin formulations contained much 
higher doses (>1000 mg NA) and aimed a maximal systemic exposure to specifically treat 
lipid-disorders. In complete contrast, in our approach we aimed a topical exposure of 
NA/NAM in the colon with minimal increase in systemic resorption to improve the gut 
microbial composition in obesity and type 2 diabetes. In summary, our data indicate that the 
developed NA and NAM microcapsules show a preferable safety profile with no severe side 
effects and no systemic accumulation in healthy human volunteers. 
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In the present study, we found that the effect on both, the Bacteroidetes abundance and the 
systemic metabolism is specific to microencapsulated NA, while no effect was seen for any 
form of the NAM formulations. In this respect it is important to mention that bacteria have 
been classified by virtue of their ability to synthesize NAD de novo from aspartic acid and/or 
the vitamin precursors NAM, NA and NR (Gazzaniga et al., 2009). Thereby, the ability to use 
NAM was predicted on the basis of possession of homologs of nicotinamidase (PncA) and 
nicotinamide phosphoribosyltransferase (NadV). Remarkably, Bacteroidetes were reported to 
be deficient in both genes resulting in the inability to metabolize NAM (Gazzaniga et al., 
2009). This finding explains the specificity of the increase in Bacteriodetes abundance to the 
delayed-release NA intervention found in our study. 
It has to be mentioned that the proof-of-concept and safety study reported here represents a 
“phase 1 clinical trial” equivalent and was therefore performed in healthy human volunteers 
showing no major insulin resistance (Supplementary Table 3.3). The HOMA index was 
normal in those subjects at the beginning and did not significantly change within the normal 
range during the intervention. However, we would like to point out that this finding does not 
argue against an effect of microencapsulated NA on systemic insulin sensitivity, since even a 
metformin therapy over a time period of 6 months does not further improve a normal HOMA 
in non-obese subjects as shown by independent researchers (Trolle et al., 2007). In addition, 
the HOMA index is known not to detect early stages of insulin resistance, therefore the 
emphasis has recently shifted towards myokines and hepatokines as alternative clinical 
biomarkers for liver and skeletal muscle insulin resistance (Park et al., 2015). Myostatin is 
expressed in skeletal muscle (Hittel et al., 2010) and is causally involved in muscle insulin 
resistance, since myostatin null mice are protected from insulin resistance induced by diet-
induced obesity (Park et al., 2015). In humans, myostatin plasma levels have been shown to 
be strongly correlated to insulin resistance (Hittel et al., 2010). On the hepatic site, fetuin-A 
was shown to be a natural inhibitor of insulin receptor tyrosine-kinase (Srinivas et al., 1993) 
and to be associated with insulin resistance in human subjects (Stefan et al., 2006). Of 
interest, strong associations of fetuin-A with the degree of insulin resistance were reported 
especially in non-diabetic subjects (Ishibashi et al., 2010), making this hepatokine an 
interesting candidate for our proof-of-concept and safety study. Indeed, both myostatin and 
fetuin-A levels were significantly reduced by microencapsulated NA, suggesting beneficial 
effects on skeletal muscle and liver insulin resistance. Importantly, both factors did not 
respond to free NA, indicating that the effect is most likely of an indirect nature, presumably 
via the beneficial changes of the microbiome. Beside biomarkers for insulin sensitivity of 
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skeletal muscle and liver we measured osteopontin serum concentrations as a marker for 
adipose tissue inflammation (Lund et al., 2009). Osteopontin levels also decreased under 
microencapsulated NA, suggesting anti-inflammatory properties in addition to the beneficial 
metabolic effects (Kiefer et al., 2010). 
 
In summary, in the present study we present evidence (I) that the reduced α-diversity and 
Bacteroidetes abundance found in obese subjects is associated with a lower dietary niacin 
intake and (II) that a gut-targeted NA supplementation by delayed-release microcapsules is 
able to beneficially affect both, the microbiome and the systemic insulin sensitivity.  
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3.7 Supplemental Information 
 
Supplementary Table 3.2: Baseline characteristics of the niacin bioavailability cohort 
 NAM group  NA group  all subjects  
age (years) 27.50 ± 4.81a 26.20 ± 5.07 26.85 ± 4.86 
gender  5 male, 5 female 5 male, 5 female 10 male, 10 female 
height (m) 1.75 ± 0.08 1.78 ± 0.79 1.76 ± 0.08 
weight (m) 73.70 ± 13.66 75.16 ± 19.22 74.43 ± 16.25 
BMI (kg/m2) 22.78 (21.66; 26.80)b 22.91 (20.40; 24.90) 22.78 (21.25; 25.57) 
NAM (μg/l)c 12.67 ± 2.76* 18.53 ± 7.52* 15.60 ± 6.28 
uric acid (μmol/l) 284.80 ± 81.79 296.20 ± 63.60 290.50 ± 71.55 
creatinine (μmol/l) 80.80 ± 13.11 86.70 ± 9.56 83.75 ± 11.57 
eGFR (ml/min/1.73) 102.80 ± 12.18 94.20 ± 13.26 98.50 ± 13.16 
AST (U/l) 20.15 (17.85; 26.70) 20.65 (19.82; 29.88) 20.65 (19.03; 26.35) 
ALT (U/l) 18.85 (9.15; 31.55) 20.55 (11.80; 26.33) 20.55 (11.43; 30.75) 
γ-GT (U/l)d 17.00 (9.00; 28.28) 16.50 (12.00; 26.75) 17.00 (12.00; 26.50) 
amean ± sd (all such values); bmedian; 25th, 75th percentiles in parentheses (all such values); cbaseline NA serum 
levels of all subjects were below the detection limit of 12 μg/l and are therefore not included in this table; dfor γ-
GT one value was slightly below the detection limit of 7 U/l and set tot 7.0 for the calculations; *significant 
differences between NA- and NAM-group; unpaired t-test (p<0.05). Abbreviations: BMI= body mass index; 
NAM=nicotinamide; GFR= glomerular filtration rate; AST= aspartate aminotransferase; ALT= alanine 
aminotransferase; γ-GT= Gamma-glutamyl transpeptidase 
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Supplementary Table 3.3: Characteristics of niacin proof-of-concept and safety study 
cohort at baseline and after niacin intervention 
 NAM group  NA group  
 Baseline End of treatment Baseline End of treatmenta 
age (years) 39.40 ± 12.10b - 50.20 ± 7.50 - 
gender (female 
%) 100% - 60% - 
height (m) 1.70 ± 0.08 - 1.75 ± 0.06 - 
weight 73.52 ± 10.23 71.03 ± 10.46 85.64 ± 15.50 84.86 ± 15.70 
BMI 25.55 ± 2.86 25.34 ± 3.45 27.97± 4.33 27.71 ± 4.35 
mmHg (sys) 
mmHg (dia) 
121.00 ± 7.42 
72.00 ± 4.47 
108.70 ± 2.5 
72.50 ± 2.89 
119.00 ± 11.40 
75.00 ± 11.18 
116.00± 11.40 
78.00 ± 4.47 
glucose (mg/dl) 91.40 ± 5.50 89.50 ± 5.26 96.80 ± 7.63 93.40 ± 5.77 
insulin (mIU/l) 7.10 ± 5.77 5.70 ± 0.51 8.56 ± 3.24 8.98 ± 3.75 
HOMA-IR 
index 1.56 ± 1.19 1.26 ± 0.10 2.06 ± 0.81 2.05 ± 0.83 
uric acid 
(μmol/l) 274.60 ± 45.23 285.75 ± 55.17 304.20 ± 37.38 298.60 ± 32.73 
LDL (mmol/l) 2.88 ± 1.02 3.01 ± 0.49 3.50 ± 1.08 3.67 ± 1.08 
HDL (mmol/l) 1.75 ± 0.32 1.95 ± 0.35 2.07 ± 0.52 2.11 ± 0.48 
Lp(a) (nmol/l) 17.10 (7.60, 193.95)c 
108.10 
(9.18, 219.48) 
24.50 
(7.35, 127.70)d 
23.30 
(9.60; 137.70)e 
triglycerides 
(mmol/l) 1.04 ± 0.52 0.80 ± 0.14 1.06 ± 0.17 0.98 ± 0.19 
CRP (mg/l) 2.07 (0.99, 4.13) 
2.27 
(0.77, 3.28)  
1.52 
(0.89, 7.71) 
1.30 
(0.84; 6.14) 
AST (U/l) 21.90 (19.10, 22.90) 
22.95 
(21.93, 24.73) 
24.80 
(15.10, 27.50) 
22.60 
(15.90; 73.15) 
ALT (U/l) 20.30 (10.25, 24.50) 
18.15 
(11.65, 20.30) 
19.10 
(15.35, 24.65) 
18.70 
(16.90; 36.80) 
γ-GT (U/l) 28.00 (11.00, 28.50) 
22.50 
(11.75, 33.25) 
23.00 
(19.00, 30.00) 
20.00 
(16.00 ± 25.50) 
bilirubin 
(μmol/l) 5.60 ± 0.79 8.88 ± 2.04 6.70 ± 2.83 7.50 ± 2.22 
creatinine 
(μmol/l) 65.20 ± 7.09 70.50 ± 7.77 85.00 ± 8.06 85.40 ± 8.79 
asince one subjects of NA-group was withdrawn from the study after week 5 (due to an elevation in AST-levels), 
values measured at the end of week 5 were included instead of values measured at the end of week 6; bmean ± sd (all 
such values); cmedian; 25th, 75th percentiles in parentheses (all such values); dfor Lp(a), values for one subject was 
slightly below the detection limit of 7 nmol/l and set to 7.0 for the calculations. Abbreviations: BMI= body mass 
index; HOMA= Homeostasis Model Assessment index; mmHg=mm of mercury column; LDL= low density 
lipoprotein; HDL= high density lipoprotein; Lp(a)= lipoprotein; CRP= C-reactive protein; AST= aspartate 
aminotransferase; ALT= alanine aminotransferase; γ-GT= gamma-glutamyl-transferase 
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4.1 Abstract 
 
For ileocolon-targeted delivery systems of niacin, a precise release profile is desired. 
Therefore, shellac coated niacin microcapsules were evaluated regarding the robustness of the 
release profile in the ileocolonic region in vitro and in vivo. The effects of storage and various 
simulated gastrointestinal conditions were analyzed by using a dissolution tester. 
Furthermore, the in vivo pharmacokinetic curves of nicotinamide (NAM) were characterized 
from 10 healthy human volunteers regarding the release mechanism and interindividual 
variation.  
The results showed a high robustness of the release profile in vitro for varying gastrointestinal 
conditions. Gastric resistance was given in simulated fasted (pH 1.4) and fed state (pH 4.5) 
for at least 2 h. A reduced simulated pH value in the ileocolonic region also indicated a 
sufficient release in vitro (80 – 100 % after 26 h). Despite higher variations for encapsulated 
than for the free NAM (reference dose) in vivo, a delayed absorption time (tmax: 1 vs. 4 h) was 
obtained for all individuals indicating a precise release in the target region. Furthermore, the 
ileocolon-targeted NAM formulation resulted in decreased Cmax (1,322.7 vs. 19,690.0 µg/l) 
and AUC levels (4,207.15 vs. 17,334.20), when compared to the same reference dose. The 
profile indicated a slow diffusion driven release of NAM from the microcapsules over a 
longer period, resulting in a low systemic availability.  
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4.2 Introduction 
In recent years, there has been a growing interest in the prevention of diseases and the 
maintenance of a well-being status using alternative and more natural approaches with regard 
to pharmacologic therapies (Santini et al., 2017). Obesity and its comorbidities are a major 
problem in industrialized countries, with growing incidence also in the developing countries 
(Friedman, 2009). In the recent past, several studies showed an association between the 
composition of the gut microbiome and obesity (Bäckhed et al., 2004; Le Chatelier et al., 
2013; Ley et al., 2006). Therefore, a nutraceutical with a targeted impact on the gut 
microbiome could be beneficial for preventing obesity and comorbidities. In a previous study, 
the bioavailability of a colon-targeted nutraceutical formulation comprising the water-soluble 
vitamin niacin with its two active forms nicotinic acid (NA) and nicotinamide (NAM) was 
evaluated. We confirmed the targeted release of shellac coated NA and NAM in the 
ileocolonic region in vitro and in vivo, which is necessary to influence the gut microbiota. The 
intake of the microencapsulated NA led to favourable changes of the gut microbiome and an 
associated improvement of biomarkers for systemic insulin sensitivity and metabolic 
inflammation in healthy subjects. NAM, however, did not induced these changes (Fangmann 
et al., 2018). In a mouse model it was shown that the intake of NAM is capable to positively 
regulate the gut microbiota, the production of antimicrobial peptides and the propensity of 
inflammation (Hashimoto et al., 2012).  
However, when developing controlled delivery systems, it is important that they meet several 
requirements: targeted release in desired region of the gastrointestinal tract, reproducibility of 
the release profile and batch-to-batch reproducibility as well as stability of the release profile 
over a longer period of time (Dressman et al., 1998; Pearnchob et al., 2003). In vivo genetic 
variations, ethnic background and states of diseases mainly influence interindividual 
variabilities, whereby intraindividual variability is a result of circadian rhythm, stress and 
physical activity level as well as food ingestion. These individual differences affect for 
example the composition of gastrointestinal fluids regarding the buffer capacity, enzyme and 
surfactant concentration, volume, residence time and pH value (Dressman et al., 1998; Ibekwe 
et al., 2008; Nugent et al., 2001; Russell et al., 1993; Shani-Levi et al., 2017). The fasted and 
fed state in humans is strongly influencing the pH value of the gastric fluid, resulting in pH 
values from 1.3 to 5.0 (Dressman et al., 1990; Russell et al., 1993). However, Feldman and 
Barnett also reported that the basal gastric pH value (fasted state) can increase up to 6.8 in 
healthy subjects (Feldman and Barnett, 1991). In addition, drugs, such as proton pump 
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inhibitors, were found to increase the gastric pH value (Peghini et al., 1998). Furthermore, 
depending on meal size the gastric residence time of small pellets can increase to 125 – 141 
min (Clarke et al., 1993; Davis et al., 1984). Physiological measured pH values in the target 
area of the distal small bowel are ranging from 6.5 to 8.0 (Dressman et al., 1998; Evans et al., 
1988; Gruber et al., 1987; Ibekwe et al., 2008). Furthermore, when reaching the ascending 
colon, always a decreasing pH value of approximately 6.4/6.5 is observed (Evans et al., 1988; 
Ibekwe et al., 2008), due to short-chain fatty acids, which are produced by microbial 
fermentation (Macfarlane et al., 1992). In addition, diseases such as inflammatory bowel 
disease (IBD) can lead to a reduced be reduced intraluminal pH value in the colon (Nugent et 
al., 2001). All these pH value and residence time variations can influence the release from 
shellac coated niacin pellets. 
The aim of the present study was to characterize the robustness of the release profile of 
shellac coated NA and NAM pellets with a colon-targeted release. Firstly, the reproducibility 
and stability of the formulation was examined. Further physiological conditions were 
simulated by in vitro dissolution tests with altered pH values and residence time in fluids. 
Finally, intra- and interindividual variation were evaluated.   
 
4.3 Materials and Methods 
4.3.1 Materials 
Nicotinic acid (NA) and nicotinamide (NAM) were purchased from SternVitamin 
(Ahrensburg, Germany). Shellac solution (SSB Aquagold) was obtained from Stroever 
Schellack Bremen (Bremen, Germany). Microcrystalline pelletized cellulose (Cellets®350) 
was obtained from iPc Process Center (Dresden, Germany). Citric acid monohydrate was 
obtained from Jungbunzlauer (Basel, Switzerland) and sodium bicarbonate was purchased 
from Dr. August Oetker (Bielefeld, Germany). As a binder hydroxypropylmethylcellulose 
(HPMC) (AnyAddy®) was obtained from Harke Group (Mülheim an der Ruhr, Germany) and 
pea starch (Lycoat™ RS 780) was from Roquette (Lestrem, France). Other used chemicals 
were purchased from Carl Roth (Karlsruhe, Germany).  
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4.3.2 Methods 
4.3.2.1 Preparation of the coating solutions 
All coating solutions were dissolved and stirred at room temperature. The coating 
compositions are listed in Table 4.1. The same batch of every substance was used for the 
production of NA and NAM pellets.  
Table 4.1: Composition of the coating solutions of the investigated pellet formulations [in % 
w/w] 
Coating Ingredient 1 [%] Ingredient 2 [%] Ingredient 3 [%] Water 
[%] 
Nicotinic acid Nicotinic 
acid 
9.3 HPMC 0.7 - - 90 
Citric acid 
subcoat 
Citric acid 1 Maltodextrin 9 - - 90 
Sodium 
bicarbonate 
subcoat 
 
Sodium 
bicarbonate 
2.33 Lycoat RS 
780 
4.65 Glycerol 0.023 93 
Shellac  SSB 
Aquagold 
60 - - - - 40 
 
4.3.2.2 Production of NA pellets 
The production of the microcapsules was the same as described by Fangmann et al. 
(Fangmann et al., 2018). However, a more detailed description is the following: First, the 
nicotinic acid was applied to 175 g Cellets in a Mini Glatt fluid bed coater (Glatt, Binzen, 
Germany) with bottom spray using a 0.5 mm two-way nozzle, an atomizing air pressure of 0.6 
bar, an inlet air pressure of 0.4 bar and a spraying rate of 1.2 g/min. Inlet air temperature was 
set to 39 °C, which resulted in a product temperature of about 32.4 °C. The final weight gain 
(w.g.) was about 16 %. During the application of the NA-coating, the coating solution was 
continuously stirred. Afterwards, an inner shellac coating (2 % w.g.), a sodium bicarbonate 
subcoating (1 % w.g. referred to sodium bicarbonate) and an outer shellac coating (20 % w.g.) 
was applied to 200 g vitamin coated Cellets. The atomizing air pressure was set to 0.6 – 0.7 
bar, the inlet air pressure to 0.35 bar, a product temperature of about 33.7 °C and the spraying 
rate was increased from 0.43 – 0.87 g/min, except for the subcoating with 0.57 g/min. After 
the last coating step, the pellets were dried at 50 °C in a drying oven for 1 h.  
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4.3.2.3 Production of NAM pellets 
As mentioned above, the production of NAM pellets is also described by Fangmann et al. 
(Fangmann et al., 2018). First, vitamin cores, consisting of 96 % NAM and 4 % HPMC as a 
binder, were produced from an extern company using a ProCell fluidized bed granulator with 
Vario 3 (Glatt Ingenieurtechnik, Weimar, Germany). Afterwards an inner shellac coating 
(50 % w.g), a citric acid subcoating (1 % w.g. referred to citric acid) and an outer shellac 
coating (10 % w.g.) were applied to 150 g NAM-cores (315 – 400 µm). The conditions for the 
two shellac coatings were similar to the shellac coatings of NA pellets. For the application of 
the citric acid, a higher product temperature of about 36 °C and a lower spray rate of 0.58 
g/min were chosen. After the inner and the outer shellac coating, the pellets were dried at 50 
°C in a drying oven for 1 h. 
 
4.3.2.4 In vitro dissolution test  
All in vitro drug release studies were carried out using a standard dissolution paddle apparatus 
at 100 rpm and 37 °C (DT 70, Pharmatest Group, Hainburg, Germany). Each experiment was 
conducted in triplicate with 0.5 g of pellets in 250 ml of the dissolution medium. During the 
experiments, the amount of released NA or NAM was recorded by UV/vis spectrophotometer 
(Helios γ, Thermo Fisher Scientific, Waltham, USA) at the wavelength of 262 nm.  
As dissolution media were used the following: Simulated gastric fluid (pH 1.4) was adjusted 
to USP gastric fluid without pepsin (U.S. Pharmacopeial Convention, 2005), citrate buffer 
(pH 4.5) was modified according to (Gomori, 1955) and phosphate buffer (pH 6.8 and 7.4) 
was prepared according Soerensen’s buffer. A detailed composition of the buffers is shown in 
Manuscript III (in submission).  
To calculate the percentage of released vitamin, the maximum NA or NAM amount was 
determined by stirring (100 rpm) 0.5 g of NA or NAM pellets in 250 ml phosphate buffer at 
pH 7.4 for 1.5 h at 37 °C in the above-mentioned dissolution tester. The niacin concentration 
of the solution corresponded to 100 % niacin release.  
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4.3.2.5 Reproducibility and stability of the in vitro dissolution profile of NA and NAM 
pellets 
The general in vitro profile to check the reproducibility and stability of NA and NAM pellets 
was conducted as described in previous studies (Fangmann et al., 2018; Manuscript III, in 
submission). Briefly, 1h at pH value 1.4; 0.5 h at pH value 4.5; 2h at pH value 6.8 and 1.5 h at 
pH value 7.4.  
For stability tests, NA and NAM pellets were stored in a drying oven at 20 °C with a relative 
humidity (r. h.) of 31 % for a period of 24 months. The first year, every three months and 
afterwards every 6 months, an in vitro dissolution test was examined. After 18 months, a part 
of the stored NA and NAM pellets was transferred to a yoghurt cup and stored in a fridge (4 
°C; r. h.: 47 %) for six or eight weeks. The in vitro dissolution profile was checked after 1, 2, 
4, 6 (and 8) weeks of storage.  
 
4.3.2.6 Robustness of the in vitro dissolution of NA and NAM pellets in varied gastric 
conditions 
Gastric resistance of NA and NAM pellets under varied conditions was conducted for 2 h in 
pH value 1.4, 4.5 and 6.8 under the same conditions as described above.  
 
4.3.2.7 Robustness of the in vitro dissolution of NA and NAM pellets in varied conditions 
of the target region (ileum/colon) 
The elevated dissolution profiles started with 1 h pH value 1.4 and 0.5 h pH value 4.5. After 
2 h in phosphate buffer at pH value 6.8 either the exposition was elevated for 22.5 h or the 
pellets were transferred to another vessel filled with phosphate buffer at pH value 7.0 for 
22.5 h. These experiments were conducted in triplicate instead of the elevated profile to pH 
value 7.0, which was a single measurement.  
 
4.3.2.8 Scanning electron microscope pictures 
After the elevated dissolution profile at pH 6.8, NA and NAM pellets were separated from the 
dissolution medium and dried in a desiccator over night. Afterwards microcapsules were 
prepared on a holder with carbon Leit-tabs (Plano GmbH, Wetzlar, Germany). Some of them 
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were cut using a scalpel. Before examination in a Hitachi S-4800 (Hitachi High Tech., Tokyo, 
Japan) scanning electron microscope (SEM) at an accelerating voltage of 3 kV, microcapsules 
were sputter-coated with a layer of 8-10 nm gold-palladium using a Leica EM SCD 500 
(Leica Microsystems GmbH, Wetzlar, Germany) high-vacuum sputter coater.  
 
4.3.2.9 In vivo bioavailability study  
The bioavailability study was examined according to Fangmann et al. (2018). Ten subjects 
received either NA or NAM in its free form (30 or 900 mg) and in its encapsulated form with 
increasing doses (NA: 30, 150 and 300 mg; NAM: 900, 1500 and 3000 mg). For 8 hours 
every hour and after 10 and 12 h blood samples were taken to be determined by the 
concentration of NA and NAM in serum. A detailed description is given by Fangmann et al. 
(Fangmann et al., 2018).  
 
In order to calculate the half-life (t1/2) the following equations were used. ke is the elimination 
constant. Whereby Cmax is defined as the highest measured NAM concentration and C12 as the 
reached NAM concentration after 12 h. Δt is the difference of the time between Cmax and C12 
in h. It was assumed that the elimination follows a first order kinetic. Half-life was calculated 
for every subjects. Afterwards the results were presented as mean. 
𝑡1
2
=
ln(2)
𝑘𝑒
                                          𝑘𝑒 =  
ln 𝐶𝑚𝑎𝑥 − ln𝐶12
∆𝑡
 
 
4.3.2.10 Statistical analysis 
Statistical analyses were performed using SPSS version 24.0 for windows (SPPS, Chicago, 
IL; USA). GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA) was used 
for graphic data analyses and calculation of area under the curves (AUCs), in order to 
evaluate total uptake of niacin. If serum levels after 12 hours were not matching baseline 
serum levels (for 3000 mg dose), NAM serum level curves were extrapolated by means of 
trend lines in Excel version 2010 (Excel, Microsoft cooperation, Redmond, WA, USA). Data 
are presented as means ± SD (standard deviation). Saphiro-Wilk-test was used to determine 
deviations from normal distribution and according to distribution Spearman correlation 
analysis was performed. The half-life was analysed by ordinary one-way ANOVA with Tukey 
multiple comparison test and a significance level of 0.05 using GraphPad Prism Software. 
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4.4 Results and Discussion 
To evaluate the precision of the site-specific release of the encapsulated niacin, 1.) the 
reproducibility, 2.) the robustness and stability of the release profile, 3.) the release 
mechanism and 4.) the interindividual variation were determined in in vitro and in vivo 
studies.  
4.4.1 Reproducibility and stability of in vitro dissolution profile 
The in vivo validity of the in vitro release profile was confirmed in a previous study 
(Fangmann et al., 2018). NA pellets were produced in duplicate and caused similar release 
profiles (Figure 4.1A). Four NAM batches showed differences of about 9.4 percentage points 
after 120 minutes and 6.62 percentage points after 210 minutes (Figure 4.1B). These minor 
variations are in accordance with the results of Pearnchob et al., who described a good 
conformity between different trials of a shellac coating (Pearnchob et al., 2003). 
The stability of the mixture of all trials of NA and NAM pellets at 20 °C and 4 °C is shown in 
Figure 4.2.  At a storage temperature of 20 °C, the stability was examined for a period of 24 
months (Figure 4.2A+B). With increasing storage time the vitamin release was reduced 
especially after 18 and 24 months to 15.9 % and 18.3 %. Directly after the coating process, 
34.3 % NAM were released at pH value 6.8 after 210 min and after 3, 6 and 9 months the 
release of NAM was 31.4 %, 29.6 % and 33.0 %. Similar results were obtained regarding NA 
pellets. After 210 min at pH value 6.8, the release rate decreased from 5.6 % (after coating) to 
2.6 %, 3.5 %, 3.2 %, 3.2 %, 0.9 % and 1.2 % after 3, 6, 9, 12, 18  and 24 months of storage, 
respectively. The reduced release of NA and NAM is related to changes of the shellac coating. 
Stability tests of the vitamins themselves, showed no differences in the absorbance profile and 
intensity. Furthermore, the total vitamin content was similar compared to the beginning of the 
production process (data not shown).  
Figure 4.2C+D show the stability of the release profile for NA and NAM at a lower 
temperature (4 °C). NAM pellets were stable for up to eight weeks with no changing release 
rates. NA pellets were only stable for two weeks. After four weeks, the release rate at pH 
value 1.4, 4.5 and 6.8 was increased. At the end of week six, about 90 % of NA was released 
immediately at pH value 1.4 after 30 min. 
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Figure 4.1: Reproducibility of (A) NA and (B) NAM release from triple coated pellets with the 
same batch but different trials. All results are given as mean ± SD (n=2). NA = nicotinic 
acid; NAM = nicotinamide 
 
Figure 4.2: Stability of (A+C) NA pellets and (B+D) NAM pellets after storage (A+B) at 20 
°C for up to 24 months and after storage (C+D) at 4 °C for up to 8 weeks. All results are 
given as mean ± SD (A+B: n=3; C+D: n=2). 
 
The observed instability of shellac coatings during storage is explained by polymerization via 
esterification of the large amount of hydroxyl and carboxyl groups of the shellac components 
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(Farag and Leopold, 2009; Limmatvapirat et al., 2005; Limmatvapirat et al., 2007). 
Ammonium salt shellac is described to be more stable compared to the ethanolic shellac 
(Limmatvapirat et al., 2005), however, Limmatvapirat et al. also detected an increase of 
insoluble solids (about 25 %) of the ammonium salt form of shellac at pH value 7.0 after 3 
months of storage at 40 °C and 75 % RH. After 6 months, the amount of insoluble solids 
increased to about 50 % (Limmatvapirat et al., 2007). Pearnchob et al. also documented the 
release stability of shellac coated pellets after 6 months of storage. They demonstrated that the 
release kinetics only showed slight changes (Pearnchob et al., 2003). However, they used 
triethyl citrate as plasticizer, which also influences the stability and the amount of insoluble 
solids. Whereas, depending on the used plasticizer, hydrogen bonding between the active sites 
of shellac reduce the polymerization of shellac (Luangtana-Anan et al., 2010). Additionally to 
the reduced solubility of shellac at higher pH values with increasing storage time, it is also 
described, that shellac can lose its gastric resistance during storage (Farag and Leopold, 
2009). This observation was not confirmed in the present study, where the stability was 
investigated at a storage temperature of 20 °C for 24 months. However, at a storage 
temperature of 4 °C, NA pellets lost their gastric resistance. This may be attributed to the 
influence of the sodium bicarbonate subcoating in case of NA pellets. As described in detail 
in manuscript III (in submission), sodium bicarbonate led to an increase of the released 
compound due to an enhancement of the intrinsic pH value and the production of CO2 in 
combination with moisture. The relative humidity was higher at +4 °C (47 %) compared to 31 
% at +20 °C. The higher relative humidity of 47 % could lead to a partial dissolution of the 
sodium bicarbonate, which enhances the solubility of shellac and results in a premature 
release. 
 
4.4.2 Robustness of the in vitro dissolution profile of NA and NAM pellets under 
varied gastrointestinal conditions 
To study the robustness of the in vitro release profile, NA- and NAM pellets were subjected to 
simulated fluids of the gastric and ileocolonic region representing different gastrointestinal 
conditions. 
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Stomach conditions 
The release profile was evaluated in simulated gastric fluids representing fasted and fed state 
at pH values of 1.4 and 4.5 for 2 h (Figure 4.3). Both formulations were stable at a pH value 
of 1.4 and 4.5 (Figure 4.3A+B). The release was below 10 % after an exposition for 2 h. At 
pH value 4.5, the release of NA or NAM (3.6 % and 2.3 %) was only minimal higher 
compared to pH value 1.4 (2.5 % and 0.5 %). These results are in accordance with Czarnocka 
and Alhnan, who showed no significant release of a shellac-alginate formulation during pH 
value 2, 3 and 4 for 2 h (Czarnocka and Alhnan, 2015). Thus, a high robustness of NA and 
NAM pellets is given under varying gastric conditions. Furthermore, robustness for a longer 
gastric residence time than previously tested by Fangmann et al., was observed. They 
simulated the gastric phase with only one hour (Fangmann et al., 2018), due to the ability of 
pellets smaller than 2 mm to pass the pylorus independently of gastric emptying (Davis et al., 
1987).  
 
Figure 4.3: In vitro release of (A) NA and (B) NAM in pH 1.4 and 4.5 for 2h. All results are 
given as mean ± SD (n=3). 
 
As shown in Figure 4.4, the dissolution profile at pH value 6.8 differed completely compared 
to a pH value of 1.4 and 4.5. At pH value 6.8, about 83 % NA and 53 % NAM were released 
after 60 minutes; an increase to 97 % and 94 % was documented after 120 minutes, 
respectively. These results indicated no delayed release, if a pH value of 6.8 occurs in gastric 
lumen. This would lead to a total absorption of NA and NAM in the stomach and the upper 
small intestine, which would not affect the gut microbiota. 
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Figure 4.4: In vitro release of (A) NA and (B) NAM in pH 6.8 for 2 h. All results are given as 
mean ± SD (n=3). 
 
Target area of the ileum/colon 
The conditions in the target area, ileum and colon, in the gastrointestinal tract were varied as 
it is important, that a high amount of NA and/or NAM is available for gut microbiota. 
Therefore, an adjusted in vitro release profile was chosen in order to predict the release of NA 
and NAM under lower pH values of 6.8 and 7.0 (Figure 4.5). Both formulations released only 
minor amounts of NA (1.4 %) and NAM (0.5 %) during the first 90 min. Whereby, NA was 
released very slowly at a pH value of 6.8 (3.1 % after 210 min), 33.2 % NAM was liberated 
after 210 min. Afterwards, the pellets were exposed either to a pH value of 7.0 or were left at 
pH value 6.8 for 22.5 h. At pH value 6.8, the release increased slowly to 11 % NA after 420 
min in total. Finally, an entire release was achieved. In contrast to NA pellets, a complete 
release was not achieved during the whole exposure time of 26 h. The maximum release was 
82.8 % NAM. A higher final pH value of 7.0 led to a faster release. The complete NA and 
NAM concentration was liberated after 260 – 420 min (Figure 4.5). Differences between NA 
and NAM pellets can be explained due to differences in their physicochemical properties, 
their different production method and the use of different subcoatings. All of the mentioned 
parameters are influencing the dissolution profile. The citric acid subcoating in case of NAM 
pellets will be the factor, which is responsible for the incomplete release of NAM at pH value 
6.8 (Manuscript III, in submission).  
In general, it can be noticed that the lower the pH value the slower the release rate of NA and 
NAM due to a decrease of the coating swelling, which leads to a reduced diffusion capacity. 
After a total residence time of 300 min, 5.8 % and 45.4 % NA were released at a pH value of 
6.8 and 7.0, respectively. NAM pellets released 43.2 % and 75.4 % NAM at pH value 6.8 and 
7.0 after 300 min. The results of Fangmann et al. showed a release of about 95 % NA or 
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NAM after 300 min with an end pH value of 7.4. However, although the release of NA and 
NAM was slowed down with decreasing pH values, the long residence time in the colon 
should lead to a sufficient release in the targeted region. The human colon transit time can 
vary between 8 – 72 h (Kararli, 1995) with an average of about 36 h (Lesmes and 
McClements, 2009). Small pellets resulted in a longer transit time of 28 h compared to single 
unit dosages (15 h) (Abrahamsson et al., 1996). Therefore, a dissolution method with an 
elongation for 26 h in total was chosen, which is comparable to other in vitro colon 
simulations (Krishnamachari et al., 2007; Stein et al., 2011). It is documented that pellets are 
slowly transferred during the ascending colon, because of intensive mixing (Davis et al., 
1984). Abrahamsson et al. observed a storage of administered pellets for up to 14 h after oral 
intake in the ascending colon and up to 48 h in the transversum. Regarding the in vitro profile 
of the present study (Figure 4.5), during this time a release of about 50 % NA and 60 % 
NAM at pH value 6.8 is expected. At a pH value of 7.0, a total release of NA occurred already 
after 6.5 h, whereby a total release of NAM after 18 h is expected to occur in the region of the 
ascending/transversal colon. 
 
 
Figure 4.5: In vitro release of (A) NA and (B) NAM with elevated exposure at pH 6.8 or 7.0 
after 1h at pH 1.4, 0.5 h at pH 4.5 (and 2 h at pH 6.8). All results are given as mean ± SD (pH 
6.8: n=3; pH 7.0: n=1). 
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Structural properties of the pellets 
As demonstrated in microscope (Figure 4.6A+G) and SEM pictures (Figure 4.6B+H), most 
of the capsules were intact after the in vitro digestion for 26 h at an end pH value of 6.8. Open 
NAM pellets were empty and the intact Cellet was found in the NA capsule (Figure 4.6C+I). 
The structure of the cross section of the remaining shellac coating showed a spongy and 
porous structure in both microcapsules (Figure 4.6D+J). In contrast to NA pellets, the outer 
areas of the shellac coating of NAM pellets were less perforated than the middle area. This 
could be explained due to the thicker coating layer of NAM pellets and also due to the 
sustaining property of the citric acid subcoating (Manuscript III, in submission). In addition, 
intact NAM pellets showed only a few pores on the surface and some of them were still 
including a small NAM core (Figure 4.6E+F). These cores may be attributed to the lower in 
vitro release after 26 h. NA was totally released from NA pellets and additionally the surface 
of closed microcapsules was rough and porous (Figure 4.6K+L). It is suspected that the 
swelling and perforation of the shellac coating led to a penetration of the surrounding fluid, 
dissolution of the encapsulated compound and finally to a diffusion driven release of the 
vitamin, which is also confirmed by the concentration dependent slope of the in vitro curve 
after reaching a pH value of 6.8. In addition, both, NA and NAM have a low molecular 
weight of 123.11 and 122.13 g/mol and are moderately or highly water-soluble (15 g/l and 
691 g/l), which enables an easy diffusion (Huang and Brazel, 2001).  
 
 
Figure 4.6: Light microscope pictures (A+G) and SEM pictures (B-F and H-L) of dried NAM 
pellets (top) and NA pellets (bottom) after 26 h in vitro dissolution as shown in figure 4.4 with 
a final pH of 6.8. A,B,G,H: overview of pellets; C+I: open pellet; D+J: cross-section of open 
pellet; E+K: intact pellet; F+L: surface of intact pellet 
 
Furthermore, the results of the elongated dissolution profile show differences compared to the 
results as illustrated in Figure 4.4. A significant difference was observed in the release rate at 
pH value 6.8 with or without previous contact to a lower pH value. Whereby the pellets, 
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which were exposed directly to a pH value of 6.8 showed an almost complete release after 
2 h, pellets, which were first added to pH value 1.4 and 4.5 resulted in a (very) slow release 
rate at pH value 6.8 after 2 h (up to 6 % NA and 34 % NAM). This effect was also 
documented for a tablet coating with Eudragit L30 D-55, which is also a pH dependent 
coating material that dissolves above a pH value of 4 – 6 It was suggested, that the penetration 
of acid delays the dissolution of the polymer and therefore the release. With increasing 
exposure time in gastric fluids, the subsequent release rate at higher pH values was decreasing 
(Menge, 2016). Thus, it is suggested, that only minor amounts of NA or NAM are released at 
pH 6.8, when the pellets were previously exposed to gastric fluids with a lower pH value. 
 
4.4.3 Dissolution mechanism and the bioavailability of NAM 
A diffusion driven in vivo release of NAM is also hypothesized with regard to the curve 
characteristics measured in the human bioavailability study (Figure 4.7). The same dose of 
microencapsulated NAM compared to the free administered NAM resulted in a significantly 
delayed absorption (tmax: 4 vs. 1 h) without sharp peak and lower AUC levels (4,207.15 vs. 
17,334.20), which could be related to low absorption rates due to a slowed release from the 
microcapsules and therefore to lower NAM levels in the gut lumen. Furthermore, as shown in 
Figure 4.8, the half-life (t1/2) is slightly enhanced from 1.4 h for free NAM to 1.8 h for 
encapsulated NAM (900 and 1500 mg dose), although this effect was not statistically 
significant (p=0.4531). In comparison to NA, the half-life of NAM is much longer, both in the 
liver and the blood of rats (1.0 h vs. 5.3 h) (Petrack et al., 1966). In humans, 1 g of 
administered NAM resulted in a comparable half-life of about 1.7 h, in a dose-dependent 
manner. The higher the administered amount of NAM the higher the half-life (Stratford et al., 
1992). In the present study, the half-life tended to increase for the encapsulated form despite 
the lower systemic NAM levels. This finding strengthen the hypothesis that NAM is released 
from shellac coated microcapsules over a longer period in the distal intestine, which results in 
absorption over a longer period and thus enhances the half-life. Furthermore, tmax increased 
from 900 to 3000 mg encapsulated NAM (Table 4.2). This result confirms a retarded release 
of NAM within the first 3 – 4 h i.e. low uptake in the small intestine. Afterwards, NAM is 
liberated slowly, whereby the release occurred over a longer period of time resulting in an 
accumulation of NAM and a shift in tmax. In comparison, colon-targeted pharmaceutical 
formulations such as guar gum-based 5-fluorouracil or flurbiprofen tablets for the treatment of 
colon cancer or colon inflammation, showed a higher tmax and increased AUC levels for their 
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encapsulated drug compared to the free form. This indicated a high systemic availability 
despite the delayed release. Higher AUC levels were attributed to a slowly absorption of the 
drugs in the colon due to less surface area. Furthermore, they detected a sharp absorption peak 
which was related to an erosion based release after guar gum degradation by microbial 
enzymes (Krishnaiah et al., 2003; Vemula and Bontha, 2013). These results support the 
hypothesized mechanism for a diffusion driven release of NAM from the present 
microcapsules in vivo. In addition, the in vitro release of NA and NAM from shellac coated 
microcapsules is mainly driven by diffusion, when the pH value did not exceed a pH value of 
7.3. After reaching a pH value of 7.4, a combination of diffusion and erosion processes is 
suggested, due to a fast dissolution of the shellac itself. The reduced affinity to NAM carriers 
in the colon (Km= 2.5 ± 0.8 µM) (Kumar et al., 2013) compared to the small intestine (Km= 
0.53 ± 0.08 µM) (Nabokina et al., 2005), will also affect the systemic availability and results 
in lower tmax concentrations and AUC levels.  
The presented SEM pictures of shellac shells after in vitro digestion showed a spongy 
structure similar to the structure of the digested capsules by Fangmann et al. This indicate a 
similar pH value for in vitro and in vivo, e.g. between 6.8 and 7.3 (Fangmann et al., 2018). 
Some capsules from the stool samples were completely open, which can be related to shear 
stress under in vivo digestion compared to in vitro. Intense muscle contractions, a higher 
viscosity and pressure in the lumen of the human lower intestine can affect the integrity of the 
capsules (Takaya et al., 1998), whereas in vitro the low viscosity of the aqueous solution 
causes lower shear stress during mixing. 
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Figure 4.7: Pharmacokinetic curves after the administration of (A) 900 mg free NAM as 
reference dose, (B) 900 mg encapsulated NAM, (C) 1500 mg encapsulated NAM and (D) 
3000 mg encapsulated NAM (mean ± SD, n=10). 
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Figure 4.8: Half-life (t1/2) of NAM after administration of 900 mg free, 900 mg and 1500 mg  
encapsulated NAM  
 
  
Table 4.2: tmax after oral administration of free or microencapsulated (enc.) nicotinamide 
(NAM) 
subjects tmax 900 mg 
free NAM [h] 
tmax 900 mg 
enc. NAM [h] 
tmax 1500 mg 
enc. NAM [h] 
tmax 3000 mg 
enc. NAM [h] 
S1 1 4 4 6 
S2 1 4 5 7 
S3 1 4 4 7 
S4 1 4 6 5 
S5 1 4 5 7 
S6 1 3 5 8 
S7 1 4 4 6 
S8 1 4 4 7 
S9 1 4 4 7 
S10 1 3 4 5 
Mean 1 3.8 4.5 6.5 
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4.4.4 Robustness of NAM microcapsules in vivo  
As summarized in Table 4.3, the human bioavailability study indicated higher variabilities of 
serum NAM level after oral administration of encapsulated niacin compared to the reference 
free dose. The coefficient of variation increased with increasing dose. This result indicated 
that the release of NAM is strongly influenced by individual variations, which is enhanced for 
higher doses. To determine the robustness of the NAM release from microcapsules in vivo, 
the reproducibility of the main release area (referred to tmax) and the dose-dependent increase 
of Cmax and AUC within the subjects were evaluated. No significant correlations of the AUC 
levels (p=0.098) or Cmax (p=0.206) within the subjects was found between the 1500 mg and 
the 3000 mg NAM dose (Figure 4.9A+B). Only, 30.4 % of the variation in AUC and 19.2 % 
of the variation in Cmax is determined by the dose increase from 1500 to 3000 mg NAM. The 
high variation is mostly dependent on intra- and interindividual fluctuations. Thus, the subject 
with the highest AUC or Cmax at 1500 mg NAM has not the highest levels after 3000 mg 
NAM. These effects are additionally illustrated in Figure 4.9C+D. Despite individual 
variabilities in Cmax and AUC, tmax showed a maximal variability of 3 h between the subjects 
(Table 4.2). Thus, a robust targeted release in the desired region of the ileocolon is proposed, 
which is also related to the use of a multiparticular dosage form. The risk of loss of the 
functionality of the coating is significantly reduced compared to a single unit dosage form like 
tablets (Srivastava and Mishra, 2010; Wesdyk et al., 1990). Furthermore, small pellets are not 
dependent from gastric emptying, which is the most influencing factor of the gastrointestinal 
transit time, and therefore are less influenced by fasted or fed state (Clarke et al., 1993; Davis 
et al., 1987; Dressman et al., 1998; Ibekwe et al., 2008; Malagelada et al., 1984). 
 
Table 4.3: Overview of the variations in AUC levels of NAM group 
AUC mean ± SD Coefficient of variation [%] 
900 free 78,334.20 ± 19,538.11 24.94 
900 enc. 4,287.15 ± 2,571.91 59.99 
1500 enc. 21,011.90 ± 17,616.94 83.84 
3000 enc. 135,748.20 ± 105,826.64 77.96 
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Figure 4.9: Interindividual variations within the NAM group (A) correlation of AUC levels 
between 1500 mg and 3000 mg encapsulated NAM; (B) correlation of Cmax between 1500 mg 
and 3000 mg encapsulated NAM; (C) AUC levels of single probands after administration of 
1500 mg and 3000 mg NAM; (D) Cmax of single probands after administration of 1500 mg and 
3000 mg NAM 
 
4.5 Conclusion 
A high robustness of the coating process as well as the release profile of the colon-targeted 
developed NA and NAM pellets (Fangmann et al., 2018) was given under different varied 
gastrointestinal conditions in vivo and in vitro.  
The coating process of NA and NAM pellets with ileocolon-targeted delivery resulted in a 
good reproducibility. Gastric resistance is maintained for up to 24 months at 20 °C storage 
conditions, whereby the intestinal release was slightly reduced with increasing storage time. 
Targeted release characteristics of shellac coated NA and NAM pellets are provided for a 
storage at 20 °C for up to 12 months. Storage of 4 °C with a relative humidity of 47 % 
resulted in a loss of gastric resistance for NA after 4 weeks. NAM pellets were intact after 
eight weeks of storage at 4 °C.  
Manuscript II: Precision of in vitro and in vivo shellac coated niacin release 
83 
 
In vitro, both formulations showed gastric resistance at elevated pH values up to 4.5, 
corresponding to a fed status of the stomach in vitro. Even unexpected lower pH values than 
described for the targeted region still resulted in a sufficient release of NA and NAM, 
especially in combination with a prolonged transit time.  
The in vivo serum levels of NAM resulted in high variations in Cmax and AUC levels after the 
administration of microencapsulated NAM due to intra- and interindividual variations. The 
time of release and absorption, however, was relatively robust and occurred in the human 
ileocolonic region.  
Both, the in vitro and the in vivo results proposed a diffusion driven release of NAM from the 
capsules. 
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5.1 Abstract 
Formulations for the controlled release of substances in the human terminal ileum and colon 
are essential to target the gut microbiome and its interactions with the intestinal mucosa. In 
contrast to pharmaceutical enteric coatings, reliable food-grade alternatives are still scarce. 
Shellac coatings have been used for various active ingredients, but their stability is affected by 
the physicochemical properties of the encapsulated substances. It is well known, that shellac 
release can be modulated by an acidic subcoating. Here, we hypothesized that a triple shellac 
coating with an adjusted intermediate coating (acidic or alkaline) can be effectively used to 
counteract the differences in pH value of various encapsulated substances, allowing a precise 
targeting of the desired release pH value. First, the system was tested with riboflavin 5’-
monophosphate sodium salt dihydrate (RMSD) as a characteristic model substance. Secondly, 
it was transferred to nicotinic acid (NA) and nicotinamide (NAM) as bioactive compounds 
with different physicochemical properties: NAM, an alkaline crystalline and highly water-
soluble substance, led to a premature release from conventional shellac microcapsules, 
whereas RMSD and NA with their medium solubility and neutral to acidic pH properties 
delayed the shellac dissolution. A precise modulation of the release profile of each substance 
was possible by the addition of different intermediate subcoatings: an acidic layer with citric 
acid counteracted the premature release of the alkaline and highly soluble NAM. In contrast, 
an alkaline sodium bicarbonate intermediate subcoating enhanced shellac swelling and 
delayed the release of NA and RMSD. In conclusion, the novel triple-layer shellac coating 
provides a much higher adaptability and reliability for nutritional formulations aiming at a 
targeted release in the ileocolonic region. 
 
Keywords 
enteric coating; fluidized-bed; shellac; subcoat; targeted release; colon 
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5.2 Introduction 
The development of formulations targeting the (ileo)colonic region is gaining increasing 
interest because recent studies showed many correlations between the gut microbiome, 
nutrition and health. Nutritional compounds were found to achieve a health-promoting effect 
due to their direct influence on the microorganism composition in the lower intestine 
(Albenberg and Wu, 2014; Kau et al., 2011; Vos et al., 2010; Vos and Vos, 2012). We have 
recently shown that NA and NAM have beneficial effects on the host-microbiome interaction, 
particularly when they are administered with a targeted release in the ileocolonic region of 
mice and humans. NA results in an increase in Bacteroidetes in the microbiota profile and 
improves the markers for insulin sensitivity. NAM, on the other hand, is proposed to be a key 
regulator of the gut microbiota and of the propensity to inflammation (Fangmann et al., 2018; 
Hashimoto et al., 2012; Waetzig and Seegert, 2013). Simply increasing the content of NA or 
NAM in food would lead to a nearly total absorption in the upper gastrointestinal tract. 
Therefore, a nutritional encapsulation with an (ileo-)colon-targeted delivery mechanism is 
necessary to avoid a systemic uptake of the bioactive compound before reaching the 
ileocolonic region to ensure a high bioavailability of NA or NAM for the microbiome and the 
intestinal mucosa. The leading technology to protect bioactive compounds from the 
gastrointestinal environment is the application of an enteric coating as a protective layer 
(Czarnocka and Alhnan, 2015). The coating material needs to resist the acidic environment 
during the residence time in the stomach and small intestine. Suitable coating materials for 
oral colonic delivery are subject to various mechanisms that differ between the small intestine 
and the colon to ensure dissolution or erosion of the coating layer in the targeted region. 
Common examples are enzymatic-degradable, pH-sensitive, pressure-sensitive or time-
dependent film coatings (Maroni et al., 2013). Commonly used materials are pH-dependent 
methacrylic acid copolymers such as Eudragit® or Eudraguard biotic®. The advantage of 
these synthetic polymers is a high batch-to-batch consistency. However, they can only be 
administered for pharmaceutical or solid nutraceutical products. For an application in foods, 
shellac can be used due to its legislation as food additive. Shellac is a purified resin from the 
lac insect Laccifer Lacca, which lives on trees mainly in India and Thailand. Shellac has a 
relatively high dissolution pH value of about 7.3, which allows a targeted release in the lower 
intestine (Buch et al., 2009; Farag and Leopold, 2011a; Limmatvapirat et al., 2007; Roda et 
al., 2007). The major disadvantages of a natural polymer such as shellac are the variability of 
the raw material and the loss of gastric resistance combined with a decreased solubility in 
intestinal fluids with increased storage time due to polymerization (Farag and Leopold, 2009). 
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However, shellac films from aqueous ammoniacal solutions show a good long-term stability 
(Limmatvapirat et al., 2005; Pearnchob et al., 2003), which supports its application as food 
coating material with ileocolon targeting properties. The high dissolution pH value of shellac 
implements that the human ileum can reach pH values of >7.3, which was verified in studies 
of (Evans et al., 1988; Ibekwe et al., 2008), despite lower pH values were also identified 
similar to the upper intestine (>pH 6.5) (Dressmann et al., 1998; Gruber et al., 1987). Further, 
a lack of free water in the lower intestine can result in an incomplete dissolution and drug 
release in the desired region (Schiller et al., 2005). However, our previous work showed a 
precise release of NAM in the ileocolonic region in vivo in 10 human study subjects by using 
the triple shellac coating and the in vitro profiles as demonstrated in the present manuscript  
(Fangmann et al., 2018).  
Targeted release formulations based on pH-dependent coatings triggering a local release are 
commonly used (Khan et al., 1999; Liu et al., 2009; Liu et al., 2010; Liu and Basit, 2010; 
Roda et al., 2007; Varum et al., 2013). Partially neutralised Eudragit® S as inner coat and 
standard Eudragit® S result in an accelerated and precise release in the ileocolonic region due 
to simultaneous dissolution from its inner and outer surface (Liu et al., 2010; Varum et al., 
2013).  Regarding shellac, Farag and Leopold (Farag and Leopold, 2011a) developed 
sustained release pellets by using citric acid as subcoating to decrease the intrinsic pH value, 
when water penetrates the outer shellac coating (Farag and Leopold, 2011a). However, it is 
known that the properties of the encapsulated compound may also affect its rate of release 
(Menge, 2016; Ozturk et al., 1988; Ragnarsson et al., 1992; Sousa et al., 2002a). Following 
this, the subcoating has to be adjusted to the physicochemical characteristics of the 
microencapsulated compounds in order to precisely modulate the release profile. 
The aim of the present study was therefore to provide an ileocolon targeted shellac 
formulation optimized for the release of three representative compounds by controlling the 
effect of the encapsulated compound on shellac by using individual adapted coating 
formulations. The influence of the encapsulated substance and a double shellac coating with a 
pH-modulating intermediate subcoating (i.e., triple layer coating) on the release profile was 
investigated and the interplay between the three applied coating layers was examined with 
regard to a targeted release. First, RMSD was analysed as a commonly used model substance 
to simulate the in vitro-dissolution of coating formulations (Bajpai and Sharma, 2005; Guo et 
al., 2002; Li et al., 2013; Pajander et al., 2008). Second, the effect of the encapsulated 
compound on the transferability from a model system was evaluated regarding the 
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development of NA and NAM shellac coated microcapsules with a desired ileocolonic release 
profile. All three compounds (RMSD, NA and NAM) are hydrophilic, but differ in their 
properties such as acidity, water solubility and physical form. 
 
5.3 Materials and methods 
5.3.1 Materials 
NA and NAM were purchased from SternVitamin (Ahrensburg, Germany), and RMSD was 
from Sigma-Aldrich (Taufkirchen, Germany). Shellac solution (SSB Aquagold) was obtained 
from Stroever Schellack Bremen (Bremen, Germany). Microcrystalline pelletized cellulose 
(Cellets®350) was obtained from iPc Process Center (Dresden, Germany). Citric acid 
monohydrate was purchased from Jungbunzlauer (Basel, Switzerland), and sodium 
bicarbonate was from Dr. August Oetker (Bielefeld, Germany). The binders 
hydroxypropylmethylcellulose (HPMC) (AnyAddy®) and pea starch (Lycoat™ RS 780) were 
obtained from Harke Group (Mülheim an der Ruhr, Germany) and from Roquette (Lestrem, 
France). All other chemicals were purchased from Carl Roth (Karlsruhe, Germany).  
 
5.3.2 Methods 
5.3.2.1 Preparation of coating solutions 
For the preparation of the coating solutions, the excipients were blended with a binder: HPMC 
for coating NA or NAM microcapsules, and Lycoat for all intermediate subcoatings and the 
coating of RMSD microcapsules. After blending, the mixtures were dissolved at room 
temperature under moderate stirring in water using a magnetic stirrer. The composition of 
each formulation is listed in Table 5.1. 
Table 5.1: Composition of the coating solutions for the investigated microcapsule 
formulations [in % w/w] 
coating layer active 
ingredient 
[%] binder [%] plasticizer [%] water [%] 
NA NA 9.3 HPMC 0.7 - - 90 
NAM NAM 9.3 HPMC 0.7 - - 90 
RMSD RMSD 2.33 Lycoat RS 780 4.65 Glycerol 0.023 93 
Citric acid subcoat Citric acid 2.33 Lycoat RS 780 4.65 Glycerol 0.023 93 
Sodium 
bicarbonate 
subcoat 
Sodium 
bicarbonate 
2.33 Lycoat RS 780 4.65 Glycerol 0.023 93 
Shellac  SSB 
Aquagold 
 
60 - - - - 40 
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5.3.2.2 Production of microcapsules 
A schematic view of all coated microcapsules is shown in Figure 5.1 and will be described in 
the following section. All formulations investigated in this study are summarized in 
Table  5.2.   
 
Figure 5.1: Schematic overview of the coated microcapsules 
 
5.3.2.2.1 Production of RMSD microcapsules 
The RMSD solution was applied to Cellets in a Mini Glatt fluidized bed coater (Glatt GmbH, 
Binzen, Germany) with bottom spray using a 0.5-mm two-way nozzle. An atomizing air 
pressure of 0.5–0.6 bar, an inlet air pressure of 0.3–0.4 bar and a spraying rate of about 
0.6 g/min were used. Inlet air temperature was set to 40–45°C, which resulted in a product 
temperature of 33.1–35.0°C. The weight gain (w.g.) of RMSD was calculated to be 2%, 
whereby the total w.g. including pea starch as binder was 6% (see Table 5.2). Afterwards, the 
inner shellac coating, the intermediate coating sodium bicarbonate, and the outer shellac 
coating were applied to RMSD coated Cellets under the same conditions as described above 
with a product temperature of about 33°C (Table 5.2). For the administration of the 
intermediate subcoating, pea starch was also used as binder (Table 5.1). In the following 
sections, only the w.g. of the modulating substance is stated. Finally, the microcapsules were 
dried in an oven at 50°C for 1 h. 
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Table 5.2: Composition of the investigated microcapsule formulations (w.g. = weight gain) 
Formulation Vitamin 
coating 
[%w.g.]  Inner 
shellac 
coating 
[%w.g.] 
Subcoating [%w.g.] Outer 
shellac 
coating 
[%w.g.] 
1 RMSD 2 0 Sodium bicarbonate/Lycoat 0/0 20 
2 RMSD 2 2 Sodium bicarbonate/Lycoat 0.5/1.0 20 
3 RMSD 2 2 Sodium bicarbonate/Lycoat 1.0/2.0 20 
4 RMSD 2 2 Sodium bicarbonate/Lycoat 1.5/3.0 20 
5 RMSD 2 2 Sodium bicarbonate/Lycoat 1.7/3.4 20 
6 RMSD 2 2 Sodium bicarbonate/Lycoat 2.0/4.0 20 
7 NA 10 0 Sodium bicarbonate/Lycoat 0/0 20 
8 NA 10 2 Sodium bicarbonate/Lycoat 0/1.5 20 
9 NA 10 2 Sodium bicarbonate/Lycoat 0.5/1.0 20 
10 NA 10 2 Sodium bicarbonate/Lycoat 1.0/2.0 20 
11 NA 10 2 Sodium bicarbonate/Lycoat 1.2/2.4 20 
12 NA 10 2 Sodium bicarbonate/Lycoat 1.5/3.0 20 
13 NA 10 2 Sodium bicarbonate/Lycoat 2.0/4.0 20 
14 NAM 10 0 Citric acid/Lycoat 0/0 20 
15 NAM 10 2 Citric acid/Lycoat 0/6.0 20 
16 NAM 10 2 Citric acid/Lycoat 1.0/2.0 20 
17 NAM 10 2 Citric acid/Lycoat 2.0/4.0 20 
18 NAM 10 2 Citric acid/Lycoat 4.0/8.0 20 
19 NAM 10 2 Citric acid/Lycoat 2.0/4.0 25 
20 NAM 10 10 Citric acid/Lycoat 2.0/4.0 25 
  
 
5.3.2.2.2 Production of NA and NAM microcapsules 
First, the NA or NAM layer was applied to 195 g of Cellets in a Mini Glatt fluidized bed 
coater with bottom spray using a 0.5 mm two-way nozzle. An atomizing air pressure of 0.6 
bar, an inlet air pressure of 0.35–0.4 bar and a spraying rate of 0.7–1.2 g/min were used. The 
inlet air temperature was set to 39–42°C, which resulted in a product temperature of 32.4–
33.4°C. During the application of the NA coating, the coating solution was continuously 
stirred. The final w.g. was about 10%. Afterwards, the inner shellac coating was applied to 
100 g of NA- or NAM-coated Cellets under the same conditions. In the next step, the 
intermediate subcoating, including the pH-modulating substances sodium bicarbonate (NA 
microcapsules) or citric acid (NAM microcapsules), was applied to 90 g of Cellets coated 
with NA or NAM, respectively. In the following text, only the calculated w.g. of the 
modulating substance is stated. The intermediate subcoating with 0% sodium bicarbonate or 
citric acid acts as a blank subcoating without modulating substance and is comparable to the 
formulation with 0.5% sodium bicarbonate for NA microcapsules and with 2% citric acid for 
NAM microcapsules. Finally, the outer shellac coating was applied to 80 g of Cellets coated 
with NA or NAM, inner shellac coating and pH-modulating intermediate subcoating under the 
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same conditions as used for the inner shellac coating. All formulations are summarized in 
Table 5.2. After the last coating step, the microcapsules were dried at 50°C in a drying oven 
for 1 h. 
 
5.3.2.3 Characterization of the encapsulated compounds and shellac-coated 
microcapsules 
 
5.3.2.3.1 pH values of the encapsulated compounds 
For the characterization of the encapsulated compounds, their pH value was measured in 
solution (demineralized water) at room temperature using a pH meter (inoLab_IDS, 
Multi9420, WTW GmbH, Weilheim, Germany). The concentration of the measured solutions 
corresponds to the concentration in the coating solution (Table 5.1).  
 
5.3.2.3.2 Physical form of the encapsulated compound 
For measuring the physical form of the encapsulated compounds, differential scanning 
calorimetry (DSC) was used. First, dissolved RMSD, NA and NAM were separately spray-
dried in a Mini Glatt fluidized bed coater to get the same physical form as during coating on 
the cellulose core. The spray-drying conditions were as followed: inlet air pressure: 0.3 bar; 
atomizing air pressure: 0.6 bar; product temperature: about 34°C; spraying rate: 0.75–1.2 
g/min. Afterwards, the spray-dried substances were removed from the vessel walls and filters. 
About 4 mg of the powder were weighed and sealed in hermetic aluminum pans. Three 
samples of each substance were measured under nitrogen atmosphere by DSC (Q2000, TA 
Instruments, New Castle, DE, USA). The initial temperature was set to 20°C, afterwards a 
ramp up to 200°C (or 300°C in the case of NA) was programmed with an increase rate of 20 
K/min. Glass transition temperatures, melting and crystallization peaks were determined using 
the TA Instruments software Universal Analysis 2000. The equipment was calibrated with 
indium. The baseline was generated without a pan. 
 
5.3.2.3.3 Optical characteristics of coated microcapsules 
 
To get a further insight into the structure of RMSD, NA and NAM coated microcapsules, 
scanning electron microscope (SEM) images were taken. For this purpose, microcapsules 
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were prepared on a holder with carbon Leit-Tabs (Plano GmbH, Wetzlar, Germany). Before 
examination in a Hitachi S-4800 SEM (Hitachi High Tech, Tokyo, Japan) at an accelerating 
voltage of 3 kV, microcapsules were sputter-coated with a layer of 8–10 nm gold-palladium 
using a Leica EM SCD 500 high-vacuum sputter coater (Leica Microsystems GmbH, Wetzlar, 
Germany). 
 
5.3.2.3.4 Calculation of coating thickness 
For calculation of the coating thickness, the particle size of coated and non-coated Cellets was 
determined by laser diffraction (Horiba LA-950V2, Retsch Technology GmbH, Haan, 
Germany). To get comparable results, RMSD, NA and NAM microcapsules with the 
following coating weight gains were measured: 2% w.g. from the inner shellac coating; 1% 
w.g. from the sodium bicarbonate or citric acid in the intermediate layer; 20% w.g. from outer 
shellac coating. The measurements were performed using the dry feeder with vacuum-driven 
forced ejection, a vibration power alteration of 120 and a compressed air pressure of 0.3 MPa. 
Refractive indices were the following: cellulose: 1.63, shellac: 1.52, NA: 1.49 and NAM: 
1.47. All samples were measured in triplicate. Afterwards the increase in particle diameter 
and radius were calculated to obtain the total coating thickness. 
 
5.3.2.4 Dissolution of shellac-coated microcapsules 
In vitro dissolution tests were carried out in duplicate at 37°C with 0.5 g of NA or NAM 
microcapsules or 1 g of RMSD microcapsules in 250 ml simulated gastrointestinal fluids 
using a paddle apparatus at 100 rpm (Model DT 70, Pharmatest Group, Hainburg, Germany). 
Dissolution tests were run for 1 h at pH 1.4 to simulate fasted gastric conditions, 0.5 h at pH 
4.5 (citrate or acetate buffer), 2 h at pH 6.8 and 1.5 h at pH 7.4 (Soerensen phosphate buffers) 
(Fangmann et al., 2018; Theismann et al., 2019). The pH of 4.5 was used to simulate the 
transfer from a fed gastric to the duodenal passage, whereby the phosphate buffers simulated 
the distal parts of the small intestine. Previous results showed that citrate and acetate buffer 
only differed in handling and not in influencing the release rate (data not shown). For buffer 
exchanges, microcapsules were retrieved by filtration using paper filters, and microcapsules 
were transferred to the next buffer. The release was recorded at 30 min intervals using a 
UV/vis spectrophotometer (Helios gamma, Thermo Fisher Scientific, Waltham, MA, USA) at 
a wavelength of 262 nm for NA or NAM and at 445.5 nm for RMSD using 1 x 1 cm quartz 
cuvettes. In order to calculate the percentage of released compound, the total amount of 
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RMSD, NA and NAM or in coated microcapsules was determined at a pH of 7.4 after 30 min 
(full release) and set to 100%.  
According to the definition of the USP, gastric resistance is achieved if less than 10% is 
released during 2 h in 0.1 N HCl (pH 1.2) (Tarcha, 1991). In the present study, gastric 
resistance was defined as less than 10% release after passing a pH value of 1.4 for 60 min and 
a pH value of 4.5 for 30 min. The reduction of exposition time and the increased pH value 
was chosen because of the ability of microcapsules (< 2 mm) to pass the pylorus independent 
of gastric emptying (Davis et al., 1987). 
 
5.3.2.5 Characterization of the swelling properties of shellac 
In order to evaluate the swelling of the shellac coating, the microcapsules (n=3) were 
analyzed in the above-mentioned buffers using a transmitted light microscope (Meade 
Instruments Europe GmbH, Kempten, Germany) in combination with an electronic eyepiece 
(MikroOkular-II, Bresser GmbH, Rhede, Germany). Every 5 min, an image was taken at a 
magnification of 100x. 
 
5.4 Results 
5.4.1 RMSD microcapsules 
5.4.1.1 Physico-chemical properties of RMSD microcapsules 
RMSD was chosen as a widely used reference compound to modulate its in vitro dissolution 
profile. Regarding coating and dissolution processes, RMSD showed a moderate water 
solubility and a pH value of 6.2 in aqueous solution (2.3 % (w/w)) (Table 5.3). Figure 5.2A 
shows that RMSD was present in an amorphous form with a glass transition temperature of 
81.0 ± 0.86°C. An exothermic DSC peak occurred at 128.6 ± 1.36 °C, followed by an 
endothermic irregular signal. In combination with pea starch as binder, RMSD coated on 
Cellets resulted in a smooth surface, which was optimal for a subsequent uniform enteric 
coating (Figure 5.2B). 
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Figure 5.2: Characterization of RMSD. (A) DSC thermogram of spray dried RMSD. Arrows 
indicate the glass transition and the recrystallization peak. (B) SEM images of the surface of 
RMSD-coated Cellets. 
 
5.4.1.2 In vitro release profile modulation of RMSD microcapsules 
For modulation of the release profile of RMSD, single shellac-coated (20% w.g.) RMSD 
microcapsules were dissolved in vitro (Figure 5.3A). Gastric resistance was given. At pH 
value 6.8, 10% were released after 210 min. Reaching a pH value of 7.4 resulted in a RMSD 
release of 78.6%. To enhance the RMSD release, especially at pH 6.8, which is related to an 
ileocolonic release as shown by (Fangmann et al., 2018), a triple coating formulation, 
consisting of an inner and outer shellac coating and an intermediate sodium bicarbonate 
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coating, was applied. As shown in Figure 5.3B, the addition of sodium bicarbonate led to an 
earlier and increased release at pH 6.8 compared to the release without intermediate 
subcoating. The application of 0.5 or 1% sodium bicarbonate resulted in a release of 24% or 
20% RMSD after 210 min, respectively, despite gastric resistance. Applications of 1.5–2.0% 
sodium bicarbonate led to a loss of the gastric resistance.  
 
5.4.1.3 Cross section and coating thickness of RMSD microcapsules 
As shown in Figure 5.3C, the coating layers (RMSD, inner shellac, sodium bicarbonate, and 
outer shellac layer) were clearly distinguishable by SEM. The coating thickness of every layer 
was calculated based on the cross section: approximately 5.0, 1.5, 1.0, and 18.0 µm for 
RMSD, inner, intermediate and outer coating layers, respectively. 
 
 
Figure 5.3: In vitro release profile and cross sections of shellac-coated RMSD 
microcapsules. (A) RMSD microcapsule coated with a single shellac coating (20% weight 
gain (w.g.)). (B) RMSD microcapsules coated with an inner shellac coating (2% w.g.), a 
sodium bicarbonate intermediate subcoating (0.5–2.0% w.g.) and an outer shellac coating 
(20% w.g.). All results are shown as mean ± standard deviation (n=2). (C) Representative 
SEM image of a cross section of an RMSD microcapsule consisting of (a) Cellet core, (b) 
RMSD (2% w.g.), (c) inner shellac (2% w.g.), (d) sodium bicarbonate (0.5% w.g.), and (e) 
outer shellac layer (20% w.g.) 
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5.4.2 NA and NAM microcapsules 
5.4.2.1 Physico-chemical properties of NA and NAM microcapsules 
In contrast to RMSD, NA and NAM were chosen because of their beneficial effect on the 
intestinal microbiome (Fangmann et al., 2018; Hashimoto et al., 2012; Waetzig and Seegert, 
2013). Although NA and NAM have some biological functions in common, they differ in 
their physico-chemical properties (Table 5.3). DSC results (Figure 5.4A) indicated that most 
of the NA existed in its crystalline form. Two endothermic peaks were observed at 182.7 ± 
0.00°C and at 236.4 ± 0.08°C. The weak endothermic peak was a solid-to-solid 
transformation, whereas the second peak represented the melting point of NA. However, we 
also measured a glass transition temperature at 275.6 ± 0.42°C. Due to the peak height, the 
main part of NA appears to be present in its crystalline form. NAM only existed in its 
crystalline form with a melting point of 129.8 ± 0.31°C (Figure 5.4A). The surface of NA 
after coating on Cellets, as determined by SEM, showed some crystalline irregularities, but 
appeared predominantly smooth (Figure 5.4B). In contrast, the NAM-coated surface showed 
many cavities and irregularities (Figure 5.4C). The physico-chemical properties of RMSD, 
NA and NAM are summarized in Table 5.3. 
 
Table 5.3: Comparison of the physico-chemical properties of the compounds RMSD, NA and 
NAM 
 RMSD NA NAM 
pH 6.2 (2.3% w/w) 3.4 (9.3% w/w) 6.2 (9.3% w/w) 
pKa1 - 4.85 3.3 
pKa (strongest acid)2 -  2.79 13.39 
Water solubility (g/l)1 50 10-15 1000 
Glass transition temperature 
(DSC) (°C) 
81.0 ± 0.86 275.6 ± 0.42 - 
Melting temperature (DSC) 
(°C) 
> 130 182.7 ± 0.00 
236.4 ± 0.08 
129.8 ± 0.31 
Recrystallization temperature 
(DSC) (°C) 
128.6 ± 1.36 - - 
Surface (SEM) Smooth Moderate irregularities Cavities/irregularities 
1 (ChemBook) 2 (HMDB) 
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Figure 5.4: Characterization of NA and NAM. (A) DSC thermogram of spray dried NA 
(green) and NAM (red) .The arrows indicate the melting peaks and the glass transition. (B, C) 
SEM images of the surface of a NA-coated (B) or NAM-coated Cellet (C). 
 
5.4.2.2 In vitro release profile modulation of NA and NAM microcapsules 
Figure 5.5A+B shows the in vitro release profiles of NA and NAM microcapsules coated 
with a single shellac layer. NA microcapsules with a single shellac coating showed a very 
slow release: until a pH of 7.4 was reached (Figure 5.5A). In contrast, NAM microcapsules 
with a single shellac layer did not show gastric resistance (Figure 5.5B). In order to modulate 
the release profile of NA and NAM, different intermediate subcoatings based on sodium 
bicarbonate or citric acid were tested: for NA, sodium bicarbonate was chosen as a pH-
modulating substance in the intermediate subcoating because of its effects on the release 
profile of RMSD (Figure 5.3B). As expected, the incorporation of a sodium bicarbonate 
subcoating dose-dependently increased NA release (Figure 5.5C). The objective of 20–40 % 
release after 210 min was achieved using 1.2% sodium bicarbonate. In contrast to RMSD, 1.5 
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and 2.0% sodium bicarbonate already led to a loss of gastric resistance (Figure 5.5C). In 
addition, the results show that the earlier and enhanced release was due to sodium bicarbonate 
itself and not to the intermediate subcoating and the resulting diffusion barrier in general 
(control: 0% sodium bicarbonate). In the case of NAM, citric acid was used to aim for a 
reduced and delayed release (Figure 5.5D). After 210 min, the control intermediate 
subcoating without citric acid (0%) led to a NAM release of 58%, the addition of 1.0%, 2.0%, 
or 4.0% citric acid resulted in a reduced release. The control intermediate subcoating with 0% 
citric acid demonstrated that the effect was mainly triggered by citric acid, but indicated that 
the subcoating and the added diffusion barrier itself may also play a role. Gastric resistance 
was only obtained with 4.0% citric acid in the intermediate subcoating, although it was only 
marginally acceptable with 10% NAM release at pH 4.5 after 90 min. 
In addition to the variation of the intermediate pH-modulating subcoating, the thickness of the 
inner shellac coating can also be modified to adapt the release profile to the desired site and 
time course (Figure 5.5E). Increasing the inner shellac subcoating layer from 2% w.g. to 10% 
w.g. in combination with 2% citric acid in the pH-modulating subcoating and an outer shellac 
coating with 25 % w.g. reduced the NAM release from 31% to 21% after 210 min (Figure 
5.5E). Furthermore, gastric resistance was achieved. Previous results showed that a pH-
independent inner layer, such as maltodextrin, did not provide sufficient separation and 
resulted in a higher release compared to shellac (data not shown).  
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Figure 5.5: In vitro release profiles of shellac-coated NA and NAM microcapsules. (A) NA 
microcapsules coated with a single shellac layer (20% w.g.). (B) NAM microcapsules coated 
with a single shellac layer (20% w.g.). (C) NA microcapsules coated with an inner shellac 
coating (2% w.g.), a sodium bicarbonate intermediate subcoating (0.0–2.0% w.g.) and an 
outer shellac coating (20% w.g.). (D) NAM microcapsules coated with an inner shellac 
coating (2% w.g.), a citric acid intermediate subcoating (0.0–4.0% w.g.) and an outer shellac 
coating (20% w.g.). (E) NAM microcapsules coated with an inner shellac coating (2 or 10% 
w.g.), a citric acid intermediate subcoating (2.0% w.g.) and an outer shellac coating (25% 
w.g.). All results are shown as mean ± standard deviation (n=2). 
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5.4.2.3 Cross section and coating thickness of NA and NAM coated microcapsules 
An SEM cross section of a NA-coated microcapsule is shown in Figure 5.6A, showing four 
clearly distinguishable layers and the Cellet core. The sodium bicarbonate layer is seen as a 
small layer punctured by holes. The NA layer also shows some cracks. The indicated layer 
thicknesses based on the cross section were about 10, 2, 1.5 and 16.5 µm for the NA, inner, 
intermediate and outer coating, respectively. A similar total coating thickness of NA 
microcapsules was measured by laser diffraction: 25.59 ± 1.5 µm (1 % w.g. of sodium 
bicarbonate in the intermediate subcoating). The SEM cross section of NAM (Figure 5.6B) 
differed strongly from cross sections of RMSD (Figure 5.3C) and NA microcapsules 
(Figure 5.6A), as only two different types of layers were detectable. The outer layer had a 
thickness of about 19 µm. In total, a coating thickness of about 31 µm was indicated from 
SEM cross sections (including 4% w.g. of citric acid in the intermediate subcoating). The 
laser diffraction method calculated a total thickness of 23.26 ± 0.11 µm (1 % w.g. of citric 
acid in the intermediate subcoating).  
 
Figure 5.6: (A) SEM image of cross section of a NA microcapsule consisting of (a) inner 
Cellet, (b) NA (10% w.g.), (c) inner shellac (2% w.g.), (d) sodium bicarbonate (1.2% w.g.), 
(e) outer shellac coating (20% w.g.). (B) SEM image of cross section of a NAM microcapsule 
consisting of (a) inner Cellet, (b) NAM (10% w.g.), (c) inner shellac (2% w.g.), (d) citric acid 
(4% w.g.), (e) outer shellac coating (20% w.g.). 
 
5.4.3 Effects of the encapsulated compounds and subcoatings on the swelling 
properties of shellac 
In order to investigate the effects of the encapsulated substances and the chosen pH-
modulating intermediate subcoatings on the swelling properties of shellac, light microscopy 
images were taken using the different buffers with pH values of 1.4, 4.5, 6.8 and 7.4 also 
employed for the release profiles. 
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Due to the known effects of the encapsulated compounds on the release profiles (Ozturk et al., 
1988; Ragnarsson et al., 1992), the swelling behaviour of the single shellac coating of RMSD, 
NA and NAM microcapsules was analyzed. Figure 5.7 shows microscope images of shellac-
coated RMSD, NA and NAM microcapsules after 0, 15 and 30 min at pH 7.4. Cellets coated 
with NA and shellac (Figure 5.7A) exhibited only a slight swelling after 15 and 30 min. In 
contrast, RMSD and NAM microcapsules (Figure 5.7B+C) showed a clearly enhanced 
swelling after 15 min and an indication of the dissolution of the shellac coating after 30 min. 
According to these results, an influence of the encapsulated compound on the release profile 
was assumed, as NA appeared to inhibit the swelling of the shellac coating, whereas RMSD 
and NAM seemed to enhance it.  
 
Figure 5.7: Light microscope images showing the effect of (A) encapsulated RMSD, (B) 
encapsulated NA, (C) encapsulated NAM on the swelling of a single shellac coating (20% 
w.g.) at pH 7.4 after 0, 15 and 30 min (100x magnification). 
 
In Figure 5.8, the effect of the intermediate subcoating with sodium bicarbonate is shown. In 
Figure 5.8 A-C, CO2 bubbles arising from NA microcapsules with 1.2%, 1.5% or 2.0% w.g. 
of sodium bicarbonate at pH 6.8 are evident after 2–5 min. In the case of encapsulated RMSD 
with 2.0% w.g. of sodium bicarbonate in the intermediate subcoating (Figure 5.8D+E), 
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bubbles were not observed, although local swellings appeared, followed by swelling of the 
whole shellac coating after 2 and 3 min.  
 
Figure 5.8: Light microscope images showing the effect of sodium bicarbonate intermediate 
subcoatings at pH 6.8. (A-C) NA microcapsules with (A) 1.2% w.g. sodium bicarbonate, (B) 
1.5% w.g. sodium bicarbonate, or (C) 2.0% w.g. sodium bicarbonate. (D, E) RMSD 
microcapsules with 2.0% w.g. sodium bicarbonate after 2 and 3 min, respectively (100x 
magnification). 
 
The contrary effect was observed, when citric acid was used in the intermediate subcoating to 
reduce the fast NAM release (Figure 5.9). No or only minimal swelling of citric acid-coated 
NAM microcapsules was observed at pH 7.0 or 7.4, whereas microcapsules without an 
intermediate subcoating or microcapsules with a subcoating without citric acid increased 
significantly in their diameter due to swelling of shellac (Figure 5.9). Moreover the swelling 
of the shellac at pH 7.4 was stronger than at pH 7.0. 
 
Figure 5.9: Light microscope images showing the effect of citric acid as a pH-modulating 
substance in the intermediate subcoating on the swelling properties of NAM double shellac-
coated microcapsules at (A) pH 7.0 and (B) pH 7.4 after 30 min (100x magnification). 
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5.5 Discussion 
To improve the precision of shellac coatings for targeted release in the ileocolonic region, the 
interactions between the coating and various encapsulated compounds were investigated. For 
this purpose, a triple coating with two shellac layers and intermediate pH-modulating 
subcoating was developed. The intermediate layer should control the effects of the 
encapsulated substance. To the best of our knowledge, this formulation concept is novel 
(PCT/EP2017/058733 and PCT/EP2017/058741) and adds important new options to the 
toolbox of fully nutritional controlled-release coatings. 
 
5.5.1 Effect of physico-chemical properties of the encapsulated compounds on the 
release profiles 
The attempt to transfer the coating processes tested for RMSD microcapsules to NA and 
NAM microcapsules showed the dependence of the release profile on the compound to be 
encapsulated. A completely different release profile was observed for NAM microcapsules 
(Figure 5.5A) than for NA (Figure 5.5B). NA and NAM have different solubility, acidity and 
coating quality (Table 5.3). While it is known that several properties of the encapsulated 
compound can influence the solution profile, including particle size, solubility and pKa  
(Menge, 2016; Ozturk et al., 1988; Ragnarsson et al., 1992),  we found that the pH value of 
the encapsulated substance has a significant modulating influence on the pH-sensitive shellac 
coating. At pH values below the pKa of shellac, its carboxyl groups are protonated, which 
results in an insoluble coating and hinders the release of the encapsulated compound. As the 
pH of the surrounding medium increases, carboxyl groups dissociate, promoting water 
penetration and swelling of the coating material (Farag and Leopold, 2011a; Henning et al., 
2012; Penning, 1996). The swelling of shellac at pH 6.8 is known. This behaviour promotes 
the dissolution of an applied subcoating or the encapsulated substance itself, which in turn 
influences the dissociation of shellac and the release of the substance (Farag and Leopold, 
2011a). The pH value in aqueous solutions of NA is 3.44, which is lower than the pH values 
of NAM (pH 6.23) or RMSD solutions (pH 6.19). The lower pH value of NA could therefore 
delay the dissociation and dissolution of shellac. In contrast, the higher pH value of NAM and 
RMSD could lead to an increased intrinsic pH value, an earlier dissolution and a stronger 
swelling of shellac above pH 6.8 compared to NA. This was confirmed by the microscopic 
analyses shown in Figure 5.7. The faster and stronger swelling of the outer shellac coating 
could lead to a faster dissolution of the encapsulated substance and thus to a diffusion-related 
release at pH 6.8. At pH 7.4, shellac generally dissolves and a burst release occurs (Farag and 
Paper III: Controlling the interactions of coating and bioactive compound 
108 
 
Leopold, 2011a; Qussi and Suess, 2005). In contrast to NAM, NA and RMSD microcapsules 
showed gastric resistance. Normally, shellac is insoluble at gastric conditions due to 
protonated carboxyl groups. However, small amounts of acid water can penetrate shellac, 
especially if it is present in its ammonium salt form, as in the present study (Hagenmaier and 
Shaw, 1991; Pearnchob et al., 2004). In consequence, an interaction between NAM and 
shellac during the coating and dissolution process is plausible, which could be related to the 
higher water solubility of NAM (1000 g/l) compared to RMSD (50 g/l) or NA (15 g/l). The 
higher the water solubility of the encapsulated compound, the lower the mean dissolution time 
or lag time (with only a few exceptions) (Ozturk et al., 1988; Ragnarsson et al., 1992; Sousa 
et al., 2002a). Aqueous coating solutions can dissolve the drug during the process, resulting in 
the formation of channels in the outer coating (Guo et al., 2002; Heinämäki et al., 1994). The 
highly soluble NAM is probably more susceptible to this than NA and RMSD, although 
obvious external channels in the outer shellac coating could not be observed in the SEM (data 
not shown). A high amount of dissolved drug could also induce an increased osmotic influx 
rate of water and subsequently lead to a higher expansion of the coating and a premature 
release of encapsulated substance (Ragnarsson et al., 1992). Little irregularities or small pores 
in the coating can accelerate the release process (Bruce et al., 2003; Förmer et al., 2006; 
Henning et al., 2012; Phan The et al., 2008). These coating irregularities can be caused by the 
microcapsule shape or surface characteristics (Chopra et al., 2002). The shape of the 
microcapsules used in the present study was equally spherical due to the inert spherical Cellet 
core. Interestingly, the NAM layer (but not the NA or RMSD layers) exhibited a porous and 
uneven structure. The porosity of microcapsules affects the substance release profile, which is 
inversely related: The higher the porosity, the shorter the average dissolution time. Possible 
explanations could be the altered ability of an additional coating to adhere to the underlying 
surface, the incorporation of abraded particles from the surface during the coating process due 
to increased brittleness, or the unevenly distributed final coating due to increased surface 
roughness (Chopra et al., 2002; Sousa et al., 2002b; Tunón et al., 2003). 
DSC measurements reflect the thermal behaviour of spray-dried compounds and provide 
information on their physical form, which in the present study could be related to the surface 
properties of the RMSD, NA and NAM layers. As shown in Table 5.3, RMSD and NA were 
partially present in their amorphous or semicrystalline form, while NAM was only present in 
crystalline state. This could be responsible for the rough surface of NAM-coated Cellets. NA 
also showed a solid-to-solid transformation and a melting point of the crystalline form, which 
is in accordance with other reports (Wang et al., 2004). RMSD was recrystallized after 
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exceeding the glass transition temperature, which is typically seen for amorphous or 
semicrystalline substances (Liu et al., 1997; Mano et al., 2004). The resulting melting signal 
illustrated irregularities that may occur as a result of overlapping melt and decomposition 
peaks. Different physical characteristics have different effects on coating quality and release 
rate. The crystallinity of NAM can lead to crystal defects, which can also affect coating 
properties such as surface roughness (Murr and Inal, 1979): Penetration of the applied coating 
material into pores of the substance layer is possible if the penetration time exceeds the 
spreading time. This is the case when porosity and pore size in the substance layer increase, 
resulting in loss of coating material and reduced coating yields (Kennedy and Niebergall, 
1996; Werner et al., 2007). The pores of the NAM microcapsule surface can thus lead to 
incorporation of shellac during the coating process, which could influence the gastric 
protection properties of shellac (Chopra et al., 2002; Guo et al., 2002; Heinämäki et al., 1994; 
Tunón et al., 2003). Indeed, the cross section of NAM microcapsules showed no clear 
separation of the four administrated layers (NAM, inner shellac, citric acid, outer shellac 
coating) compared to the RMSD and NA microcapsules, which suggests an interaction of 
NAM and the shellac coating. One possibility to reduce the porous structure of NAM layers is 
the heightening of the binder level (Sinchaipanid et al., 2004).  
 
5.5.2 Effect of sodium bicarbonate on the release profile of RMSD and NA 
The combination of sodium bicarbonate as an intermediate subcoating and shellac was used in 
the present study in order to counteract the slow dissolution of shellac at pH 6.8. A beginning 
release at pH 6.8 showed a low systemic availability and a high availability in the (ileo-
)colonic region (Fangmann et al., 2018). Furthermore, pH values of lower than 7.3 can exist 
in the human gut (Dressmann et al., 1998; Gruber et al., 1987), which makes a controlled 
release at a pH value of about 6.8 advantageous. The results confirmed that the application of 
such a subcoating adapts the release profile of the encapsulated compounds to the different 
requirements. In all experiments, the pH-modulating subcoating with sodium bicarbonate led 
to an earlier release of RMSD and NA. The observed effects of the selected intermediate 
subcoating substances on the release profile could be explained by the altered intrinsic pH 
value and the dissolution behaviour of shellac (Farag and Leopold, 2011a). Above pH 6 and 
below the dissolution pH of 7.3, shellac swells and water penetrates into the microcapsule 
where it can dissolve the subcoating material (Limmatvapirat et al., 2004; Limmatvapirat et 
al., 2007). Thus, the strongest effect of an intermediate subcoating is assumed to take place at 
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pH 6.8. Sodium bicarbonate and water are generating hydroxide ions (HCO3- + H2O ↔ H2O + 
CO2 + OH-), which result in a pH of about 7.9 (2.5 g/50 ml) (pka=10.329). As a result, sodium 
bicarbonate leads to a local increase in pH and thus to accelerated shellac dissociation. 
Furthermore, the production of CO2 could also lead to an earlier release of the encapsulated 
compound, as the gastric juice resistance was suddenly lost above a critical amount of sodium 
bicarbonate used (i.e., 1.5% w.g. in NA and RMSD microcapsules). In addition, the presence 
of NA seemed to increase the CO2-producing effect of sodium bicarbonate and the penetrating 
water. Ichikawa et al. (Ichikawa et al., 1991) used sodium bicarbonate in combination with 
tartaric acid as an effervescent layer below an outer shellac layer with polyvinyl acetate. The 
CO2 formation resulted in a pill swollen like a balloon (Ichikawa et al., 1991). This floating 
drug led to a prolonged gastric residence, the drug was released continuously and could be 
absorbed in the absorption window closely after the pylorus (Surana and Kotecha, 2010). 
This, however, would be completely undesirable for formulations targeting the ileocolonic 
region. Floated microcapsules were not observed during the dissolution experiments, but the 
addition of an acid, in this case NA, could plausibly lead to a higher CO2 production 
(Binnewies et al., 2016; Choi et al., 2002; Lin et al., 2017). The resulting bubbles can rupture 
the outer shellac coating and result in the release of the encapsulated compound. Due to the 
fact that the shellac coating was applied without using any plasticizer, the elasticity and 
flexibility of the coating was low (Pearnchob et al., 2004; Qussi and Suess, 2006). This 
mechanism may also explain higher variabilities in release rate with increasing amount of 
sodium bicarbonate. The higher the production of CO2 bubbles, the more uncontrolled and 
irregular the release. The use of a plasticizer to increase the elasticity of the coating could 
reduce the release variability. However, this also may lead to a premature release in the upper 
intestine because of an increased water vapour permeability resulting from the use of 
hydrophilic plasticizers (Luangtana-Anan et al., 2010; Pearnchob et al., 2003). This depends 
on the plasticizer (Pearnchob et al., 2003; Rao and Diwan, 1997)and sometimes even no effect 
is visible (Krogars et al., 2003). 
 
5.5.3 Effect of citric acid on the release profile of NAM 
In contrast to sodium bicarbonate, citric acid with its pH value of 1.87 (pKa1=3.3; pKa2=4.76; 
pKa3=6.4) reduces the intrinsic pH-value and delays the dissolution of shellac, leading to a 
slower release rate (Farag and Leopold, 2011a). In addition, the present results showed that 
citric acid reduced the swelling properties of shellac immensely (Figure 5.9). The only 
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disadvantage of the citric acid subcoating was the challenging application during the coating 
process, because of a high risk of agglomeration. Citric acid is hygroscopic and can lead to 
increased stickiness (Dewettinck et al., 1998). Furthermore, citric acid could induce 
hydrolysis of the pea starch molecules used as binder, leading to a reduction in amylose and 
an increase in glucose (Wang et al., 2003), which further increases the stickiness. Hence, both 
effects could result in agglomeration. Another alternative to pea starch is 
polyvinylpyrrolidone (PVP), which was previously used by Farag and Leopold (Farag and 
Leopold, 2011a). However, the permission to declare pea starch as food additive in food stuff 
is advantageous over PVP. In EU, the administration of PVP as a food additive is only 
allowed in solid nutraceuticals or as a sweetener (EG Nr. 1333/2008). Due to the demanding 
handling of the citric acid subcoating, it was desirable to shorten the process time and to 
obtain a comparable release profile by adapting of the inner shellac coating. The inner shellac 
coating was administered to separate NAM from the pH-modulating intermediate coating. As 
expected, the release of the active ingredient was reduced by increasing of the inner shellac 
coating due to a thicker diffusion barrier (Chopra et al., 2002; Czarnocka and Alhnan, 2015; 
Farag and Leopold, 2011a, 2011b; Qussi and Suess, 2005; Tunón et al., 2003). Since it was 
shown that the chosen substance strongly influences the release rate, the inner shellac coating 
ensures the separation of the layer with the bioactive compound from the pH-modulating 
intermediate subcoating layer and could therefore lead to a separation of these two modulating 
effects, which is more efficient than a pH-independent inner layer. This inner shellac is an 
invention resulting from the present study (PCT/EP2017/058733 and PCT/EP2017/058741) 
and may considerably expand the applicability of shellac coating systems on cores with pH-
influencing active ingredients. 
 
5.6 Conclusions 
In summary, the properties of the encapsulated compound have a great impact on the release 
profiles of shellac-coated microcapsules. As demonstrated in the present study, the 
combination of the aqueous pH value, the water solubility, and the crystallinity of the 
encapsulated substance are factors influencing the release profile from shellac microcapsules. 
Therefore, a simple formulation transfer from one substance to other compounds with 
different properties is not possible. The novel triple-layer formulation concept described here 
shows that a precise modulation of the release profile is possible by using different acidic or 
basic pH-modulating intermediate subcoatings, e.g., sodium bicarbonate or citric acid, 
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counteracting the properties of the encapsulated compounds. We also demonstrate that 
sodium bicarbonate as a subcoating leads to an earlier and dose-dependent increased release 
rate by affecting the dissolution of shellac at pH 6.8. Therefore, sodium bicarbonate as a 
subcoating is suitable for the enhanced release of compounds with a relatively low water 
solubility, such as NA and RMSD, and can counteract the slow dissolution of shellac at lower 
pH values. In contrast, citric acid reduces the swelling of shellac, delays the release profile, 
and can counteract a premature release, for example for alkaline and highly water-soluble 
compounds, such as NAM. The present results describe valuable tools for the production of 
shellac microcapsules for different substances with the aim of a targeted release in the (ileo-
)colon, e.g. to influence the gut microbiome. However, due to the adaptability of the triple 
coating layer, also other applications are conceivable to target more proximal or distal parts in 
the human intestine.  
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6.1 Abstract  
The aim of the present study was to develop an alternative process to spray granulation in 
order to prepare high loaded spherical nicotinamide (NAM) pellets by wet extrusion and 
spheronisation. Therefore, a Quality by Design approach was implemented to model the 
effect of the process parameters of the extrusion and spheronisation process on the 
roundness, roughness and useable yield of the obtained pellets. The obtained results were 
compared to spray granulated NAM particles regarding their characteristics and their release 
profile in vitro after the application of an ileocolon targeted shellac coating. The wet 
extrusion and spheronisation process was able to form highly loaded NAM pellets (80 %) 
with a spherical shape and a high useable yield of about 90 %. However, the water content 
range was rather narrow between 24.7 and 21.3 %. The Design of Experiments (DoE), 
showed that the spheronisation conditions speed, time and load had a greater impact on the 
quality attributes of the pellets than the extrusion conditions screw design, screw speed and 
solid feed rate (hopper speed). The best results were obtained using a low load (15 g) 
combined with a high rotation speed (900 m/min) and a low time (3 – 3.5 min). In 
comparison to spray granulated NAM pellets, the extruded NAM pellets resulted in a higher 
roughness and a higher useable yield (63 % vs. 92%). Finally, the coating and dissolution 
test showed that the extruded and spheronized pellets are also suitable for a protective 
coating with an ileocolonic release profile. Due to its lower specific surface area, the 
required shellac concentration could be reduced while maintaining the release profile. 
Keywords: wet extrusion/spheronisation; Quality by Design; Design of Experiment (DoE); 
Niacin; controlled release  
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6.2 Introduction 
Advancements in drug delivery systems were and are highly present in the pharmaceutical 
and food research area. Novel approaches include macro, micro and nano particulate systems 
as well as uniparticulate or multiparticulate systems (Zaman et al., 2016). Nano particulate 
systems are often used for enhancing the bioavailability or solubility of poorly soluble 
compounds e.g. by coaxial electrospraying (Yu et al., 2019) or liposomes (Frenzel and 
Steffen-Heins, 2015). However, for high daily doses, nano systems could lead to high weight 
of the final formulation. Therefore, the improvement of micro and macro systems with high 
drug loads is of recent interest. Macro or micro particulate systems can also provide an 
enhanced bioavailability (Mueller et al., 2018; Egert et al., 2012; Petersen et al., 2016) and/or 
a side-specific delivery in the human intestine. Pelletization techniques are playing a leading 
role in the field of drug delivery systems. Pellets are small free flowing, spherical particles 
with a diameter from 0.5 – 2 mm. Pellets, as drug delivery systems, provide technological as 
well as therapeutical advantages in comparison to uniparticulate systems such as simplicity of 
coating, less bowel irritation, uniform distribution in the gastrointestinal tract and decreased 
peak plasma fluctuations (Zaman et al., 2016; Knop and Kleinbudde, 2005; Lustig-Gustafsson 
et al., 1999). Fluid-bed processes and wet extrusion-spheronisation provide high drug load 
capacity and uniformity of pellets (Zaman et al., 2016; Verstraete et al., 2017; Politis and 
Rekkas, 2011) including moderate to highly water-soluble compounds such as nicotinamide 
(NAM). NAM is one active form of the vitamin niacin. A colon-targeted delivery of NAM 
can lead to beneficial effects on the host microbiome (Hashimoto et al., 2012). Due to the 
high bioavailability of NAM and its high absorption rate in the upper intestine, a protective 
coating is suitable for a targeted delivery in the ileocolonic region. In a previous study, the 
topical delivery to the colon area of NAM was achieved by application of an adapted shellac 
coating. Shellac is a natural resin from the lac insect Laccifer Lacca. It is often used as pH-
sensitive enteric coating due to its acid character and its high dissolution pH value of about 
7.3 (Buch et al., 2009; Limmatvapirat et al., 2007; Farag and Leopold, 2011a). However, an 
adapted subcoating to the characteristics of the encapsulated compound can be advantageous 
for a targeted release (Farag and Leopold, 2011a; Fangmann et al., 2018). In recent 
publications, shellac was used as a coating for a nanocomposite with a colon targeted release 
using a modified electrospraying process (Yang et al., 2018; Wang et al., 2018). Additionally, 
shellac can be used for food as edible coatings (Kumar et al., 2018; Chauhan et al., 2015; 
Chitravathi et al., 2014) and/or nutraceuticals (e.g. niacin) because of its GRAS status and its 
legal approval as a food additive (Czarnocka and Alhnan, 2015). The NAM cores were 
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produced by continuous spray granulation, which fulfilled the requirements for the application 
of a functional coating, such as sphericity and compactness. However, the useable size range 
was rather narrow (315- 400 µm), which led to a cost and time intensive production process. 
Furthermore, a rather thick coating layer was required to achieve the desired release profile 
(Fangmann et al., 2018). Therefore, NAM cores produced by wet extrusion/spheronization 
process will be compared to the spray granulated cores in this study as an alternative process. 
The requirements for the NAM cores correspond to the definition of pellets, which are 
favored due to their small particle size (< 2mm) and their ability to pass the pylorus 
independently from gastric emptying, which lead to smaller individual variations. 
Additionally, the round shape is ideal for coating and the risk of dose dumping is lower 
compared to a coated single unit/tablet (Knop and Kleinbudde, 2005). The aim of the present 
study was therefore to modulate the extrusion/spheronisation process in order to produce 
highly loaded NAM pellets and to compare their properties to spray granulated NAM pellets. 
A Quality by Design (QbD) approach, which is often applied in the pharmaceutical industry 
to guarantee the product quality (Sovány et al., 2016; Zhang and Mao, 2016) was used to 
define the Quality Target Product Profile (QTPP) with its Critical Quality Attributes (CQAs). 
The effect of the Critical Material Attributes (CMAs) and the Critical Process Parameters 
(CPPs) on the CQAs was determined by performing Design of Experiments (DoEs) for the 
extrusion and spheronisation processes, respectively. For the wet extrusion/spheronization 
process, a high drug load of 80 % NAM combined with 20 % MCC (Avicel PH101) was 
used. MCC is known as the “golden standard” for extrusion-spheronisation processes. It is 
characterized by its high water absorption and holding capacity, which improves the wetted 
mass plasticity and the spheronisation (Dukić-Ott et al., 2009; Jain et al., 2010). Finally, the 
release profile of the coated extrudates will be compared with coated spray granulates.  
 
6.3 Materials and Methods  
6.3.1 Materials 
For wet extrusion and spheronisation processes, nicotinamide (NAM) were purchased from 
SternVitamin (Ahrensburg, Germany) and microcrystalline cellulose (MCC) Avicel Type PH 
101 was ordered from FMC Health and Nutrition (Philadelphia, USA). For the following 
coating process, shellac solution (SSB Aquagold) was obtained from Stroever Schellack 
Bremen (Bremen, Germany). Citric acid monohydrate was obtained from Jungbunzlauer 
(Basel, Switzerland) and C* Dry maltodextrin 01915 from Cargill (Minneapolis, MN, USA). 
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Other chemicals used for dissolution tests were purchased from Carl Roth (Karlsruhe, 
Germany).  
 
6.3.2 Methods 
 
6.3.2.1 Pellet preparation 
Micronisation 
In order to avoid lumps, the batch of NAM was micronized using a milling machine U5-0024 
from Quadro Engineering Inc. (Waterloo, Canada). The square impeller and the screen 
7L094R (=2.39 mm) were inserted.  
 
Extrusion and spheronization 
The wet extrusion was applied using the twin-screw extruder nano 16 from Leistritz 
(Somerville, USA) with a 1mm diameter die. Prior to the extrusion, 1000 g of micronized 
NAM and MCC, in a ratio of 80:20 (% w/w), were dry blended in a V-shaped blender 
(Pharmatech, Birmingham, England) for 20 minutes and filled in a single screw hopper 
(Brabender FlexWall, Duisburg, Germany) which fed the powder mixture into the extruder. 
Distilled water was used as binder liquid and was fed using a peristaltic pump (Watson-
Marlow Pumps, Type 120S, Falmouth, Cornwall, UK) at 4 rpm (feed rate of 1.74 g/min). The 
potentially critical factors identified for the extrusion process were the screw configuration, 
screw speed and powder feed rate. In the present study, the hopper speed was varied to 
achieve an altered solid-to-liquid ratio. Therefore, a calibration curve of the powder feed rate 
corresponding to the hopper speed was done (powder feed rate (g/min) = 0.0382*hopper 
speed – 3.6991). The used solid feed range varied between 5.3 – 7.9 g/min, which resulted in 
a liquid/solid ratio of 0.33 – 0.22. The screw configurations used are shown in Figure 6.1. 
After the extrusion process, the extrudates were spheronized using a spheroniser (made in 
house, De Montfort University, UK) with cross-hatched rotation plate with a diameter of 12 
cm. The potentially critical factors identified for the spheronisation process were rotation 
speed, time and mass load. Two spheronisation processes were carry out for every extrusion 
run. The spheronized pellets were dried at 40 °C in a drying oven over night. 
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Figure 6.1: Configuration of the two different screw designs (L1 and L2) used in the present 
extrusion DoE 
 
Spray granulation of NAM 
For spray granulation of NAM, a ProCell fluidized bed granulator with Vario 3 was used 
(Glatt Ingenieurtechnik, Weimar, Germany). For a high NAM load and a continuous process 
with a high useable yield, the following conditions were chosen after the conduction of 
preliminary experiments (not shown). First, 30 % (w/w) nicotinamide including 4 % (w/w) of 
hydroxypropyl methylcellulose (HPMC) were dissolved in tap water. The solution was 
sprayed through a bottom-spray nozzle with an increasing spraying rate of 5 – 24 g/min. The 
conditions of the process were the following: inlet air temperature: 80 – 90 °C, product 
temperature: 50 °C, air rate: 80 – 90 m3/h and an atomizing air pressure of 2 – 2.8 bar. 
 
Fluidized bed coating 
For application of a coating, a fluidized bed coater (MiniGlatt, Glatt Ingenieurtechnik GmbH, 
Binzen, Germany) was used. The applied coating consisted of an inner shellac coating, an 
intermediate citric acid coating and an outer shellac coating in accordance to previous 
experiments (Fangmann et al., 2018) to achieve an ileocolon targeted delivery of NAM. 
Therefore, an inner shellac layer was applied with a weight gain (w.g.) of 20 %, followed by a 
citric acid coating, which generated a citric acid w.g. of 0.65 % and a w.g. of 5.85 % of 
maltodextrin, which was used as binder. Afterwards, an outer shellac coating (7.5 % w.g.) 
was applied. The calculated coating w.g. were based on the coating levels for coated NAM 
cores produced by spray granulation (see below) including a roughness factor of 54 %, which 
doubled the calculated coating mass application. The triple coating was sprayed onto 80 g 
extruded and spheronized NAM: MCC pellets under the following conditions: inlet air 
pressure of 0.4 – 0.55 bar, atomizing air pressure of 0.55 – 0.70 bar, inlet air temperature of 
37 – 42 °C and a spraying rate of 0.5 – 0.95 g/min. In the end, the coated pellets were dried in 
a drying oven at 50 °C for 1 h.  
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Calculation of the coating level and coating process 
The coating level (CL) [mg/cm2] is determined as the mass of shellac (mshellac in mg) applied 
to the pellet surface (A in cm ): 𝐶𝐿 =  𝑚𝑠ℎ𝑒𝑙𝑙𝑎𝑐
𝐴
 as described by (Farag and Leopold, 2011b). 
Mshellac is the difference between the mass of the sample (msample in mg) and the mass of the 
cores (mcores in mg) in the sample. The mass of the cores in the sample was calculated to the 
following equation: 𝑚𝑐𝑜𝑟𝑒𝑠 =  100 𝑚𝑁𝐴𝑀 𝑠𝑎𝑚𝑝𝑙𝑒𝑐𝑢𝑛𝑐𝑜𝑎𝑡𝑒𝑑 𝑝𝑒𝑙𝑙𝑒𝑡𝑠, whereby mNAM sample is the NAM mass in 
the sample (mg) and cuncoated pellets the NAM content of uncoated pellets (%). The surface area 
of the sample was calculated from the average radius and the number of pellets (n): 𝐴 =
4𝜋𝑟2𝑛. The number of the pellets is the relation of mcores to muncoated pellet. The average mass of 
pellets was calculated from 500 pellets. The average radius was measured by particle size 
measurements by laser diffraction using a using the dry feeder of the particle analyzer (Horiba 
LA-950V2, Retsch Technology GmbH, Haan, Germany) with vacuum-driven forced ejection, 
a vibration power alteration of 120 and a compressed air pressure of 0.3 MPa. A refractive 
index of 1.47 was used for NAM. The NAM content, after the application of the coating layer, 
was determined spectrophotometrically at 262 nm after dissolution of about 50 mg pellets in 
100 ml Soerensen phosphate buffer at a pH value of 7.4 (Helios gamma, Thermo Fischer 
Scientific, Waltham, USA).  
 
6.3.2.2 Extrudate characterization 
Process yield 
During every run, the process yield, which was defined as the extruded mass per minute 
(g/min), was examined by weighing. The standard deviation of three measurements was 
calculated to control the process variability. 
 
Moisture content 
To measure the moisture content during process, freshly produced extrudates were analyzed 
before the spheronization process. About 2.5 g sample were weighed before and after drying 
at 105 °C in drying oven for 24 h. The experiments were done in triplicate. The water content 
is expressed as the percentage of the total weight of the wet mass. 
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6.3.2.3 Pellet characterization 
Pellet size distribution - sieve analysis 
The sieve analysis gives information about the particle size distribution after the extrusion-
spheronisation process. The dried pellets of two spheronisation processes were sieved in a 
sieve shaker AS 200 control (Retsch GmbH, Haan, Germany) using sieve sizes of 2, 1.4, 1, 
0.5 and 0.25 mm to separate the pellets according their size. The amplitude was set to 0.5 
mm/”g” and the total sieve time to 3 minutes. Afterwards, the percent weight of the fractioned 
pellets was calculated.  
The particle size analysis of spray granulated NAM pellets was done by Glatt 
Ingenieurtechnik GmbH (Weimar, Germany) using a Camsizer XT (Retsch Technology, 
Haan, Germany). 
 
Pellet shape – photo image and scanning electron microscopy (SEM) 
The shape of the spheronized pellets (n= ≥6) was evaluated by optical inspection and by 
SEM. For SEM, pellets with a diameter between 1 and 1.4 mm were prepared on a holder 
with carbon Leit-tabs (Agar Scientific, Stansted, UK). Before examination in a Zeiss EVO 15 
(Carl Zeiss Ltd, Cambridge, UK) at an accelerating voltage of 10 kV, microcapsules were 
sputter-coated with a layer of 15 nm gold using a Quorum Q150RS (Quorum Technologies 
Ltd, Laughton, UK) rotary pumped sputter coater. The pellets were categorical evaluated 
regarding their roundness and their roughness of the surface: roundness (category 1 – 5): 1 = 
irregular (like agglomerates); 3 = spherical; 5 = dumbbell-shaped or strains; roughness 
(category 1 – 5): increasing category for increasing roughness. 
For SEM pictures of the spray granulated NAM pellets were prepared and analyzed as 
described in [15].   
 
Dissolution testing after application of coating 
The in vitro drug release study was carried out using a standard dissolution paddle apparatus 
at 100 rpm and 37 °C (DT 70, Pharmatest Group, Hainburg, Germany) (Berg et al., 2012). 
The experiment was conducted in duplicate with 0.5 g of coated extrudated NAM: MCC 
pellets in 250 ml of the dissolution medium. During the experiments, the amount of released 
NAM was recorded by UV/vis spectrophotometer (Helios γ, Thermo Fisher Scientific, 
Waltham, USA) at the wavelength of 262 nm. The following dissolution media were used to 
simulate the human gastrointestinal tract from stomach to ileum to evaluate the release 
profile: Simulated gastric fluid (pH 1.4) was adjusted to USP gastric fluid without pepsin 
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(U.S. Pharmacopeial Convention), citrate buffer (pH 4.5) was modified to (Gomori, 1955) and 
phosphate buffer (pH 6.8 and 7.4) was prepared according Sorensen’s buffer. To calculate the 
percentage of released vitamin, the maximum NAM amount was determined by stirring (100 
rpm) of 0.5 g coated NAM extrudates in 250 ml phosphate buffer at pH 7.4 for 1.5 h at 37 °C 
in the above mentioned dissolution tester. The NAM concentration of the solution 
corresponded to 100 % NAM release.  
 
6.3.2.4 Quality by Design 
Quality target product profile (QTPP) and Critical Quality Attributes (CQAs) 
The target dosage form is a pellet for oral administration. It should have a uniform and 
spherical shape, a smooth surface and a narrow size distribution for an appropriate application 
of an additional coating in a further step. The size should be smaller than 2 mm to be able to 
pass the pylorus independently from gastric emptying. Furthermore, the vitamin load should 
be high to prevent a high number of capsules, which have to be swallowed to reach the daily 
dose.  
The following CQAs were determined based on previous experiments: vitamin load: ≥ 80 %; 
a roundness of category 2.0 – 4.0; a roughness of category ≤ 2 and a maximal useable yield 
(pellets with a diameter between 1 and 2 mm and an acceptable roundness).  
 
Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) 
The most critical material attributes are the high water solubility of nicotinamide (1000 g/l) 
and the corresponding vitamin to binder ratio. For these studies, the NAM:MCC ratio was 
kept constant, 80:20 % w/w. The influence of potentially CPPs such as powder mixture feed 
rate, screw speed and screw configuration (for the extrusion process) and rotation speed, 
rotation time and mass load (for the spheronisation process) on the CQAs was investigated. 
The identification of CMAs and CPPs were based on preliminary risk assessment and prior 
knowledge. Note: CMA is not an ICH (International Conference for Harmonisation) term but 
it is used here to describe the quality attributes of the materials.  
 
Design of experiments (DoE) 
The effects of the CPP’s were determined using a DoE approach using the statistical software 
JMP Pro (SAS Institute, Cary, North Carolina, USA). For the extrusion process, two 22 full 
factorial designs were determined for two different screw designs, which were already shown 
in Figure 1. Therefore, 12 experiments were run in total, including 2 replicates of the central 
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point for every investigated DoE. For the spheronisation process, a 23 full factorial design 
with 10 experiments, including 2 replicates for the central point, were performed. An 
overview of every single experiment is listed in Tables 6.1 and 6.2. Variations in the moisture 
content of the extruded mass were set by changing the hopper speed from 250 to 270, which 
resulted in a powder feed rate from 5.8 to 6.6 g/min according to the calibration curve 
(powder feed rate (g/min) = 0.0382*hopper speed – 3.6991). 
 
Table 6.1: Design of Experiment of the extrusion process and the resulted responses (for all 
runs the spheronisation process was constant with 9 min time, 75 % speed and 15 g load) 
run pattern screw 
design 
screw 
speed 
[rpm] 
hopper 
speed1 
[rpm] 
mc 
[%] 
roundness roughness py 
SD 
uy 
[%] 
1 100 L1 200 260 23.87 3 2 0.08 91.62 
2 1+− L1 300 250 23.86 3 4 1.19 91.18 
3 1−− L1 100 250 23.79 2 4 0.41 86.62 
4 1++ L1 300 270 21.70 3 2 0.23 95.79 
5 100 L1 200 260 23.55 3 3 0,12 98.12 
6 1−+ L1 100 270 21.39 3 2 0.23 97.53 
7 200 L2 200 260 23.15 2 2 0.36 98.04 
8 2−− L2 100 250 24.09 5 4 1.3 0 
9 2+− L2 300 250 22.78 4 4 0.56 42.42 
10 2++ L2 300 270 21.85 3 3 0.26 95.96 
11 200 L2 200 260 22.12 3 2 0.65 97.49 
12 2−+ L2 100 270 22.78 3 2 0.22 96.43 
1hopper speed set to 250, 260 and 270 resulted in a feed rate of 5.8, 6.2 and 6.6 g/min. mc = moisture content; py = process 
yield; uy = useable yield 
 
 
Table 6.2: Design of Experiment of the spheronisation process and the resulted responses 
(for all runs the extrusion process was constant with screw design L1, 130 rpm screw speed 
and 270 rpm hopper speed) 
run pattern time 
[min] 
speed1 
[%] 
load [g] uy [%] roundness roughness sy [%] 
1 +−+ 9 50 65 0 4 2.5 97.62 
2 −++ 3 100 65 27.05 3.5 3 97.00 
3 +−− 9 50 15 71.43 3 2 94.27 
4 −−− 3 50 15 0 5 3.5 96.93 
5 ++− 9 100 15 90.99 3 2 91.93 
6 000 6 75 40 65.29 2.5 2.5 96.28 
7 −−+ 3 50 65 0 5 4 98.94 
8 −+− 3 100 15 86.44 3 2 94.60 
9 000 6 75 40 81.38 3 2.5 96.83 
10 +++ 9 100 65 29.29 2 3 97.86 
1rotation speed of 50, 75 and 100 % are in accordance with 430, 680 and 900 m/min. uy = useable yield; sy = 
spheronisation yield 
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6.4 Results and Discussion 
6.4.1 Preliminary tests: establishing the range of solid-to-liquid ratio 
For a high vitamin load, a ratio of 80 % w/w NAM and 20 % w/w MCC was chosen. In order 
to get a paste that can be spheronised without blocking the die of the extruder, the range of the 
solid-to-liquid ratio had to be evaluated before a systematic investigation. Distilled water was 
added to the extruder with a constant rate of 1.74 g/min. The solid feed rate was increased 
from 5.3 to 7.9 g/min to evaluate the particle shape changes (Figure 6.2). 15 g of the formed 
extrudates were spheronised for 3 min, dried and photographed. A low solid feed rate resulted 
in big and irregular agglomerates (A-C), whereby with increasing solid feed rates the amount 
of fines and dumbbell-shaped particles or strands increased (G-I). The optimal solid feed rate 
was between 6.2 and 6.6 g/min, which led to spherical particles (D-F). The differences 
regarding the particle size distribution of different solid feed rates were confirmed by sieve 
analysis (Figure 6.3). The lower the solid feed rate, the higher the amount of large particles 
(> 14 mm and > 2mm). The higher the solid feed rate, the higher the amount of fine particles 
(< 1 mm). The highest amount of the useable particles (1 – 2 mm) was obtained for a solid 
feed rate of 6.2 – 6.7 g/min.  
 
Figure 6.2: NAM-MCC-Pellets (80:20) after extrusion and spheronisation (3 min, 15 g) with 
different solid feed rates (g/min): 5.3 (A), 5.5 (B), 5.6 (C), 6.2 (D), 6.4 (E), 6.6 (F), 6.7 (G), 
7.4 (H), 7.9 (I). The granulating liquid was distilled water with a constant feed of 1.74 g/min. 
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Figure 6.3: Particle size distribution (%) after sieve analysis of NAM-MCC-Pellets (80:20) 
after extrusion and spheronisation (3 min, 15 g) with different solid feed rates (g/min). The 
granulating liquid was distilled water with a constant feed of 1.74 g/min. 
 
The effect of the solid feed rate on the moisture content of the extrudates is illustrated in 
Figure 6.4. Furthermore, the resulting particles formed after spheronisation are shown in 
Figure 6.4. A low solid feed rate resulted in big and irregular particles due to a high moisture 
content of 25.5 %. The wet extrudates tended to stick together during spheronisation and 
formed irregular and large particles, like a “rolling snowball”. A low moisture content (19.2 
%) produced brittle extrudates that formed dumbbell-shaped particles. Only in a narrow water 
content range between 24.7 and 21.3 % (corresponding to a solid feed rate of 5.5 and 6.6 
g/min respectively), spherical particles were generated. It is known that the moisture content 
of extrudates influences the spheronisation success. The extrudates must be brittle enough to 
be broken down into short strands during the spheronisation, but not so friable, that they 
disintegrate completely. Furthermore, the material has to be sufficiently plastic, that the 
broken strands can be rolled into spheres by the action of the friction with the plate. However, 
if the material is too wet, lumps will be formed during spheronization (Dukić-Ott et al., 2009; 
Jain et al., 2010; Vervaet et al., 1995). The range of water level over which spherical pellets 
were formed is influenced by the incorporated drug characteristics. It is documented that the 
ideal water level decreased with increasing water solubility of the drug, due to loss of solid 
matter by dissolution of the drug (Lustig-Gustafsson et al., 1999, Jover et al., 1996). The 
optimal water content for glucose, which has the same water solubility as NAM (1000 g/l), 
was 30.0 % vs. 23.6 % for NAM. The difference is explained by the higher amount of drug 
Paper IV: Nicotinamide pellets produced by wet extrusion/spheronisation process 
131 
 
used in the present study (80 %) compared to others, who used 50 % drug and 50 % MCC 
(Lustig-Gustafsson et al., 1999). Decreasing the MCC fraction to a lower concentration as 50 
% (w/w) can lead to negative effect on the process yield and on the pellet properties 
(Verstraete et al., 2017). As shown in the present study, Podczeck et al. also showed pellets 
with good properties using 20 % MCC and 80 % drug (lactose, ≈195 g/l water solubility). The 
optimal water content was 23.66 % for a formulation with 80 % lactose. A lower water 
content (21.66 %) was required for the more water-soluble ascorbic acid (≈400 g/l) (Podczeck 
et al., 2008). 
 
 
Figure 6.4: (A) Effect of solid feed rate (g/min) on moisture content of wet extrudates (NAM: 
MCC; 80:20) and (B) the resulting shape of spheronised particles. The granulating liquid was 
distilled water with a constant feed of 1.74 g/min.   
 
6.4.2 Design of Experiment – Extrusion process 
To evaluate the effect of the extrusion process parameters on the particle characteristics, 
the parameters for the spheronisation process (load: 15 g, rotation speed: 75 %, time: 9 
min) as well as the formulation composition were held constant. During the extrusion 
process the factors screw design, screw speed and hopper speed (= solid feed rate; 
powder feed rate (g/min) = 0.0382*hopper speed – 3.6991) were varied. The effect of the 
above factors on the responses such as moisture content and process yield variations (SD 
of process yield) of the extrudates and roundness, roughness and useable yield of the 
spheronised particles was examined using a DoE approach. The coefficient of 
determination (r2) varied in a broad range depending on the responses. The r2 of the 
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roughness (0.845) and the useable yield (0.817) indicated a good fitting between the 
independent variables and responses in the model, in contrast to the moisture content 
(0.577), the process yield SD (0.544) and the roundness (0.470). However, only the 
model for the prediction of the roundness gave no significant results (p=0.1471). The 
outcomes of all tested combinations are shown in Table 6.1. The changes on the screw 
speed values showed no significant effect on all responses measured. Therefore, the 
screw speed was excluded from the model for a better predictability. The hopper speed 
had a significant effect on the roughness (p=0.0002) and the useable yield (p=0.0087) of 
the particles as well as on the process yield variations (p=0.0154) and the moisture 
content (p=0.0041). Furthermore, the combination of hopper speed and screw design 
influenced the useable yield significantly (p=0.0221). The interaction profiles between 
screw design and hopper speed on the responses are shown in Figure 6.5. As can be seen, 
there was no interaction between screw design and hopper speed for the responses 
roughness of the particles, moisture content and process yield of the extrusion (B, D, E). 
A lower hopper speed, however, led to an increased roughness, a higher moisture content 
and a higher variability of the process yield (B, D, E).  There was a clear interaction 
between screw design and hopper speed for the responses roundness and useable yield 
(A, C). The useable yield of the particles was relatively constant and independent from 
the screw design when using a hopper speed set to 270 (6.6 g/min). The lower hopper 
speed set to 250 (5.8 g/min) in combination with screw design L2 resulted in a drastic 
decrease of the yield (C). This result was in accordance with the roundness of the 
particles: the higher hopper speed (270) led to more spherical particles in combination 
with screw design L1 (A). SEM pictures of all runs are shown in Figure 6.6. They were 
used to assess the roundness and roughness of the particles. In general, it is seen that the 
screw design L2 always resulted in more irregular shaped particles. Modelling a 
maximization of the desirability (0.95) of all responses, a combination of the screw 
design L1 and a hopper speed set to 263 was proposed (Figure 6.7). 
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Figure 6.5: Interaction profile of the extrusion process variables hopper speed and screw 
design on the responses roundness (A), roughness (B), useable yield (C), process yield SD (D) 
and moisture content (E).  
 
 
B 
C D 
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E 
Paper IV: Nicotinamide pellets produced by wet extrusion/spheronisation process 
134 
 
 
Figure 6.6: SEM pictures of spheronised NAM: MCC-particles after DoE for extrusion 
process with screw design L1 (A) and L2 (B) with varying screw speed (y-axis) and hopper 
speed (x-axis). 
 
 
Figure 6.7: Proposed extrusion configurations for a maximized desirability of all responses 
(CQAs) measured (useable yield, process yield SD, roughness, roundness, moisture content). 
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In the present study, a lower hopper speed (= higher water content) resulted in a higher 
roughness, although a higher density was documented for a higher water content after 
spheronisation (Baert and Remon, 1993). However, it is reported that for twin-screw 
granulation a higher powder feed leads to an increased channel fill and torque, which 
increases the strength and decreases the porosity of the resulting granules (Dhenge et al., 
2011). This could be an explanation for the observed lower roughness of the spheronised 
particles of the present study using a higher powder feed. Furthermore, the implementation of 
kneading elements can result in denser granules after extrusion (Seem et al., 2015), which was 
not shown in the present results. The screw speed showed no significant effects on the particle 
characteristics, although the screw speed can also influence the barrel fill and the density of 
the extrudates. However, if the screw speed was too low, blockages were observed, which is 
in accordance with a high fill level and an increased material compaction (Seem et al., 2015; 
Dhenge et al., 2010). The roundness of the particles was not significantly affected by 
variations of the extrusion process, which could be related to a higher impact of the 
spheronisation process and the moisture content (Di Pretoro et al., 2012; Hasznos et al., 2008) 
and will be discussed later. Whereby, the moisture content is significantly influenced by the 
hopper speed, due to an independent feed of the powder and the granulating liquid. 
 
6.4.3 Design of Experiment – Spheronisation process 
The results of the DoE for the spheronisation process are shown in Table 6.2. The extrusion 
process was done at the following constant conditions: screw design L1, screw speed of 130 
rpm and a hopper speed set to 270 (6.6 g/min). During spheronisation, the effects of the 
factors load, speed and time on the roundness, roughness, useable yield and spheronisation 
yield were investigated. Compared to the extrusion process, the spheronisation process 
showed a better fitting between the independent factors and the responses, which is 
demonstrated by higher r2 of the roughness (0.976), spheronisation yield (0.958), roundness 
(0.741) and useable yield (0.614). The spheronisation load had a significant effect on the 
useable yield (p=0.0380), the roughness (p=0.0026) and the spheronisation yield (p=0.0016), 
whereby the speed affected significantly the roundness (p=0.0202), roughness (p=0.0111) and 
the spheronisation yield (p=0.0238). The rotation time showed significant influences on the 
roundness (p=0.0426) and roughness (p=0.0026) of the particles and the spheronisation yield 
(p=0.0321). Furthermore, the combination of speed and time significantly affected the particle 
roughness (p=0.0026). The interaction profiles of the factors load, speed and time are 
exhibited in Figure 6.8. Regarding roundness, a higher speed always resulted in rounder 
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particles, independently of the load. A low spheronisation time leads to more dumbbell-
shaped particles and strands, especially in combination with a low speed. However, this effect 
was reduced in combination with a high speed. If the rotation time was too long, while 
rotating with a speed of 100 %, the resulting particles were more irregular (A). The roughness 
of the particles was increased by increasing load and due to a low speed in combination with a 
low rotation time (B). The useable yield is only affected by the rotation speed and load: the 
yield was always higher with the highest speed and the lowest load (C). The spheronisation 
yield was dependent on all process parameters, whereby a high load, a low speed and a low 
time resulted in the lowest abrasion of the particles and therefore in the highest spheronisation 
yield (D).  
The corresponding SEM pictures of the ten runs (Figure 6.9), show irregular particles due to 
a high load and dumbbell-shaped particles after spheronisation with a low speed. In 
comparison to the extrusion process, it is demonstrated that the spheronisation process has a 
higher impact on the desired responses (CQAs) of the particles. For a maximization of the 
desirability (0.77) of all responses, a combination of a load of 15 g, a rotation time of 3 min 
and a rotation speed of about 91 % is proposed after modelling (Figure 6.10). The effect of 
the spheronisation conditions on the pellet characteristics has often been evaluated and always 
showed a great impact, which is in line with the findings of the present study. As expected, 
the spheronisation yield (remained quantity after abrasion during spheronisation) was affected 
by all three tested parameters time, speed and load. The lower the speed, the higher the load 
and the lower the time, the lower would be the particle-plate interactions, which lead to 
abrasions and loss of material (Baert et al., 1993; Dukić et al., 2007; Newton et al., 1995). The 
particle-plate and particle-particle interactions are relevant for the roundness, roughness and 
useable yield of the spheronised particles. The spheronisation process depends on friction 
between particles-particles and particles-plate. Low speeds resulted in low interactions and 
therefore in failure of rounding the particles (Newton et al., 1995) which is in accordance with 
the present results, where the particles were still strands or dumbbell-shaped. Other authors 
also documented a high impact of the spheronisation speed on the roundness of the particles, 
whereby an increase of spheronisation speed resulted in a higher pellet sphericity (Sovány et 
al., 2016; Baert et al., 1993; Dukić et al., 2007; Krueger et al., 2013). A recent article showed 
that an initial high-speed spheronisation was required to reduce the extrudates. Followed by a 
medium speed to minimize the fines but to ensure enough round off of the extrudates (Shah et 
al., 2017). Furthermore, for a low water content, the spheroniser speed became more 
important than the time (Baert et al., 1993). Whereby, the time also played a major role for the 
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roundness of the particles also in dependence of the speed (Baert et al., 1993; Pandey et al., 
2018). In the present study, a longer rotation time led to more spherical particles at a low 
speed, compared to a shorter time, but this relationship was statistically not significant. The 
load had no significant effect on the roundness with is in accordance with Krueger et al. 
(2013). However, for a higher load a longer spheronisation time was needed to form round 
particles (Newton et al., 1995), which makes an adjustment of the spheroniser speed, time and 
load indispensable. Additionally, the roughness of the particles was significantly influenced 
by spheroniser speed and time. Especially, a high rotation speed for a short time resulted in 
the lowest roughness of the particles. It is documented, that the spheronisation speed has to be 
optimized to obtain the desired densification of the particles, which can be insufficient for low 
speeds (Verveat et al., 1995; Newton et al., 1995) and would explain the higher roughness at 
low speeds in the present study. However, contrary results were shown regarding the rotation 
time. Krueger et al. reported a lower porosity and denser particles with increasing times, 
whereby the reduction of the porosity was lower, when the pellets consisted of the drug 
chloramphenicol instead of lactose-monohydrate (Krueger et al., 2013). Therefore, the higher 
surface roughness after longer spheronisation times could also be related to the encapsulated 
NAM. 
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Figure 6.8: Interactions of the spheronisation process variables rotation time, speed and load 
on the responses roundness (A), roughness (B), useable yield (C) and spheronisation yield 
(D). 
A B 
C D 
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Figure 6.9: SEM pictures of spheronised NAM: MCC-particles after DoE for spheronization 
process with the highest spheroniser load (65 g) (A), midpoint of the spheroniser load (40 g) 
(B) and the lowest spheroniser load (15 g) with varying spheronisation speed (y-axis) and 
time (x-axis) 
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Figure 6.10: Proposed spheronisation configurations for a maximized desirability of all 
responses 
 
6.4.4 Verification of the spheronisation model 
As already mentioned, the coefficient of determination (r2) varied according to the responses 
useable yield (r =0.614), spheronisation yield (r =0.958), roughness (r =0.976) and roundness 
(r =0.741). The obtained equations for these responses in term of the used factors (rotation 
speed, time and load) are as follows: 
 
𝑠𝑝ℎ𝑒𝑟𝑜𝑛𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑦𝑖𝑒𝑙𝑑 = 96.226(𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡) − 0.7237(𝑡𝑖𝑚𝑒) − 0.7962(𝑠𝑝𝑒𝑒𝑑) +
1.711(𝑙𝑜𝑎𝑑) + 0.6087(𝑡𝑖𝑚𝑒 ∗ 𝑙𝑜𝑎𝑑) + 0.37125(𝑠𝑝𝑒𝑒𝑑 ∗ 𝑙𝑜𝑎𝑑)  
 
𝑢𝑠𝑒𝑎𝑏𝑙𝑒 𝑦𝑖𝑒𝑙𝑑 = 45.187(𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡) + 20.2925(𝑠𝑝𝑒𝑒𝑑) − 24.065(𝑙𝑜𝑎𝑑)  
 
𝑟𝑜𝑢𝑔ℎ𝑛𝑒𝑠𝑠 = 2.7(𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡) − 0.375(𝑡𝑖𝑚𝑒) − 0.25(𝑠𝑝𝑒𝑒𝑑) + 0.375(𝑙𝑜𝑎𝑑) +
0.375(𝑡𝑖𝑚𝑒 ∗ 𝑠𝑝𝑒𝑒𝑑) + 0.125(𝑠𝑝𝑒𝑒𝑑 ∗ 𝑙𝑜𝑎𝑑)  
 
𝑟𝑜𝑢𝑛𝑑𝑛𝑒𝑠𝑠 = 3.4(𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡) − 0.5625(𝑡𝑖𝑚𝑒) − 0.6875(𝑠𝑝𝑒𝑒𝑑) + 0.1875(𝑡𝑖𝑚𝑒 ∗ 𝑠𝑝𝑒𝑒𝑑) 
                                                                             
For the practical verification of the calculated spheronisation model, the following extrusion 
and spheronisation conditions were used to achieve a high desirability (0.70) of the measured 
responses: screw design L1, screw speed 200 rpm, hopper speed set 270 (6.6 g/min), rotation 
speed of 100 %, rotation time of 3.5 minutes and a load of 15 g. Therefore, only the 
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spheronization model was verified due to similar extrusion conditions as used for the DoE. 
The run was conducted for about 3 hours. Every 15 minutes, the moisture content of the 
extrudates was measured. The mean was 23.6 ± 0.58 % for 13 measurements in total. The 
process yield of 44 measurements during the process was 7.95 ± 0.65 g/min, which confirmed 
a constant process. Furthermore, all runs resulted in well-formed particles with a spherical 
shape (roundness: 2.5) and a low roughness of 2 (Figure 6.11). In comparison, the model 
proposed a roundness of 3 and a roughness of 1.95. The mean useable yield of three different 
runs was 91.61 ± 1.83 % compared to the predicted 89.54 %. Thus, the model prediction of 
the spheronisation process is in good accordance with the measured values.  
 
Figure 6.11: SEM pictures of spheronised particles (NAM: MCC) of three different runs (A-
C) with the same process parameter constellation. Extrusion: screw design L1, screw speed 
200 rpm, hopper speed set to 270 (6.6 g/min); Spheronization: speed 100 %, load 15 g, time 
3.5 min. Magnification: 50-times, 100-times and 1000-times from left to right. 
 
6.4.5 Comparison of NAM pellets produced by wet extrusion/spheronization and spray 
granulation  
As indicated in Figure 6.3 and 6.12, the resulting pellet diameter is bigger for NAM 
extrudates than for NAM spray granulates. This is due to the die diameter of 1 mm for the 
extruder. A smaller die diameter would reduce the particle diameter. However, the useable 
size of the NAM pellets produced by spray granulation was in a narrow range between 315 
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and 400 µm (Fangmann et al., 2018); bigger particles were irregular and therefore not 
applicable for the coating process. The useable yield of the spray granulated particles was 
about 63 % (Figure 6.12) and lower compared to the spheronised NAM extrudates (92 %). 
Using a high drug load of 96 % in the spray granulated pellets, the conditions were optimized 
in pre experiments (data not shown) to achieve a high yield, spherical particles and a 
continuous and stable granulation process. Possibly, the coating of a NAM-HPMC-mixture on 
spherical cores (like Cellets®) could lead to a higher yield but would also reduce the relative 
load of NAM. Furthermore, as shown by SEM pictures in Figure 6.13, the spray granulated 
NAM pellets showed some irregularities in their shapes. The crystalline structure of NAM is 
clearly demonstrated, whereby the roughness is less pronounced compared to the extrudates, 
although a higher concentration of NAM is present in the granules (94 % vs 80 %). This 
suggests a higher compactness of the pellets, which were produced by spray granulation. 
 
Figure 6.12: Particle size distribution of spray granulated NAM pellets 
 
 
Figure 6.13: SEM pictures of NAM pellets produced by spray granulation 
Paper IV: Nicotinamide pellets produced by wet extrusion/spheronisation process 
143 
 
After the extrusion/spheronisation process, the resulted pellets were evaluated regarding their 
dissolution profile without and with an enteric coating, according to Fangmann et al. [15] 
(Figure 6.14A+B). In a simulating fluid with a pH value of 6.8, both, the spray granulated as 
well as the extruded uncoated NAM pellets liberated NAM immediately within 10 minutes. 
Thus, no delay of NAM is attributed to the usage of MCC or HPMC in the formulation as it is 
described for poorly water-soluble compounds (Dukić-Ott et al., 2009; Manda et al., 2019). 
This is mainly explained due to the very high water solubility of NAM (1000 g/l). After the 
application of the shellac coating with an intermediate citric acid sub-coating on the NAM 
extrudates, the release of NAM was clearly delayed in simulated gastrointestinal fluids (pH 
1.4 – 7.4) (Figure 6.14B).  The modified shellac coating prevented a premature release at 
gastric conditions (2.5 % after 60 min at pH 1.4), followed by a continuous release at pH 
value 6.8 (from 22.5 % after 30 min to 82.9 % after 120 min) and a complete release is 
reached at a pH value of 7.4. The release profile of the spray granulated NAM pellets with a 
comparable coating level showed a slower release profile at pH 6.8 (up to 34.4 % after 210 
min in total) (Figure 6.14B) (Fangmann et al., 2018). This could be related to the higher 
roughness of the extruded pellets, which increases the porosity of the coating layer and 
therefore increases the release rate of NAM. A 1.6-fold higher coating thickness (5.8; 7.6 and 
10.0 mg/cm2) of the extruded NAM pellets (Figure 6.14C), resulted in a slower release at pH 
6.8 (up to 12.2 % after 210 min in total). The exact accordance of the release profile of coated 
extruded and spray granulated particles would be existing with a coating layer in between. 
However, both processes are suitable for the production of NAM pellets and a further uniform 
coating. Furthermore, the spray granulation process as well as the twin-screw extrusion can be 
easily scaled up and performed as continuous processes. On the one hand, the narrow water 
level range (< 10 %) may cause problems for further scale-up processes for wet extrusion and 
spheronisation (Lustig-Gustafsson et al., 1999). On the other hand, the release profile 
indicates that lower shellac amount is required for a targeted release. Only 3.6 % (w/w) 
coating weight gain was needed for the application of a coating level of 1 mg/cm2, compared 
to 12 % (w/w) for the spray granulates. Related to 100 g NAM, the required addition of 
shellac was reduced from 60 g to min. 27.5 g for spray granulated compared to wet extruded 
NAM pellets, respectively. Due to the resulting thicker coating level for extruded pellets, it is 
proposed that the required amount could be further decreased (max. to 16.5 g of shellac per 
100 g NAM).  
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Figure 6.14: Release rate of NAM from (A) uncoated spray granulated and extruded NAM 
and (B) from triple shellac coated spray granulated and extruded NAM pellets with a coating 
thickness of 3.7/4.9/6.2 mg/cm2 and 3.6/4.6/6.0 mg/cm2 and (C) from triple shellac coated 
extruded NAM pellets with a coating thickness of 5.8/7.6/10.0 mg/cm2 at simulated 
gastrointestinal conditions (mean ± SD; n=2). 
 
6.5 Conclusion 
All in all, the extrusion/spheronisation process demonstrates an opportunity to produce highly 
NAM loaded pellets with a useable yield of about 90 %. The pellets were spherical and had a 
rough surface. In comparison to spray granulated NAM pellets, the extruded NAM pellets 
resulted in a higher roughness and the useable yield was increased. Finally, the coating and 
dissolution test showed that the extruded and spheronised pellets are also suitable for a 
protective coating with an ileocolonic release profile in vitro. The Quality by Design (QbD) 
proved to be a suitable method to better understand the effects of the Critical Process 
Parameters (CPPs) on the Critical Quality Attributes (CQAs) of the desired product in an 
efficient way. It was shown, that the prediction model was in good agreement with the 
measured outputs. The Design of Experiments (DoE), showed the spheronisation conditions 
speed, time and load had a greater impact on the CQAs of the pellets than the extrusion 
conditions screw design, screw speed and solid feed rate (hopper speed). The roundness was 
significantly affected by the rotation speed and time, whereby the roughness varied depending 
on the spheroniser load, time, speed*time and the solid feed rate. Furthermore, the spheroniser 
load, solid feed rate and the solid feed rate*screw design significantly impacted the useable 
yield. The screw speed showed no significant effect. The moisture content is one of the most 
critical factors for an optimal spheronisation result. Therefore, the moisture content need to be 
adjusted to the formulation characteristics to ensure an optimal product. The spheronisation 
conditions must be adjusted using a multivariate approach. 
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7.1 Abstract 
The aim of the present study was to encapsulate niacin in pectin-zein hydrogel beads by 
ionotropic gelation as a vegan colon-targeted delivery system of niacin. The effect of niacin, 
and process parameters for two different production process (one-step vs. two-step) were 
evaluated regarding the resulting morphology, encapsulation efficiency (EE) and release 
profile of niacin in vitro. The results showed, that a direct dripping into a CaCl2-zein solution 
(one-step) always resulted in red blood cell shaped particles, whereby a separate cross-linking 
and coating step (two-step) produced flat beads. The EE of varied in a broad range (< 1 - > 50 
%) depending on the water solubility of the encapsulated compound, production process and 
particle formulation. The relatively low EE is explained due to the high water solubility of 
niacin (NA: 18 g/l; NAM: 1000 g/l). Furthermore, none formulation was able to prevent a 
premature release of niacin during the simulated gastric phase independently of the 
morphology and the production process. Due to a successful encapsulation and release of 
whey protein isolate (WPI) into the pectin-hydrogel beads, further developments are needed 
to protect a water-soluble molecular such as niacin. 
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7.2 Introduction 
Niacin is a water-soluble vitamin and includes the two active forms nicotinic acid (NA) and 
nicotinamide (NAM). Their coenzymes NAD/H and NADP/H are essential for the energy 
metabolism in humans (Kirkland, 2012). Furthermore, a recent study showed a beneficial 
effect of a gut targeted release of nicotinic acid on the abundance of Bacteroidetes, which is 
associated with an improvement of biomarkers for systemic insulin sensitivity and metabolic 
inflammation. The application of NAM did not result in such beneficial effects (Fangmann et 
al., 2018). However, Hashimoto et al. and Singh et al. postulated NAM related anti-
inflammatory effects in the colon (Hashimoto et al., 2012; Singh et al., 2014). The colon 
targeted release of NA and NAM was achieved using an adapted shellac coating applied via 
fluidized bed coating (Fangmann et al., 2018). Shellac is the refined form of the natural insect 
resin lac. Due to its acidic character, it is often used as coating material for a delayed or colon 
targeted release (Al-Gousous et al., 2015; Pearnchob et al., 2003; Roda, 2007). However, 
fluidized bed coating in combination with a high amount of shellac to get the desired release 
profile is cost intensive and is therefore only of restrictive use (Desai and Jin Park, 2005; 
Teunou and Poncelet, 2002). Thus, an alternative encapsulation material and process for 
niacin is desirable.  
Hydrogel beads formed of a combination of pectin and zein, already showed promising results 
regarding a colon targeted release profile for encapsulated indomethacin and bovine serum 
albumin (BSA) (Liu et al., 2006). In general, hydrogels beads can be formed using the ionic 
gelation technique. An aqueous polymer solution is added dropwise into a crosslinking 
solution with counter ions, which results in a formation of spherical particles (Patil et al., 
2010; Patil et al., 2012). Pectin is able to form beads in the presence of calcium ions and can 
further act as colon-targeted material due enzymatic degradation by the gut microbiota 
(Sriamornsak, 2011; Willats et al., 2006). Zein, a water insoluble hydrophobic storage protein 
from corn, is used as additional coating material to achieve low water penetration (Chotiko 
and Sathivel, 2017; Liu et al., 2006). Furthermore, pectin is a natural polysaccharide and still 
postulated as safe food additive without ADI (acceptable daily intake) after the re-evaluation 
if the EFSA in the year 2017 (Mortensen et al., 2017). The re-evaluation of shellac is still in 
progress (EFSA, 2018). Furthermore, the substitution of shellac against pectin and zein would 
result in a product, which is also applicable for a vegan lifestyle.  
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Before evaluation of the pectin-zein-system as an alternative drug delivery system with a 
delayed release of niacin, the bead formation was studied due to a documented influence of 
the bead shape on the release (Guo and Kaletunç, 2016; Harvestine et al., 2014). Therefore, 
the aim of the present study is to evaluate the pectin-bead formation while encapsulation of 
niacin. The effects of the process conditions and different encapsulation materials were 
analysed regarding the morphology of the hydrogel beads and the resulting encapsulation 
efficiency. Furthermore, first experiments were done to evaluate the gastric resistance 
characteristics.  
 
7.3 Materials and Methods 
7.3.1 Materials 
Nicotinic acid (NA) and nicotinamide (NAM) were purchased from SternVitamin 
(Ahrensburg, Germany). Three different types of pectin were used from Herbstreith & Fox 
(Neuenbürg, Germany). Their characteristics are shown in Table 7.1. Zein (was purchased 
from Sigma-Aldrich GmbH (München, Germany). Shellac solution (SSB Aquagold) and 
shellac flakes (SSB 57 Pharma FL) were obtained from Stroever Schellack Bremen (Bremen, 
Germany). Whey protein isolate (WPI) BiPro® was from Davisco Foods (Minnesota, USA). 
Pectinase Fruktozym® was obtained from Erbslöh Geisenheim AG (Geisenheim, Germany). 
The activity was declared with ≥ 75 ASV-U/ml. Other used chemicals were purchased from 
Carl Roth (Karlsruhe, Germany).  
Table 7.1: Characteristics of the three pectin types used in the present study 
 Pektin Classic 
CU 902 (P5.9) 
Pektin Classic 
AF 707 (P36) 
Pektin Classic 
CU 201 (P69) 
Appearance/colour yellowish yellowish yellowish 
Degree of esterification  5.9 % 36 % 69 % 
Degree of amidation - - - 
Content of galacturonic acid 76 % 79 % 88 % 
pH value (2.5 % in dist. H2O, 
20 °C) 
4.0 3.0 3.1  
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7.3.2 Methods 
7.3.2.1 One-step procedure of pectin-zein hydrogel bead production 
The one-step production was conducted according to Liu et al. (2006). First, pectin (P69, P36 
or P5.9) were dissolved in milliQ water, P36 was heated up to be dissolved. The pectin 
concentration was either 2 % or 4 % (w/w). NA or NAM was added to the polymer solution 
(0.5, 5 or 20 % (w/w)). The pectin(-vitamin) solution was directly dropped into a cross-
linking solution consisting of calcium chloride (0.5 % (w/w)) and zein (1, 3 or 5 % (w/w)) 
dissolved in 75 % ethanol under constant stirring (100, 150 or 200 rpm) from a dropping 
distance of 9.5, 1.5 or 0.5 cm above the water surface. The used technique in the present study 
is illustrated in Figure 7.1 and a scheme of the procedure is shown in Figure 7.2A. For bead 
formation, a tube with a diameter of 0.9 mm was used, which was connected to a syringe 
pump. The beads cured for 15 minutes in the cross-linking solution (non-isotonic process). In 
some experiments, the cross linking solution contained the same vitamin concentration as in 
the polymer solution (isotonic process). The formed beads were collected in a sieve. Ethyl 
acetate and distilled water were used for washing. Beads were air dried on a filter paper over 
night.  
 
7.3.2.2 Two-step procedure of pectin-zein hydrogel bead production 
In the first step, the pectin solution (P5.9, 4 % (w/w) or P36, 8 % (w/w)) combined with 
different amounts of NAM (0, 5 or 20 % (w/w)) was dropped into the cross-linking solution 
(Figure 7.1) only consisting of calcium chloride dissolved in distilled water (0.5, 2 or 4 % 
(w/w)) under constant stirring (150 rpm). The formed beads were cured for 30 minutes in the 
cross linking solution (non-isotonic or isotonic conditions). In the second step, the beads were 
stirred in a zein solution (1, 5 or 15 % (w/w)), which was dissolved in 75 % ethanol, for 60 
minutes at 250 rpm (Figure 7.2B). The pectin-zein beads were washed and dried as described 
in the one-step-procedure. In some cases, multiple zein coating were conducted with an 
intermediate drying step.  
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Figure 7.1: Picture of the pectin bead preparation technique used in the present study 
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Figure 7.2: Overview of the one-step production process (A) and the two-step production 
process (B) for pectin bead formation 
 
7.3.2.3 Feasibility study of the encapsulation processes using whey protein isolate (WPI) 
Instead of niacin, WPI was encapsulated to study the feasibility of the two production 
processes. The influence on the morphology, the encapsulation efficiency and the release 
profile was examined. Therefore, 2.5 % (w/w) of WPI was added to the P5.9 pectin solution 
(4 % w/w). This solution was dropped into a non-isotonic cross-linker solution by the one-
step and the two-step procedure. Afterwards the beads were dried over night.  
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7.3.2.4 Two-step procedure of pectin-zein-fibrils hydrogel bead production 
Whey protein isolate (WPI) fibrils were added to the pectin-vitamin solution and produced as 
described in the two-step procedure. Only pectin P5.9 was used. The production of the WPI-
fibrils was according to (Serfert et al., 2014). WPI was added to milliQ-water (2.5 % (w/w)). 
Afterwards the pH value was adjusted to pH 2 (±0.05) using 6N HCl. The solution was stirred 
at 250 rpm in a water bath at 90 °C for 5 hours, cooled down and stored at +4 °C. Before 
adding the final solution to the pectin, NAM (3.3 % (w/w)) was added to the fibril solution 
(1.67 % (w/w)) and the pH value was adjusted to pH 4 (±0.05) using 6N HCl. The resulting 
fibril concentration is related to the concentration of WPI in the stock solution. Subsequently, 
pectin (4 % (w/w)) was added. The cross-linking bath was prepared isotonic with a calcium 
chloride concentration of 6 % (w/w). The following steps were equivalent to the two-step 
procedure of pectin-zein hydrogels with a zein concentration of 5 % (w/w).  
 
7.3.2.5 Two-step procedure of pectin-shellac(-fibrils) hydrogel bead production 
To get a direct comparison of the pectin-zein-hydrogels, also pectin-shellac hydrogels were 
developed and characterized. Therefore, shellac from ethanolic solution and shellac from an 
aqueous solution of alkali salts (water dispersable shellac; wd-shellac) was used as outer 
coating material instead of zein. The used pectin type was P5.9 (4 % (w/w)) in combination 
with or without fibrils (1.67 % (w/w)) as described above. The NAM concentration was 5 % 
(w/w) for pure pectin beads and 3.3 % (w/w) for pectin-fibril beads. After dropping the pectin 
solution into the calcium chloride bath (6 (with fibrils) or 2 % (w/w)), the formed beads were 
stirred at 250 rpm for 1 h in an ethanolic shellac solution or in wd-shellac (5 % w/w) for 1, 5 
or 15 minutes. Afterwards, the beads were air dried overnight.  
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Figure 7.3: Overview of the one-step procedure process parameter variations to study their 
effects on the bead morphology 
 
vitamin type and concentration *
0 % NAM 0.5 % NAM 5 % NAM 10 % NAM 15 % NAM 20 % NAM 30 % NAM 0.5 % NA 5 % NA
pH-value of cross-linking-zein-solution *
2 4 6 6,8 ** 11,8
CaCl2-concentration in cross-linking-zein-solution *
0,5 % 2% 4 % 6 %
needle type and diameter  *
0,9 x 40 mm (sloped) 0,8 x 22 mm (blunt) 0,4 x 20 mm (sloped) 0,4 x 25 mm (blunt)
stirring rate in cross-linking-zein-solution *
100 rpm 150 rpm 200 rpm
dripping distance *
0.5 cm 1.5 cm 9.5 cm
pectin type and concentration (2 % / 4 %) 
P5.9 P36 P69
* experiments were only done using P5.9 
** pH-value of the cross-linking-zein solution without adjustment 
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Figure 7.4: Overview of the two-step procedure process parameter variations to study their 
effects on the bead morphology 
 
7.3.2.6 Viscosity of polymer solutions 
The viscosity of the polymer solution before and after the addition of NAM was examined 
using a viscometer (Haake Viscotester iQ, Thermo Fisher Scientific, Waltham, USA). About 
15 ml of the solution was added. Viscosity tests were run at 20, 50, 100 and 200 rpm.  
 
7.3.2.7 Morphology of hydrogel beads 
The gross morphology of the hydrogel beads was documented by using a light microscope 
(Motic Microscoped, Wetzlar, Germany), which was connected to a camera (Canon Legria 
HF20, Tokyo, Japan). The images were recorded with a 20-times and 50-times magnification. 
* experiments were only done using P5.9 
** pH-value of the cross-linking-zein solution without adjustment 
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Samples were prepared either from dried hydrogel beads or from fresh beads after different 
production steps.   
For scanning electron microscope (SEM) pictures beads were prepared on a holder with 
carbon Leit-tabs (Plano GmbH, Wetzlar, Germany). Some of them were cut using a scalpel. 
Before examination in a Hitachi S-4800 SEM (Hitachi High Tech., Tokyo, Japan) at an 
accelerating voltage of 3 kV, microcapsules were sputter-coated with a layer of 8-10 nm gold-
palladium using a Leica EM SCD 500 (Leica Microsystems GmbH, Wetzlar, Germany) high-
vacuum sputter coater.  
 
7.3.2.8 Encapsulation efficiency 
The encapsulation efficiency (EE) of NA or NAM was defined as the ratio of the actual 
content of the encapsulated substance and the theoretical amount in dried hydrogel beads, 
which was calculated according to the following equation: 
𝐸𝐸 [%] =
(
 
 
 
 
𝑎𝑐𝑡𝑢𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 [
𝑚𝑔
𝑚𝑙 ]
𝑠𝑎𝑚𝑝𝑙𝑒 𝑤𝑒𝑖𝑔ℎ𝑡 [𝑚𝑔] ∗ (
𝑎𝑑𝑑𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 [
𝑚𝑔
𝑚𝑙 ]
𝑑𝑟𝑦 𝑚𝑎𝑠𝑠 [
𝑚𝑔
𝑚𝑙 ]
)
)
 
 
 
 
∗ 100 
 
Before measuring the EE, dried pectin-zein(-protein) hydrogel beads were dissolved in 
McIlvaine citrate-phosphate buffer with a pH value of 5.0. Furthermore, pectinase was added 
to macerate the beads and to achieve a total release of the encapsulated vitamin. Samples were 
taken after 5 hours under stirring. Afterwards, the samples were filtered through 0.2 µm 
syringe filters (regenerated cellulose membrane, Macherey-Nagel GmbH & Co. KG, Düren 
Germany) and frozen at -18 °C until they were subjected to HPLC analysis.  
For pectin-shellac hydrogel beads and for WPI loaded beads, the same sample preparation 
was done with the exception of used Soerensen phosphate buffer with a pH value of 7.4 
instead of the citrate-phosphate buffer with a pH value of 5.0, to dissolve the shellac coating. 
In case of WPI loaded beads, a higher pH value was chosen due to the IEP of WPI at pH 
value 5.35 – 5.41, which would result in a low solubility of WPI and therefore in an 
Manuscript V: Niacin loaded pectin-zein-hydrogel beads 
163 
 
incomplete determination of the encapsulated amount. Furthermore, the sample collection was 
taken after stirring overnight.  
 
7.3.2.9 In vitro gastric resistance  
In vitro dissolution tests were carried out in triplicate at 37 °C at 100 rpm using a basket 
apparatus (DT 70, Pharmatest Group, Hainburg, Germany). Depending on the EE, amounts of 
150 – 5000 mg beads were weight into 250 – 400 ml simulated gastric fluid. As simulated 
gastric fluid either a McIlvaine buffer of pH 3.5 or a buffer with a pH of 1.4 was used as 
described in Manuscript III (in submission). After 30 and 60 minutes, a sample was taken to 
determine the released amount of vitamin. The samples were filtered through 0.2 µm syringe 
filters and frozen at –18 °C.  
For the shellac coated beads, the whole gastrointestinal tract was simulated. Therefore, after 
the gastric residence time, the beads were transferred to Soerensen buffers with a pH value of 
6.8 for 2 h, followed by a pH value of 7.4 for 1.5 h. In addition, the release of β-LG from WPI 
loaded beads was documented during a simulated gastric phase (pH 3.5) for 1 h, followed by 
the small intestine at a pH value of 7.4 for 4 h and the colon at a pH value of 5.0 with added 
pectinase.  
 
7.3.2.10 Determination of NA and NAM 
Frozen samples were defrosted and mixed thoroughly prior to the NA and NAM content 
analysis by RP-HPLC (reversed phase high performance liquid chromatography) using the 
Agilent 1100 Series with diode array detector (Agilent Technologies, Santa Clara, USA) and 
C18-Sphinx column (Nucleodur Sphinx RP, 5 µm, Macherey-Nagel, Düren, Germany). The 
injection volume was 10 µl at a flow rate of 1 ml/min using eluent A (0.1 % (v/v) TFA in 
milliQ water) and eluent B (0.1 % (v/v) TFA in acetonitrile). The elution used gradient steps 
of 95 % A (0 – 1 min), 95 – 5 % A (1 – 10 min), 5 % A (10 – 10:50 min) and 5 – 95 % A 
(10:50 – 12 min). The column temperature was set to 20 °C and the detection wavelength was 
262 nm.  
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7.3.2.11  Determination of beta-lactoglobulin (β-LG) from WPI 
Bevor quantification of β-LG, samples were filtered through 0.2 µm syringe filters (PET-
30/13 membrane, Macherey-Nagel GmbH & Co. KG, Düren Germany). Afterwards the 
measurements were performed using a Thermo Scientific Dionex UltiMate 3000 HPLC 
(Waltham, USA) with a diode-array detector and PLRP-S column (300 Å, 8 µm, 150 x 4.6 
mm, Agilent Technologies, Santa Clara, USA). For the analytical separation the injection 
volume was 40 µl at a flow rate of 1 ml/min and a column temperature of 40°C using Eluents 
A (0.1 % (v/v) TFA in water) and B (0.1 % (v/v) in ACN). The elution used gradient steps of 
35-38 % B (1-8 min), 38-42 % B (8-16 min), 42-46 % B (16-22 min), 46-100 % B (22-22.5 
min) and 100-35 % B (23-23.5 min). The detection wavelength was 205 nm. 
 
7.3.2.12 Statistical analysis 
All results are expressed as arithmetic means and standard deviation of the replicated 
analyses. The EE was analyzed by ordinary one-way ANOVA with Tukey multiple 
comparison test and a significance level of 0.05. The statistics and the figures were done with 
GraphPad Prism (version 6, GraphPad Software, San Diego, CA, USA).  
 
7.4 Results 
The viscosity of the pectin solutions used for hydrogel bead formation was determined before 
and after addition of NAM (Figure 7.5A+B). In general, the P36 indicated a higher viscosity 
at room temperature compared to P5.9 and the viscosity decreased if temperature was 
increased to 45 °C. Furthermore, the higher the pectin concentration, the higher the viscosity. 
The addition of fibrils (1.67 % (w/w)) led to a higher viscosity with an increase of about 100 
mPa·s, whereas the addition of WPI resulted in no change of the viscosity. Moreover, as 
illustrated in Figure 7.5B, the addition of NAM resulted in a significant reduction of the 
viscosity. Different viscosities showed a different behavior in dripping. The pectin solution of 
8 % P36 (w/w) at room temperature was too viscous to drop (about 1800 mPa·s).  
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Figure 7.5: Viscosity (mPas) of polymer solution without (A) and with (B) added 
nicotinamide (NAM) 
 
7.4.1 Feasibility study of the encapsulation of WPI 
According to the results shown by Liu et al. (2006), the encapsulation of bovine serum 
albumin (BSA) into pectin-zein hydrogel beads led to a colon-targeted release. In the present 
study, WPI was encapsulated to prove the production process and the process parameters 
regarding their feasibility to encapsulate and to achieve a colon-targeted release.  
As shown in Figure 7.6, the morphology of WPI loaded pectin beads depends on the 
production process. Whereas the two-step procedure led to spherical particles, the one-step 
beads resulted in red blood cell shaped beads. The encapsulation efficiency varied from 26.9 
% (one-step) to 19.6 % (two-step). The release of β-LG from WPI loaded pectin beads was 
recorded (Figure 7.7). During the first 90 minutes, no release occurred, afterwards the release 
increased to 90 % after 300 minutes at a pH value of 7.4. The release of β-LG was slower, 
when the beads were produced by the two-step method. These results indicated appropriate 
parameters of the pectin-zein hydrogel bead preparation and a low release during the gastric 
phase (pH 3.5). WPI is mainly consisting of β-lactoglobulin (75 %) and α-lactalbumin with a 
molecular weight (MW) of about 18 and 14 kDa, which is lower compared to BSA (66.5 kDa) 
and could explain the faster drug release. Despite the fact that WPI tends to build some 
oligomers (<10 nm) at a pH value of 3.5 (Keppler et al., 2017), which could delay the release 
of WPI at this pH value, the same study also showed that the zeta-potential is approximately 
+20 mV, thus the protein is able to dissolve in the dissolution medium. In addition, Liu et al. 
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gave evidence that BSA encapsulated in similar beads was also able to be liberated at these 
conditions (Liu et al., 2006), although BSA has a higher molecular weight and its isoelectric 
point (pH 4.5 – 5.0) (Phan et al., 2015) is even lower than WPI (pH 5.0) (Keppler et al., 
2017). 
In conclusion, the feasibility of the process is given despite less favorable properties of the 
protein source WPI compared to BSA.  
 
Figure 7.6: Morphology of WPI loaded pectin hydrogel beads prepared by the (A) one-step 
procedure and (B) two-step procedure. Light microscope, 50-times magnification.   
 
 
Figure 7.7: Release of beta-lactoglobulin from WPI loaded pectin hydrogel beads produced 
by the one-step and the two-step procedure (mean ± SD, n=3). 
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7.4.2 Morphology of pectin hydrogel beads prepared by one-step procedure 
Three different pectin types (DE 69 %; 36 % and 5.9 %) with a concentration of 2 and 4 % 
(w/w) were compared in their ability to form hydrogel beads with encapsulated NAM (Figure 
7.8). As expected, the hydrogel bead formation using a pectin with the highest DE (69 %) 
resulted in very soft hydrogel beads after dripping, whereby the beads lost their cohesion after 
drying. In contrast, LM pectin with a DE of 36 and 5.9 % led to a bead formation at a 
concentration of 2 and 4 % (w/w). Non-spherical particles were formed with a shape of red 
blood cells (biconcave disk with a flattened center). Higher pectin concentration of 4 % (w/w) 
always resulted in the formation of more regular and voluminous beads.  
Further experiments were conducted with the pectin type P5.9 exhibiting the lowest DE and a 
processing at room temperature. Regarding the effect of the encapsulation compound on the 
morphology, pectin-zein hydrogel beads were prepared without NAM (Figure 7.9A). No 
effect on the sphericity has been seen. Both, before and after drying the beads showed a 
hollow on their surface. The exclusion of ethanol in the cross-linking solution (Figure 7.9B) 
resulted in beads that are more spherical after dripping, which formed a disky shape after 
drying.  
 
 
Figure 7.8: Comparison of one-step-procedure hydrogel beads made from different pectins 
P69 (orange box), P5.9 (green box) and P36 (purple box) with different concentration of 2 % 
(w/w) (always left) and 4 % (w/w) (always right) before (top) and after (bottom) drying. Light 
microscope pictures; 20 times magnification.  
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Figure 7.9: Effect of encapsulated NAM and zein coating on the morphology of P5.9 hydrogel 
beads. (A) Hydrogel beads of 4 % (w/w) P5.9 without encapsulated NAM produced in a one-
step-procedure with zein-CaCl2-precipitation (75 % EtOH) bath before (top) and after 
(bottom) drying. (B) Hydrogel beads of 4 % (w/w) P5.9 with 0.5 % (w/w) NAM dripped in 
CaCl2-precipitation bath dissolved in water before (top) and after (bottom) drying. Light 
microscope pictures; 20 times magnification (left); 50 times magnification (right). 
 
7.4.2.1 Dripping height 
However, the influence of further process parameters was investigated to analyze the resulting 
bead shapes during the one-step procedure. As shown in Figure 7.10, the dripping height 
(distance between needle and solution surface) was reduced from 9.5 cm to 1.5 and 0.5 cm. 
The highest distance resulted in irregular and flattened particles, whereby a distance of 1.5 cm 
produced red blood cell shaped particles as already observed. A minimal distance of about 0.5 
cm resulted in drop-shaped beads. For further experiments, a dripping height of 1.5 cm was 
chosen.  
Parameters such as stirring rate (100, 150 and 200 rpm), CaCl2 concentration (0.5, 2, 4 and 6 
% (w/w)) and pH value of the precipitation bath (2, 4, 6, 6.8 and 11.8 by addition of HCl or 
NaOH) had no effect on the morphology of formed beads. The use of a smaller needle (0.4 
mm inner diameter) resulted in smaller beads with the same shape compared to the bigger 
needle (0.9 mm inner diameter) (data not shown).  
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Figure 7.10: Effect of dripping height on P5.9 hydrogel beads formation in a one-step-
procedure. Left: 9.5 cm; middle: 1.5 cm; right: 0.5 cm distance between needle and solution 
surface. Light microscope pictures; 20 times magnification (top); 50 times magnification 
(bottom). 
 
7.4.2.2 NAM and NA concentration 
The addition of NAM to the pectin solution was increased from 0.5 to 5, 10, 15, 20 and 30 % 
(w/w). With increasing NAM concentration the total encapsulation of NAM was reduced, 
whereby a notable crystallization of NAM on the bead surface occurred (Figure 7.11A). The 
concentration of 0.5 and 5 % NA (w/w) showed the same shape (hollow surface) as 
demonstrated with NAM. In case of 5 % NA a clearly separation of the NA in the inner core 
was found (Figure 7.11B).  
 
 
Figure 7.11: Effect of the encapsulated compound at its concentration on dried P5.9 hydrogel 
beads of one-step-procedure. (A) 0.5, 5, 10, 15, 20 and 30 % (w/w) NAM. (B) 0.5 and 5 % 
(w/w) NA. Light microscope pictures; 50 times magnification. 
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7.4.3 Morphology of pectin hydrogel beads prepared by two-step procedure 
The results for the pectin P5.9 and P36 beads regarding morphology in the two-step procedure 
are illustrated in Figure 7.12. It is shown, that a pectin concentration of 4 % (w/w) resulted in 
almost spherical particles with a small hollow at the surface. Furthermore, the surface seemed 
to be more wrinkled compared to the one-step produced particles. The enhancement of the 
pectin concentration to 6 % (P5.9) or 8 % (P36) led to bigger and more regular and spherical 
particles.  
Furthermore, the effect of the CaCl2 concentration in the cross-linking solution was examined 
using 4 % P5.9 pectin (Figure 7.13). The results showed no clear trend regarding the 
sphericity of the hydrogel beads. However, the lowest CaCl2 concentration of 0.5 % resulted 
in beads with the smallest diameter. The enhancement to 4 % CaCl2 led to very irregular 
beads, whereby a concentration of 6 % showed more or less regular and round beads.  
Process parameter such as drying in a drying oven and pH value of the CaCl2 bath (2, 4, 6, 9.8 
and 11.8 adjusted with HCl or NaOH) had no influence on the morphology of the beads.  
 
Figure 7.12: Comparison of two-step-procedure hydrogel beads made from different pectins 
P5.9 (green box) and P36 (purple box) with different concentration of 4 % (w/w) (always left 
hand side) and 6 % (w/w) (right hand side for P5.9) or 8 % (w/w) (right hand side for P36) 
after drying. Light microscope pictures; 20 times magnification (top); 50 times magnification 
(bottom). 
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Figure 7.13: Effect of different CaCl2 concentrations on P5.9 hydrogel bead formation in a 
two-step-procedure after drying from the precipitation bath. From left to right: 0.5, 2, 4 and 6 
% CaCl2 (w/w). Light microscope pictures; 20 times magnification (top); 50 times 
magnification (bottom). 
 
The enhancement of the NAM concentration from 5 to 20 % (w/w) in the dripping solution 
resulted in drop shaped particles (Figure 7.14). After drying, NAM crystallized at the surface.  
 
Figure 7.14: Effect of NAM concentration on P5.9 hydrogel bead formation after dripping in 
CaCl2 bath before (top) and after (bottom) drying. Left: 5 % (w/w) NAM, right: 20 % (w/w) 
NAM. Light microscope pictures; 20 times magnification. 
 
Further, WPI fibrils were added to enhance the sphericity. As demonstrated in Figure 7.15, 
the inclusion of fibrils caused a structuring effect leading to spherical beads.  
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Figure 7.15: Effect of fibril inclusion on morphology of P5.9 hydrogel beads (two-step-
procedure) after drying. Light microscope pictures; 20 times magnification (left); 50 times 
magnification (right). 
 
Additionally, P5.9 beads were also evaluated after a coating step in eth. shellac or wd-shellac 
(instead of zein). As demonstrated in Figure 7.16, the shape was not changed and was still 
flat with hollow surface for eth. shellac (A) and wd-shellac for 1 min (B), whereby the wd-
shellac began to gel after approximately 5 minutes, which resulted in irregular coated beads 
(C).  
 
 
7.4.4 Encapsulation efficiency (EE) of NA and NAM  
All hydrogel bead combination, which were evaluated for the EE are shown in Table 7.2. In 
general, the two different procedures significantly influenced the EE. A higher EE was 
generated using the one-step procedure. Furthermore, beads showed always a significant 
higher EE, when the conditions were isotonic compared to non-isotonic: 52.63 vs. 18.72 % 
EE of NAM for one-step produced  pectin-zein beads and 18.10 vs. 3.75 % EE of NAM for 
two step produced pectin-zein beads. Furthermore, it was evident, that the EE of NA (43.64 
A B C A B 
Figure 7.16: Effect of ethanolic shellac coating for 60 min (A), wd-shellac coating for 1 min (B) 
and wd-shellac coating for 5 min (C) on morphology of P5.9 hydogel beads (two-step-procedure) 
after drying. Light microscope pictures; 20 times magnification (A); 10 times magnification (B, 
C). 
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%) was significantly higher than of NAM (18.72 %). The enhancement of the zein 
concentration showed no significant effect on the EE, regardless of the pectin type P5.9 or 
P36 and the pectin concentration. The use of 8 % P36 resulted in a significant higher EE 
(24.64 %) compared to 4 % P5.9 (18.72 %).  In case of the two-step procedure, it was evident 
that the use of 4 or 8 % of P36 and 1 % zein had no significant effect on the EE. The EE for 
different coating materials with isotonic procedure showed the following order: ethanolic 
shellac (28.41 %) > zein (18.10 %) > wd-shellac (11.84 %). The lower incubation time (1 
min) in wd-shellac resulted in a higher EE compared to an incubation time of 5 or 15 min. 
Moreover, the addition of fibrils led to a significant reduction in the EE for all coating 
formulations with zein (11.81 %), ethanolic shellac (17.52 %) and wd-shellac (5.96 %).  The 
lowest EE was observed for beads, which were subsequently coated three times in a zein 
coating solution (0.68 %). If the beads were dried between the coating steps, the EE was 8.73 
% after four coating cycles.   
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Table 7.2: Encapsulation efficiency (EE) of NA or NAM of different formulations after one-
step- or two-step-procedure (n=3). Abbreviations: NA=nicotinic acid; NAM: nicotinamide; 
iso.=isotonic; n. iso.= non isotonic. Different letters indicate a statistically significance 
(p=0.05) in one group (one-step or two-step-procedure). 
procedure vitamin pectin 
conc. 
pectin 
type 
iso. 
vs. n. 
iso. 
coating 
material 
conc. 
coating 
material 
additives EE ± SD 
(sign.) 
one-step NA 4 % P5.9 n. iso. 1 % zein (15 min) - 43.64 ± 1.95 % 
(a) 
one-step NAM 4 % P5.9 n. iso. 1 % zein (15 min) - 18.72 ± 0.35 % 
(b) 
one-step NAM 4 % P5.9 iso. 1 % zein (15 min) - 52.63 ± 0.89 % 
(c) 
one-step NAM 4 % P5.9 n. iso. 3 % zein (15 min) - 18.10 ± 0.35 % 
(b) 
one-step NAM 4 % P5.9 n. iso. 5 % zein (15 min) - 17.89 ± 0.19 % 
(b) 
one-step NAM 8 % P36 n. iso. 1 % zein (15 min) - 24.64 ± 0.34 % 
(d) 
one-step NAM 8 % P36 n. iso. 5 % zein (15 min) - 23.48 ± 0.25 % 
(d) 
         
two-step NAM 4 % P5.9 n. iso. 1 % zein (60 min) - 3.75 ± 0.18 % 
(ac) 
two-step NAM 4 % P5.9 n. iso. 15 % zein (60 min) - 2.71± 0.01 % 
(ab) 
two-step NAM 4 % P5.9 iso. 1 % zein (60 min) - 18.10 ± 1.00 % 
(d) 
two-step NAM 4 % P5.9 iso. 5 % zein (3x wet; 60 
min) 
- 0.68 ± 0.06 % 
(b) 
two-step NAM 4 % P5.9 iso. 5 % zein (4x dried; 
60 min) 
- 8.73 ± 0.11 % 
(e) 
two-step NAM 4 % P5.9 iso. 5 % eth. shellac - 28.41 ± 0.13 % 
(f) 
two-step NAM 4 % P5.9 iso. 5 % wd-shellac 
(1min) 
- 26.98 ± 2.73 % 
(f) 
two-step NAM 4 % P5.9 iso. 5 % wd-shellac 
(5min) 
- 10.80 ± 0.23 % 
(eg) 
two-step NAM 4 % P5.9 iso. 5 % wd-shellac 
(15min) 
- 11.84 ± 1.11 % 
(g) 
two-step NAM 4 % P36 n. iso. 1 % zein (60 min) - 2.94 ± 0.06 % 
(ab) 
two-step NAM 4 % P36 iso. 1 % zein (60 min) - 17.99 ± 0.12 % 
(d) 
two-step NAM 8 % P36 n. iso. 1 % zein (60 min) - 3.88 ± 0.08 % 
(ah) 
two-step NAM 8 % P36 n. iso. 5 % zein (60 min) - 5.51 ± 0.28 % 
(ch) 
two-step NAM 8 % P36 iso. 1 % zein (60 min) - 16.82 ± 0.11 % 
(d) 
two-step NAM 4 % P5.9 iso. 5 % zein (60 min) + fibrils 11.81 ± 0.03 % 
(g) 
two-step NAM 4 % P5.9 iso. 5 % eth. shellac (60 
min) 
+ fibrils 17.52 ± 0.77 % 
(d) 
two-step NAM 4 % P5.9 iso. 5 % wd-shellac 
(15min) 
+ fibrils 5.96 ± 0.52 % 
(ah) 
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7.4.5 Gastric resistance of pectin-zein hydrogel beads 
Several bead formulations were evaluated for their release profile in an in vitro dissolution 
tester simulating gastric conditions (pH 3.5 for 1 h) (Figure 7.17). It is clearly shown that 
none of the formulation covered with zein by one-step or two-step procedure (Figure 
7.17A+B) showed gastric resistance. After 30 min of incubation 80 – 100 % NA or NAM 
were released. The release was independent of the vitamin, the pectin type and concentration, 
the production process, the EE (high vs. low vitamin content), the zein concentration and the 
sphericity.  
In comparison, the release after coating with ethanolic shellac was comparable to zein coated 
beads and resulted in no delayed release. In contrast, the incubation of NAM-pectin beads for 
15 min in wd-shellac led to a gelation of the whole shellac solution. However, it also resulted 
in a reduction of the release: below 40 % released NAM were detected after 60 min at pH 
value 3.5 (Figure 7.17C).  
The addition of fibrils caused no effect on the release: The zein and ethanolic shellac coated 
beads indicated a complete release of NAM after 30 min, whereby the release of NAM from 
pectin-wd-shellac beads was slightly higher compared to the formulation without fibrils. 
Interesting is, that the release of NAM was only slightly enhanced to about 60 % after 
crushing the wd-shellac coated beads (Figure 7.17D).  
Based on these results, the release profile of NAM from pectin-wd-shellac beads after an 
incubation for 1 and 5 min in the shellac solution was evaluated under simulated 
gastrointestinal conditions (stomach to ileum) (Figure 7.18). After 60 min at gastric 
conditions (pH 3.5), the beads were transferred to small intestine conditions (pH 6.8) and 
conditions of the ileum (pH 7.4). The release increased from 36 or 53 % after 30 min at pH 
3.5 to 73 or 88 % after 180 min at pH 6.8 for 5 and 1 min shellac incubation, respectively. 
After 240 min at pH 7.4, the whole amount of encapsulated NAM was released. The release 
was slightly higher for beads coated only 1 min vs. 5 min.  
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Figure 7.17: Release of nicotinic acid (NA) or nicotinamide (NAM) from hydrogels at pH 3.5 
after 30 and 60 minutes (mean±SD, n=3). (A) Hydrogels prepared by one-step-procedure 
with zein coating; (B) Hydrogels prepared by two-step-procedure with zein coating; (C) 
Hydrogels prepared by two-step procedure with shellac coating; (D) Hydrogels prepared by 
two-step-procedure with added fibrils and different coatings. Unless otherwise noted, NAM 
was encapsulated. 
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Figure 7.18: Release profile of two-step-hydrogels with NAM encapsulated in 4 % P5.9 and 
coated with wd-shellac for 1 or 5 minutes (mean±SD, n=3). 
 
7.4.6 Surface characteristics of coated pectin hydrogel beads 
The surface of pectin hydrogel beads was characterized by SEM (Figure 7.19). All bead 
formulations showed large cracks and pores (highlighted by red arrows and circles). 
Furthermore, the two-step produced beads led to a wrinkled surface (C-F). The enhancement 
of the zein concentration to 15 % led to a clear separation of pectin bead and zein covering 
(E). In general, the surface of one-step produced beads showed a smoother surface (A+B) 
compared to the two-step process. Bead containing fibrils had a rough surface with some 
holes in the inner core (G).  
The wd-shellac coated NAM-pectin bead is shown in Figure 7.20. A part of the shellac 
coating was already lost and showed a small gap between the pectin bead and the outer 
shellac coating. Furthermore, the cross section of the shellac coating reflected small 
crystalline areas. The surface was rough and small microstructures were detected.  
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Figure 7.19: SEM pictures of surface characteristics of different hydrogel beads.(A) One-step 
P5.9 bead; 5 % NAM; n. iso.; 1 % zein. (B) One-step )P5.9 bead; 5 % NA; n. iso.; 1 % zein. 
(C) Two-step P36 bead; 5 % NAM, n. iso; 1% zein. (D) Two-step P5.9 bead; 5 % NAM, n. 
iso; 1% zein. (E) Two-step P5.9 bead; 5 % NAM, n. iso; 15% zein. (F) Two-step P5.9 bead; 5 
% NAM, n. iso; 4x zein. (G) Two-step P5.9 bead with added fibrils; 3.3 % NAM; n. iso.; 1 % 
zein 
 
 
Figure 7.20: SEM pictures of two-step P5.9 hydrogel bead coated with wd-shellac for 1 min. 
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7.5 Discussion 
In general, the shape of particles can influence the release rate of the encapsulated compound. 
The low specific surface area of spherical particles is associated with a lower dissolution rate 
than for disc or red blood cell shaped particles (Guo and Kaletunç, 2016; Harvestine et al., 
2014). The shape of such particles can be influenced by dripping distance, the polymer 
viscosity and surface tension, the drying conditions, hardening addition and hardening time, 
crosslinker type, concentration and temperature, addition of fillers and the surface tension of 
the gelling bath (Bourgeois et al., 2005; Chan et al., 2009; Chan et al., 2011; Davarcı et al., 
2017; Guo and Kaletunç, 2016; Henning et al., 2012; Nithitanakool et al., 2013; Smrdel, 
2008; Sriamornsak and Nunthanid, 1999). Therefore, in the present study varying process 
conditions were studied for effect on the shape of niacin loaded pectin hydrogel beads. 
Furthermore, the influence of different forms and formulations of pectin hydrogel beads were 
evaluated regarding their encapsulation efficiency and gastric resistance. 
 
7.5.1 Morphology of pectin hydrogel beads 
As expected, pectin with the highest DE (P69) was not able to form stable hydrogel beads, 
whereas P36 and P5.9 produced stable beads. This can be explained by the higher amount of 
free carboxylic groups that react with the calcium ions to form a gel. Zones with a low DE in 
the molecule are necessary to obtain crosslinking by Ca2+ (Sande, 2005). However, the DE 
did not influence the bead morphology, both DE resulted in bowl-like indentations of the bead 
surface. This is contrary to the results of Liu et al., who used the same one-step production 
procedure. They generated roughly spherical pectin and pectin-zein beads, while using an 
alkaline de-esterified citrus pectin (2 % w/v) with a corresponding DE of 10 – 16 % (Liu et 
al., 2004; Rubinstein et al., 1993)). This was comparable to the DE of P5.9 in the present 
study, which was desterified using an alkaline process. They encapsulated indomethacin and 
BSA (Liu et al., 2006), which could also influence the morphology of hydrogel beads due to 
the lower water solubility of indomethacin compared to niacin and the higher molecular 
weight of BSA. However, the encapsulation of WPI in the feasibility study also resulted in 
flattened particles with a hollow, when produced by the one-step method, despite WPI has a 
lower solubility and a higher molecular weight (MW) compared to NAM. In fact, other 
publication also showed calcium pectinate beads (DE: 27 – 32 %) with a hollow at the surface 
(Bourgeois et al., 2005; Nithitanakool et al., 2013; Sriamornsak and Nunthanid, 1999), which 
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is comparable to the present results. They explained the deformation as a result of 
insufficiently strong beads and a collapse during the drying process. In the present study, the 
hollow surface was formed already prior to the drying step of the one-step produced particles. 
Therefore, the influence of ethanol as solvent in the zein bath and CaCl2 cross-linking solution 
was considered. It is mentioned, that ethanol could lead to a precipitation of alginate and a gel 
collapse, which results in a decreased volume (Moe et al., 1993). This could also apply to the 
present observation with pectin, due to loss of elasticity (Chotiko and Sathivel, 2017). 
Furthermore, the surface tension influences the bead formation due to changed impacts 
between the liquid pectin drop and the cross-linking bath. Davarci et al. documented a higher 
penetration depth of alginate droplets when the surface tension of the CaCl2 solution 
decreased, which is in accordance to the present results. The reduced surface tension also led 
to more spherical beads, which was explained due to a higher penetration depth (> 15 mm) 
(Davarcı et al., 2017). Despite 70 % ethanol solution used in the present study exhibits a 
lower surface tension of 25.48 mN/m (Vazquez et al., 1995) compared to the lowest surface 
tension of the CaCl2 solution measured by Davarci et al. (37.05 mN/m) were deformed. For 
Ca-alginate beads it was documented, that the formation of spherical beads was strongly 
dependent on the liquid properties such as surface tension and viscosity of the alginate 
solution. When an alginate bead was dropped into the cross-linking solution, two forces were 
competing, which affected the drop shape: the viscous-surface tension forces of the drop and 
the impact-drag forces of the surrounding fluid. If the viscosity of the drop was too low, the 
viscous-surface tension forces were lower than the minimum forces required to counteract the 
impact-drag forces, which led to a deformation of the drop. For alginate a minimal viscosity 
of 50 – 60 mPa*s was documented (Chan et al., 2009). The P5.9 solution of the present study 
had a viscosity of 112 and 69 mPa*s without and with 5 % (w/w) NAM, which is above the 
critical viscosity to counteract the impact-drug forces. Nevertheless, a deformation was 
observed with both solutions.  
In the present study, the dripping distance showed a significant influence on the bead shape. 
This was also described for alginate beads produced by ionotropic gelation. A dripping 
distance of more than 6 cm illustrated flattened particles (Fundueanu et al., 1999; Smrdel, 
2008), whereby smaller distances led to beads with a short tail (Fundueanu et al., 1999). 
Hydrogel beads consisting of a combination of pectin and alginate resulted in disk shaped 
particles with increasing dripping distance (Guo and Kaletunç, 2016), which is in accordance 
with the present results. However, the red-blood cell shape could not be prevented by 
changing the dripping distance. The stirring rate showed no effect on the shape of pectin 
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beads, which could be explained by the low sheer stress at a stirring rate of 100 to 200 rpm. 
During the formation of flattened particles were formed above 600 rpm (Smrdel, 2008).  
The variation of the CaCl2 concentration only affected the shape of pectin beads in the two-
step procedure. In comparison with others, the effect of CaCl2 concentration was often studied 
with regard to its effect on the EE and the release of the encapsulated compound. Sriamornsak 
showed a slower release of BSA with increasing CaCl2 concentrations, which was explained 
due to a stronger gel (Sriamornsak, 1999). A stronger gel at higher CaCl2 concentrations could 
be an explanation for a stronger cohesion and therefore for a more spherical bead. Sande et al. 
postulated a high gel strength for pectin calcium gels with 12 – 14 mg Ca/g pectin. In the 
present study, significantly higher ratios were used amounting to 680 – 2770 mg Ca/g pectin.  
The increase of the NAM concentration above 5 % (w/w) in the pectin solution resulted in 
overloaded beads with visible NAM crystals on the surface. The crystallization could occur 
due to the high NAM content in the zein coating solution, which diffused from the pectin core 
during dripping process. NAM will be adsorbed at the surface and crystallizes during the 
drying process. Furthermore, the encapsulated NAM could migrate to the periphery of the 
beads along with the water flux during drying, which lead to an accumulation in the surface 
(Shariff et al., 2007; Smrdel, 2008). These overloaded beads would lead to a premature 
release of NAM due to an insufficient incorporation and coating. Therefore, only NAM 
concentration below 10 % will be suitable for encapsulation by pectin hydrogels. While 
dropping the pectin solution with 20 % NAM into a CaCl2 bath, drops did not immerse into 
the cross-linking solution, but floated on the water surface, which resulted in coalescence of 
the single beads. Therefore, the dripping height was adjusted, which led to the formation of 
drop-shaped beads. This could be related to the significantly decreased viscosity after the 
addition of NAM. A decreased viscosity led to a decreased velocity of the drop, which results 
in a lower immersion into the cross-linking solution and a sticking to the liquid surface 
(Davarcı et al., 2017; Guo and Kaletunç, 2016). Furthermore, the low ratio of pectin to NAM 
could result in an inefficient encapsulation of NAM and a less compact gel (Nithitanakool et 
al., 2013). 
The addition of WPI and WPI-fibrils resulted in voluminous and spherical particles, this was 
related to the structuring and/or filling effect of the proteins on the loose pectin network 
(Mohammadian and Madadlou, 2018). Although the viscosity of the pectin-fibril solution was 
higher than the pectin-WPI solution, no effects on the shape were observed.  
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7.5.2 Encapsulation efficiency 
The EE of niacin in the present study was low compared to others studies encapsulating 
indomethacin, BSA, FITC-dextran, sulphamethoxazole, anthocyanins and beta-lactamase 
(Bourgeois et al., 2005; Chotiko and Sathivel, 2017; Henning et al., 2012; Liu et al., 2006; 
Munjeri et al., 1997; Sriamornsak and Nunthanid, 1998). The differences could be related to 
many different process parameters such as different pectin types (Jung et al., 2013; 
Sriamornsak and Nunthanid, 1998), pectin concentrations (Lee et al., 2009; Nithitanakool et 
al., 2013), different production processes (Lee et al., 2009; Sriamornsak et al., 2010), different 
drug loads (Lee et al., 2009; Sriamornsak and Nunthanid, 1998) and different characteristics 
of the encapsulated compound (Munjeri et al., 1997; Sriamornsak and Nunthanid, 1998). The 
present study showed no clear effect of pectin type/DE and concentration on the EE, which 
supports the hypothesis, that the water-solubility of niacin is the main influencing factor 
regarding the low EE. Niacin, especially NAM, is highly water-soluble (NA: 15 g/l; NAM: 
1000 g/l), which could lead to a high diffusional loss of NA and NAM from the beads into the 
cross-linking solution (Sriamornsak and Kennedy, 2007). This loss will be mainly driven by a 
concentration gradient, which also explains the higher EE of isotonic conditions. Munjeri et 
al. also documented a lower EE for soluble substances like sulphamethoxazole (67 – 82 %) 
than for the insoluble indomethacin (82 – 98 %) (Munjeri et al., 1997). This is also confirmed 
by the encapsulation of NA, which have a higher EE compared to NAM with the highest 
water-solubility. Furthermore, the lower EE in case of two-step beads could be explained due 
to a longer incubation time (Lee et al., 2009), a second bath (Henning et al., 2012) and no 
protecting coating in the cross-linking bath (Chotiko and Sathivel, 2017), which enables the 
leaching of NAM. As a result, the pectin-zein beads, which were coated three times by zein 
showed the lowest EE. The leaching of NAM was reduced, when ethanolic shellac was used 
as coating material, due to a lower solubility of NAM in ethanol compared to water (about 
666 g/l). Therefore, the ionic gelation is widely used for encapsulation of hydrophobic 
compounds (Kurozawa and Hubinger, 2017). For hydrophilic compounds changes in the 
formulation e.g. an additional coating or polymers are necessary (Liu et al., 2003; Sande, 
2005). Chotiko and Sathivel also observed, that the addition of WPI led to an enhanced EE 
due to a blockage of the diffusion. However, this effect was not significant and was not 
confirmed in the present study when fibrils were added (Chotiko and Sathivel, 2017). The 
lower NAM content in the dripping solution with fibrils could also be responsible for the 
lower EE compared to the beads without fibrils (Nithitanakool et al., 2013). 
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7.5.3 Gastric resistance 
The present study showed no influence of the shape or sphericity of the pectin beads on the 
release of NAM. All formulations, except of the wd-shellac coated beads, resulted in an 
approximately total release already after 30 min. In comparison to Liu et al., who also used 
the one-step procedure for pectin-zein hydrogel beads, a successful encapsulated 
indomethacin and BSA with a colon-targeted delivery was achieved (Liu et al., 2006). 
However, Chotiko and Sathivel also prepared pectin-zein(-WPI) hydrogel beads to 
incorporate anthocyanin extract and documented a release of 50 – 80 % anthocyanin extract 
after 30 min at simulated gastric fluid. They observed, that zein only randomly covered the 
pectin bead. Furthermore, wide cracks were seen on the SEM pictures similar to the present 
studies. This could lead to a premature release of niacin. Additionally, as already mentioned, 
niacin is highly water-soluble and has a low molecular weight of about 121 Da, which 
supports a high diffusion rate and therefore a fast release (Chotiko and Sathivel, 2017; 
Sriamornsak and Kennedy, 2007). This is an explanation for the lacking effect of the shape on 
the release: NAM diffused very fast, leading to no detectable difference of the release after 30 
minutes.  
The additional experiments of encapsulating WPI confirmed this theory. Both, the one-step 
and two-step produced WPI pectin hydrogel beads covered with zein protected the β-LG for 
90 minutes followed by a continuous release to 90 % at a pH value of 7.4 after 5 h in total. β-
LG has a MW of about 18 kDa and therefore diffuses slowly compared to niacin. Further, it 
was found that the α-lactalbumin (14 kDa) was released slightly faster than β-LG (data not 
shown). Furthermore, the different bead shapes, resulting from the different production 
methods, led to a faster release from the red blood cell shaped particles compared to the 
spherical beads. 
The addition of fibrils did not delay the release of NAM, although fibrils lead to a protection 
of drugs and a reinforcement of the structure of microcapsules, when applied by a number of 
layers (Mohammadian and Madadlou, 2018; Rossier-Miranda et al., 2010). 
The only significant effect on NAM release was found when using wd-shellac as coating 
solution. Therefore, a total replacement of shellac while generating gastric resistant beads was 
not possible. However, depending on the EE, the use of shellac could be reduced to 0.37 g 
shellac per g NAM compared to the applied amount of shellac in our previous study (0.63 g 
shellac/g NAM), when a coating time of 1 min was chosen. The delayed release when using 
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wd-shellac is explained by the formation of hydrogen bonds between carboxylate groups of 
shellac via calcium ions (Ben Messaoud et al., 2016). This forms irreversible water unsoluble 
salts, which decreases the film swelling and could delay the release of niacin (Farag and 
Leopold, 2011). However, an improvement of the gastric resistance need further 
investigations. The adjustment of the pH value during the application of the shellac coating 
(Henning et al., 2012) or an additional heating of the capsules above the Tg of shellac (about 
60 °C) (Ben Messaoud et al., 2016) could be interesting with regard to an influence on the 
release.  
 
7.5.4 Surface characteristics of pectin-zein hydrogel beads 
In general, the surface of the one-step produced beads seemed to be smoother than the two-
step produced beads, which could be attributed to a stronger interaction between pectin and 
zein during the one-step procedure (Liu et al., 2006). The observed cracks and pores on the 
surface of the pectin-zein hydrogel beads are in accordance with the results shown by Chotiko 
and Sathivel (Chotiko and Sathivel, 2017). Liu et al. did not describe this phenomenon and 
showed gastric resistance, which indicates no or only minimal cracks in the coating, that 
would not induce a premature release of the large BSA molecule or the low soluble 
indomethacin (Liu et al., 2006). As shown in the present study as well as by others, when zein 
was used without further additives, brittle coatings are formed (Parris and Coffin, 1997), 
which could induce crack formation during drying. One opportunity to soften the zein coating 
and to prevent cracks could be the addition of plasticizer. Glycerol or polyethylene glycol 
increased the flexibility of zein film and could prevent the formation of cracks (Kadam et al., 
2017; Paramawati et al., 2001; Parris and Coffin, 1997), whereby the water vapor 
permeability also rose (Paramawati et al., 2001; Parris and Coffin, 1997), which could be 
contraindicative for the present aim. The integration of catechin led to highly flexible zein 
films while maintaining their integrity and hydration barrier. Other polyphenolic acids could 
result in films with a higher porosity or the loss of their integrity (Arcan and Yemenicioğlu, 
2011). Furthermore, the addition of titanium dioxide to zein film could enhance the hardness 
of zein films, which lead to a reduction in brittleness and an increase in hydrophobicity 
(Kadam et al., 2017). 
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The addition of fibrils resulted in more spherical particles with an irregular surface. 
Furthmore, the holes inside the bead, as shown by SEM pictures, were formed due to the 
foaming properties of fibrils (Mohammadian and Madadlou, 2018). 
With respect to the surface characteristics of shellac coated pectin beads, a rough surface was 
observed. It is suggested, that the visible microspheres on the surface were generated under 
the reaction between shellac and calcium (Xue and Zhang, 2009). Furthermore, an 
incorporation of NAM into the shellac layer is suggested because of crystalline areas in the 
SEM pictures. This would explained the continuous release of NAM after crushing. 
Moreover, SEM pictures showed no direct contact between pectin core and shellac layer. This 
interspace was also observed in a combination of alginate beads and shellac. The authors 
suggested an induced shrinking by depletion of cross-linked calcium ions, which resulted in 
an interspace (Ben Messaoud et al., 2016). 
 
7.6 Conclusion 
Encapsulation degree of niacin (NA and NAM) into pectin-zein and pectin-shellac beads 
varied in a broad range < 1 % to > 50 %. In most cases, flattened, non-spherical particles were 
formed with a red blood cell shape, when produced by the one-step procedure. This was 
independent from the encapsulated compound (NAM, NA or WPI) or the process parameters. 
Only the incorporation of whey protein isolate (WPI), or WPI fibrils and an enhancement of 
the pectin concentration resulted in almost spherical particles by using the two-step procedure. 
Only the release profile of β-LG was influenced by the shape of the beads. The more spherical 
bead resulted in a slower release of β-LG. No effect on the niacin release profile was observed 
due to the fast release of NAM during the first 30 min. The small niacin molecule facilitated 
an easy diffusion through the small cracks observed in the zein coating, so none of the tested 
pectin-zein formulations protected niacin against gastric conditions. Only a coating of wd-
shellac (ammonium salt of shellac) resulted in a reduced release due to the formation of 
unsoluble calcium shellac. The low encapsulation efficiency (EE) of niacin was due to the 
high water-solubility of niacin, which resulted in a high leaching especially in case of the two-
step procedure.  
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8 General discussion 
The objective of the present thesis was to develop a nutraceutical formulation with an 
enhanced availability of the vitamin niacin (NA and NAM) in the ileocolon region of the 
human gastrointestinal tract to induce beneficial effects on the gut microbiome. Therefore, a 
shellac based triple coating on niacin pellets and niacin loaded pectin-zein hydrogel beads 
were evaluated regarding its suitability as colon delivery system. The evaluation was based on 
in vitro dissolution profiles and a human bioavailability study in case of shellac coated niacin 
microcapsules. The pharmacokinetics in vivo were examined by the research group of Prof. 
Dr. Matthias Laudes (UKSH Kiel) and are also part of the dissertation of Daniela Fangmann 
(Fangmann, 2017). Further insights were gained into the interactions of the encapsulated 
compounds and the protecting materials, which influenced the release profile.  
 
8.1 Suitability of food-grade film and gel forming materials for a colon-targeted 
delivery of niacin 
In order to beneficially influence the gut microbiota, a targeted release into the (ileo)colonic 
region has to be ensured (Schreiber et al., 2014). Thus, in the pharmaceutical industry, pH-
dependent coating materials (e.g. Eudragit® S100, S 12,5 or FS 30 D) are commonly applied. 
These polymers are anionic with a high amount of functional carboxylic groups, which are 
protonated and therefore unsoluble at low pH values. At higher pH values higher than 7, the 
carboxylic groups will be deprotonated and the polymer gets soluble, which leads to a release 
of the encapsulated compound (Evonik; Yoshida et al., 2013). However, these polymers are 
only permitted for the use in pharmaceuticals. Due to the high demand for nutraceuticals 
(Czarnocka and Alhnan, 2015; Das et al., 2012; Santini et al., 2017), recent developments of 
Evonik Industries combined the same polymers with a permission for the use in solid 
nutraceuticals or supplements (Eudraguard® biotic) with an upper limit of 100.000 mg/kg.  
Food-grade alternatives for colon-targeted delivery systems are limited and still scarce. 
Referring to hypothesis 1, it was proved that pH-sensitive film and gel-forming materials 
such as shellac and pectin are suitable for a colon-targeted delivery of niacin (Paper I, 
Manuscript II and Manuscript V). This hypothesis was based on the properties of the 
materials as described in the sections below. Both, shellac and pectin are legislated as food 
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additives without restrictions concerning the concentration. An acceptable daily intake-level 
(ADI) does not exist. 
 
8.1.1 Shellac as coating material for niacin pellets 
In Paper I and Manuscript II it was hypothesized (Hypothesis 1a) that shellac is a suitable 
food-grade coating material for niacin to prevent a previous liberation under gastric and small 
intestine conditions and to lead to a sufficient release in the ileocolonic region. This was 
confirmed by in vitro dissolution tests simulating gastrointestinal conditions from stomach to 
ileum and a human bioavailability study (section 8.3). However, only the adjustment of the 
shellac coating formulation to the properties of NA and NAM using a novel triple shellac 
coating with a pH-influencing intermediate subcoating led to a precise release (section 8.4). 
Independently from the encapsulated compound, shellac behaves similar as the synthetic 
coating polymers (Eudragit®). The carboxylic groups within the shellac molecule are 
protonated and insoluble at low pH value. Above a pH value of 7.3, shellac dissolves after 
deprotonation of the carboxylic groups (Al-Gousous et al., 2015; Limmatvapirat et al., 2007; 
Pearnchob et al., 2003; Penning, 1996) and can liberate the encapsulated compounds. The pka 
of shellac is between 6.9 and 7.5, thus the deprotonation begins at a pH value of 6.8. This 
leads to swelling of the shellac coating into a gel-like stage (Farag and Leopold, 2011a), 
which promotes the water influx and the solubilization and release of the protected material 
such as niacin. The ammonium salt form of shellac is soluble in water, which is advantageous 
because organic solvents are dispensable. The administration of the water soluble ammonium 
salt of shellac on NAM pellets or NA coated Cellets (diameter of 350 – 500 µm) by fluidized 
bed coating was successful without further complications. Good coating results with a smooth 
surface and a uniform coating layer were achieved as demonstrated by SEM pictures (Figure 
3.2A+B), which also confirmed a sufficient protection of the encapsulated compound.  
 
8.1.2 Pectin as material for niacin loaded hydrogel beads  
Due to its lower production cost as well as being derived from plant material, pectin is an 
interesting alternative to shellac. Therefore, the mechanism of ionotropic gelation using pectin 
to encapsulate niacin was evaluated in Chapter 7. It was hypothesized (Hypothesis 1b) that 
pectin in combination with a zein coating exhibits similar features as the shellac 
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encapsulation. The feasibility was demonstrated for β-lactoglobulin. The free carboxylic 
groups of low methoxylated pectin are able to form a gel by cross-linking with calcium ions, 
which results in a reduced solubility while maintaining the degradation by enzymes of the gut 
microbiota (Liu et al., 2003; Maroni et al., 2013; Willats et al., 2006). Additionally, the water 
insoluble zein coating should led to a reduced water absorption, which could reduce the 
release during stomach and small intestine (Liu et al., 2003; Liu et al., 2006; Rubinstein, 
2000). However, none of the pectin-zein hydrogel beads were sufficient to protect a premature 
release of niacin under simulated gastric conditions. The rapid and complete release of niacin 
is explained due to the physico-chemical properties of niacin in contrast to β-LG and will be 
discussed below (Chapter 8.4). The zein coating was not able to inhibit the release of niacin 
loaded pectin beads, which was confirmed by large cracks in SEM pictures (Figure 7.19). 
Thus, in contrast to the hypothesis, no effect of the morphology of the pectin-zein beads on 
the release profile have been seen. In comparison to the zein coating, wet pectin-niacin 
hydrogel beads were also coated with water-soluble shellac under stirring. In vitro dissolution 
tests resulted in a reduced release at gastric conditions of about 50 % after 60 min compared 
to the zein coating, whereby a gastric resistance was not achieved (Figure 7.17). This effect is 
explained by the formation of irreversible insoluble calcium shellac, which can delay the 
release  (Farag and Leopold, 2011a).  
 
8.2 Robustness of the release profile in vitro of triple shellac coated niacin pellets 
despite influencing extrinsic factors 
In contrast to synthetic materials, natural materials are determined by natural fluctuations, 
which can influence their properties and the resulting release of the encapsulated compound 
during storage (Buch et al., 2009; Farag and Leopold, 2011b). Further, variations in intestinal 
fluid compositions can influence the dissolution profile. In chapter 4, it was hypothesized 
(Hypothesis 2) and confirmed that the novel triple shellac coating enables a robust release 
profile despite the changing extrinsic factors. 
 
8.2.1 Influence of the storage conditions on the release profile 
Coated NA and NAM pellets were stored for a period of 24 months at 20 °C. With increasing 
storage time, a slight reduction of the released vitamin was observed, especially at a pH value 
of 6.8 (Figure 4.2A+B). However, the gastric resistance was maintained. The reduced release 
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is caused by aging of shellac. This leads to polymerization processes via esterification of the 
large amount of hydroxyl and carboxyl groups of the shellac components (Farag and Leopold, 
2009; Limmatvapirat et al., 2005; Limmatvapirat et al., 2007). Due to the use of the 
ammonium salt form of shellac, only slight effects on the release profile were detected. The 
ammonium acting as counter ion for the carboxyl groups, which hinders the esterification. 
This process is reversible due to evaporation of ammonia (Limmatvapirat et al., 2007).  
The storage of the microencapsulated NA and NAM at 4 °C for 8 weeks showed no 
differences in the release of NAM, whereby the NA release was increased after 4 weeks. After 
6 weeks, 90 % of the encapsulated NA was already liberated during the first 30 min (Figure 
4.2C+D). This effect could be attributed to the sodium bicarbonate containing intermediate 
subcoating in NA pellets. The higher relative humidity of 47 % could lead to a partial 
dissolution of the sodium bicarbonate, which enhances the solubility of shellac and results in a 
premature release. Thus, the robustness of the release profile is dependent on the storage 
conditions especially in case of NA pellets using a sodium bicarbonate intermediate 
subcoating. 
 
8.2.2 Influence of simulated gastrointestinal conditions on the release profile  
Shellacs dissolution is dependent on the pH value of the surrounding solution. The pH value 
of the stomach can vary from 1.3 to 5.0 in fasted or fed state, with pH level peaks of 6.7 
(Dressman et al., 1990; Russell et al., 1993). The present NA and NAM pellets showed gastric 
resistance at a pH value of 1.4 and 4.5 for 2 h due to protonated carboxyl groups in the shellac 
coating (Figure 4.3). If the stomach pH value starts with a pH value of 6.8, as it can be 
present in a few healthy people (Feldman and Barnett, 1991) or in patients with a proton-
pump-inhibitor (Peghini et al., 1998), NA and NAM are completely liberated within 2 h 
(Figure 4.4). This is mainly explained by the application of the water-soluble ammonium salt 
shellac. In contrast to ethanolic shellac, the carboxylic groups in the ammonium salt shellac 
film are affiliated to the ammonium ion (Limmatvapirat et al., 2005), which enables a higher 
solubility and water vapor permeability. After contact to acid solutions, the carboxyl groups 
are getting protonated and the ammonium ion is replaced, which results in an insoluble and 
protecting outer layer (Henning et al., 2012; Penning, 1996). Without further exposition to an 
acidic milieu, the water uptake of water-soluble shellac is increased, which resulted in a fast 
release at a pH value of 6.8. An exposition to the gastric fluid (pH 1.4) for 1 h, therefore, 
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resulted in a reduced release in the subsequent digestion fluids. This was also documented for 
a tablet coating with Eudragit L30 D-55, which is also a pH dependent coating material that 
dissolves above a pH value of 4 – 6. It was suggested, that the penetration of acid delays the 
dissolution of the polymer and therefore the release. The longer the exposition the more 
delayed was the following release (Menge, 2016). Except for people with an enhanced basal 
gastric pH value up to 6.8, the present shellac coated pellets indicated a high robustness 
during the simulated gastric residence time. 
In contrast to the stomach and the upper intestine, in the targeted ileocolonic region, a 
maximal amount of released vitamin is desired. However, especially regarding the high 
dissolution pH value of shellac (7.3), it is often criticized (Farag and Leopold, 2009; 
Limmatvapirat et al., 2007), that the pH value of the human digestion fluids does not reach 
such high values (Dressman et al., 1998; Gruber et al., 1987), which could led to an 
insufficient release. Therefore, the amount of released NA and NAM from shellac coated 
particles were recorded in a simulated prolonged phase in the ileocolonic and colonic region 
at lower pH values of 6.8 and 7.0. The results showed a retarded release at lower pH values , 
however, after 26 h 80 % of NAM and 100 % of NA was released at a pH value of 6.8 
(Figure 4.5), which suggest a suitable amount for the gut microbiota and a robustness for 
varying pH values in the colonic region. The lower release of NAM is attributed to the citric 
acid subcoating as described below. SEM pictures of in vitro digested pellets after 24 h at a 
pH value of 6.8, showed remaining shellac shells with a porous structure, which indicated a 
sufficient release of NA and NAM through pores (Figure 4.6). These pictures were in 
accordance to the SEM pictures of the digested pellets from stool samples of human subjects 
(Figure 3.3A). Therefore, a lower pH value than the dissolution pH value of shellac is 
obvious for humans, but due to the porous shellac, coating a sufficient release of the water-
soluble vitamin niacin is assumed. This could be more problematic for low water-soluble 
substances. 
 
8.3 In vitro dissolution test and in vivo bioavailability 
In Paper I and Manuscript II the hypothesis (Hypothesis 3) was confirmed that the 
adjustment of the shellac coating for niacin by in vitro assay enables a targeted release in the 
ileocolonic region in humans. The in vitro assay simulated the pH conditions and residence 
times in the human stomach, small intestine and ileum. The gastric residence time was 
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reduced to 60 – 90 min due to the fact that microcapsules smaller than 2 mm, as in the present 
study, are able to pass the pylorus independently from gastric emptying. After 60 minutes, the 
pH value was enhanced to 4.5 for 30 min to simulate the transition from fasted to fed status. 
During this phase no or only minor amounts (maximum 10 %) of niacin should be liberated. 
The small intestine was represented at a pH value of 6.8 for 2 h. During this pH value a 
slowly release of niacin was desired (up to 40 %) due to a documented comparable pH value 
in the target region of the ileum. Finally, the ileum was simulated with a pH value of 7.4 for 
1.5 h, which should lead to a total release of the encapsulated niacin. The transit times and pH 
values simulating the gut from stomach to ileum are based on human studies with comparable 
pellet sizes in the literature (Abrahamsson et al., 1996; Clarke et al., 1993; Davis et al., 1987; 
Dressman et al., 1990; Evans et al., 1988; Ibekwe et al., 2008; Russell et al., 1993). According 
to this profile, which was hypothesized to give a precise prediction of the release behavior in 
vivo, the coating formulation to the encapsulation of NA and NAM was adapted. The applied 
shellac amount, drying time and coating composition to achieve a sufficient barrier with 
gastric and small intestine resistance was based on previous experiments with the reference 
model substance RMSD. These experiments showed that a shellac w.g. of 15 % could not 
lead to a gastric resistance. A w.g. of 20 % shellac resulted in a sufficient release protection 
under simulated gastric condition, whereby the release at pH 6.8 was low. Therefore, a triple 
coating layer with an intermediate pH-modulating subcoating was developed, which should 
lead to a precise release in the ileocolonic region (Chapter 8.4.4). Further transfer on the 
bioactive substances NA and NAM required an adjustment of the coating formulation to the 
properties of NA and NAM, which also influenced the release profile (Chapter 8.4). 
However, the adaption of the coating formulation resulted in an in vitro profile with no 
release of NA and NAM at the simulating gastric conditions (pH 1.4 and pH 4.5); followed by 
a beginning release at pH value 6.8 (NA: 6 % and NAM: 35 % after 2 h) and a burst release at 
pH value 7.4 (Figure 3.2C+D), which suggested a targeted release in the human ileocolonic 
region. 
The human study, conducted by the research group of Prof. Dr. Laudes (Chapter 3), 
confirmed the designed in vitro model and the ileocolon-targeted release of niacin. Further, it 
suggested a comparable diffusion driven release from the microcapsules as hypothesized after 
the in vitro dissolution test. These observations based on the pharmacokinetic curves of free 
and microencapsulated NA and NAM, which were administered to 10 healthy subjects each. 
NAM serum levels were measured hourly for 8 h and after 10 and 12 h. No flush symptoms 
occurred, although microencapsulated vitamin doses up to 300 mg NA were administered. 
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High blood concentrations of niacin are associated with facial flushes and liver dysfunctions 
(SCF, 2002). The microencapsulation of NA resulted in no significant increase of the serum 
concentration compared to the reference dose (free NA) due to the triple shellac coating. This 
would explain the absence of side effects. Furthermore, the pharmacokinetic curve of NAM 
showed four-times lower niacin serum levels (AUC: 4,207.15 vs. 17,334.20) and ten-times 
lower Cmax (1,322.7 vs. 19,690.0 µg/l) for the dose of microencapsulated NAM (900 mg) 
compared to the same reference dose (900 mg free NAM). In addition to the reduced niacin 
absorption, also delayed serum peak levels were observed for microencapsulated NAM after 4 
– 8 hours in contrast to 1 h for free NAM (Figure 3.3B and 4.7). The delayed peak levels and 
the low AUC levels indicated a negligible release in the first 3 h and a slow diffusion driven 
release process of NAM after 3 – 4 h over a longer period, which corresponds to the 
ileocolonic region regarding the average human gastrointestinal transit time (Clarke et al., 
1993; Pišlar et al., 2015). This observation is in accordance with the in vitro release profile 
and confirms the ability of the developed assay to predict an ileocolon targeted release in vivo. 
However, a reduced affinity to NAM carriers in the colon compared to the small intestine 
could also influence the lower systemic availability (Kumar et al., 2013; Nabokina et al., 
2005). Although the NAM serum level were affected by inter- and intraindividual variations 
(Table 4.3), the AUCs under application of 3000 mg NAM was not significantly increased 
compared to the reference dose. Furthermore, tmax was only slightly affected (Table 4.2), 
which could be explained by the use of the multiparticular dosage form, which is less 
influenced by fasted or fed state regarding its transit time during gastric and small intestine 
(Clarke et al., 1993; Davis et al., 1987; Dressman et al., 1998; Ibekwe et al., 2008; 
Malagelada et al., 1984).  Therefore, a  high availability of niacin for the gut microbiome was 
proposed for the novel shellac encapsulation of niacin, which was confirmed by Fangmann 
(Fangmann, 2017). Microencapsulated NA led to a significant increase in Bacteroidetes 
abundance in stool samples (Figure 3.3C). Fangmann also demonstrated (Chapter 3), that 
the microencapsulated NA beneficially affected biomarkers such as myostatin, fetuin-A and 
osteopontin, which are associated with insulin resistance of skeletal muscle and liver as well 
as adipose tissue inflammation (Hittel et al., 2010; Ishibashi et al., 2010; Lund et al., 2009; 
Park et al., 2015; Stefan et al., 2006). This effect is attributed to an indirect effect via 
beneficial changes of the microbiome (Fangmann, 2017) and thus a targeted release in the 
ileocolonic region. 
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8.4 Modeling and controlling intrinsic factors influencing the release profile of the 
encapsulated compound 
In Paper III, it was hypothesized (Hypothesis 4) and confirmed that a precise targeting can 
be achieved by modulating simultaneously the influencing intrinsic factors of release. Further, 
it was confirmed that the main intrinsic factors are determined by the properties of the 
encapsulated compounds such as the intrinsic pH value, the water solubility and the surface 
structure and influences the shellac coating properties and the resulting release profile. 
Furthermore, the effect of the encapsulated compound such as water solubility and molecular 
weight was also evaluated producing pectin-zein hydrogel beads in Manuscript V. In case of 
shellac coated NA and NAM microcapsules, it was confirmed, that different subcoatings of 
the triple shellac coating can precisely modulate the release profile by counteracting the 
influence of the encapsulated compound. This was achieved by controlling the pH-dependent 
swelling and dissolution of the surrounding shellac layer (Paper III). 
 
8.4.1 Influence of the water solubility and the molecular weight 
In case of the produced pectin hydrogel beads by ionotropic gelation, the high water solubility 
of NAM and the low molecular weight (MW) of niacin from about 122 g/mol were the 
leading factors for the low encapsulation efficiency (EE) and the fast release (Table 7.2 and 
Figure 7.17). NAM, the encapsulated compound with the highest water solubility of 1000 g/l, 
resulted in the lowest EE of 19 or 4 %, depending on the one-step or two-step production 
process; followed by β-lactoglobulin (β-LG) in form of whey protein isolate (WPI) with a 
lower solubility (about 30 g/l) and an EE of 21 and 15 %. NA showed the highest EE of 43 % 
for the one-step procedure due to the lowest water solubility of 18 g/l. Substances with a high 
solubility in the cross-linking solution lead to high diffusion loss during bead formation 
(Jyothi et al., 2010; Munjeri et al., 1997). Furthermore, niacin loaded pectin hydrogel beads 
always resulted in an immediate release after 30 min under gastric conditions, independently 
of the production process, the coating concentration, the pectin type and concentration or the 
addition of WPI-fibrils as fillers. Thus, the hypothesized effect of the morphology on the 
release profile was not confirmed for niacin. In contrast, the encapsulation of WPI/β-LG were 
resistant at a pH value of 3.5 for 1 h with an increasing release up to 92 % at a pH value of 7.4 
over a period of 4 h (Figure 7.7). Furthermore, the more spherical particles resulted in a 
slower release compared to the red blood cell shaped particles. This indicated an effect of the 
morphology on the release profile, whereby the effect is attributed to the properties of the 
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encapsulated compound. Substances with a high solubility and a low MW facilitates an easy 
diffusion through small pores, cracks and a swollen pectin gel, which was also documented 
for anthocyanin molecules with a MW of  449 Da (Chotiko and Sathivel, 2017; Munjeri et al., 
1997). β-LG has a MW of about 18 kDa, which delayed the release. This also explains, why 
the encapsulation of the low water soluble indomethacin and of bovine serum albumin (BSA) 
with a high MW of about 66.5 kDa resulted in a colon-targeted release while using the same 
one-step encapsulation method as in the present thesis (Liu et al., 2006).  A targeted delivery 
using pectin hydrogel beads is depending on the water solubility and the MW of the 
encapsulated compound and is more efficient for compounds with low solubility and higher 
molecular weight.  
The water solubility of the compound also influenced the release profile using shellac as 
coating material administered by fluidized bed coating. Therefore, RMSD, NA and NAM 
were coated on Cellets to directly compare their influence on the applied shellac coating. In 
contrast to NA and RMSD pellets, single shellac coated NAM Cellets resulted in a premature 
release under gastric conditions (Figure 5.3 and 5.5). NAM is the vitamin with the highest 
water solubility of 1000 g/l compared to RMSD (50 g/l) or NA (18 g/l). The higher the water 
solubility the higher the interaction between an aqueous coating material and the compound 
itself. In the present thesis, the water-soluble ammonium salt of shellac was used, which could 
induce channel formations in the coating layer. This can lead to an increased water influx, 
dissolution and release of the compound (Guo et al., 2002; Heinämäki et al., 1994). 
Furthermore, in case of highly water soluble substances the amount of dissolved drug in the 
core increases, which is associated with a higher osmotic driven influx rate of water through 
the coating and finally resulting in a faster release (Ragnarsson et al., 1992).  
 
8.4.2 Influence of the surface characteristics of the encapsulated compound 
The formation of channels or infiltration of coating material is enhanced for porous 
subsurfaces and can lead to a reduced coating thickness (Chopra et al., 2002; Guo et al., 2002; 
Heinämäki et al., 1994; Tunón et al., 2003; Werner et al., 2007). SEM pictures of the surface 
from RMSD, NA and NAM coated Cellets showed a porous and irregular surface for NAM 
(Figure 5.2B and 5.4B+C). Further, the cross-section of triple coated NAM pellets showed 
no distinguishable coating layers in comparison to RMSD and NA coated pellets, which 
indicated an incorporation of the coating material into the existing NAM pores during the 
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coating process (Figure 5.6B). DSC measurements indicated that NAM was present in its 
crystalline form and not in an amorphous form (Figure 5.2A and 5.4A), which could induce a 
higher surface roughness (Murr and Inal, 1979). Therefore, the physical form and the 
resulting surface characteristic is of immense importance.  
 
8.4.3 Influence of the aqueous pH value of the encapsulated compound  
Due to the pH-dependent dissolution of shellac, the pH value of the encapsulated compound 
can also influence the dissolution of shellac and therefore its release (Menge, 2016; Ozturk et 
al., 1988). This was demonstrated by microscope pictures in the present study (Chapter 5), 
the swelling of the single shellac layer at pH value 7.4 was reduced if the acidic NA was 
encapsulated compared to the neutral to slightly alkaline RMSD and NAM (Figure 5.7). A 
reduced swelling and dissolution of the coating layer results in a lower water uptake and 
therefore in a lower dissolution and release of the encapsulated compound (Farag and 
Leopold, 2011a). 
 
8.4.4 Adaption of a pH-modulating subcoating to control the effect of the encapsulated 
compound 
A triple coating, consisting of an inner shellac coating, an intermediate subcoating and an 
outer shellac coating, was able to counteract the influence of RMSD, NA or NAM to achieve 
an ileocolon-targeted release in vitro. In case of NAM Cellets, the intermediate subcoating 
contained citric acid. Citric acid was already described to prolong the release of shellac 
encapsulated theophylline when applied as a subcoating due to a decreased intrinsic pH value 
which delayed the dissolution of shellac (Farag and Leopold, 2011a). In the present study, the 
citric acid coating reduced the swelling of shellac at pH value 7.0 and 7.4 (Figure 5.9) and 
therefore was able to prevent the premature release of the high water soluble and crystalline 
NAM. Depending on the citric acid concentration, the in vitro dissolution test showed gastric 
resistance with a slow increasing release at a pH value of 6.8 and a total release after reaching 
a pH value of 7.4 (Figure 5.5D).  
In contrast, RMSD and NA with a lower water solubility showed only minor amounts of 
released vitamin at pH value 6.8, when a single shellac layer was applied. Therefore, a novel 
alkaline intermediate subcoating including sodium bicarbonate was applied. The sodium 
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bicarbonate led to an increased intrinsic pH value, which accelerated the swelling and 
dissolution of shellac at a pH value of 6.8 and finally increased the release of NA or RMSD 
(Figure 5.8). With the optimal sodium bicarbonate concentration in the intermediate 
subcoating, the release at pH value 6.8 was enhanced from 4 to 29 % for NA and from 10 to 
24 % for RMSD after 2 h compared to the single shellac coating (Figure 5.5C and 5.3B).  
The interplay between the encapsulated substance, the coating and the intermediate 
subcoating is crucial for the development of targeted release systems by influencing the pH-
dependent swelling and dissolution of shellac. In the present thesis, it was shown that the 
adapted intermediate subcoating to the encapsulated compound, embedded from an inner and 
outer shellac coating, resulted in a controlled and precise release of NA and NAM in the 
ileocolon region in vitro and in vivo.  The inner shellac coating also led to a more separated 
effect of the encapsulated compound and the effect of the intermediate subcoating (Figure 
5.5E). This shellac microcapsule formulation and composition is patented for the topical 
intestinal delivery of niacin (PCT/EP2017/058733, Supplemental 11.2).  
 
8.5 NAM pellets produced by a two-step wet extrusion-spheronisation process 
In Paper IV, it was hypothesized (Hypothesis 5) and confirmed that the wet extrusion and 
spheronisation process is superior compared to the spray granulation in order to obtain high 
yield of spherical NAM pellets requiring lower addition of shellac. A mixture of NAM and 
MCC was extruded and afterwards spheronized in order to obtain spherical and smooth 
particles. The influence of the process parameter on the roundness, roughness and useable 
yield were evaluated in an experimental design (DoE) (Chapter 6). The main effect was 
reported for the moisture content of the extrudates and the spheronisation speed, time and 
load. In order to get spherical particles, the water content of the extrudates needed to be 
adjusted in a narrow range to generate an optimal brittleness and plasticity to form spherical 
particles (Figure 6.4) (Dukić-Ott et al., 2009). Only spherical particles provide a uniform 
distribution of the coating material. NAM required a low water content (23.6 % ref. to total 
mass), due to loss of solid by dissolution of NAM during the extrusion process (Jover et al., 
1996; Lustig-Gustafsson et al., 1999). This is attributed to the high water-solubility of 1000 
g/l of NAM. Regarding the spheronisation process, a combination of a high speed, a low load 
and a short rotation time resulted in the highest yield with the most spherical and smooth 
particles. The effect of the spheronization process on the morphology of the particles is 
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mainly attributed to the resulting plate-particle and particle-particle-interactions, which varied 
with the spheroniser speed, load and time. Low rotation speed results in low interactions and 
therefore in failure of rounding the particles (Baert et al., 1993; Dukić et al., 2007; Krueger et 
al., 2013; Newton et al., 1995; Sovány et al., 2016). In addition, for a higher load a longer 
spheronisation time is needed to form round particles (Newton et al., 1995), which makes an 
adjustment of the spheroniser speed, time and load indispensable. The yield of the extrusion-
spheronisation process was markedly higher (92 %) than for the spray granulation process. 
The larger diameter of about 1.2 mm, measured by laser diffraction method, resulted in a 
lower specific surface area. The coating level was calculated as used by Farag and Leopold 
(2011b) with an additional roughness factor (+ 54 % additional coating material), due to an 
observed higher roughness of the extruded particles compared to the spray granulated 
particles (Figure 6.11 and 6.13). The additional coating material was not required and 
resulted in higher coating levels for the extruded particles, which led to a reduced NAM 
release (Figure 6.15C). However, an ileocolonic release was achieved and required a lower 
use of shellac as coating material based on the NAM content. Related to 100 g NAM, the 
required addition of shellac was reduced from 64 g to 34 g for spray granulated and wet 
extruded NAM pellets, respectively. Due to the resulting thicker coating level for extruded 
pellets, it is proposed that the required amount could further be decreased to about 22 g of 
shellac per 100 g NAM.  
 
8.6 Closing remarks and outlook 
The present thesis clearly indicated that the design of a specific in vitro digestion for the 
ileocolon target region enables to precisely modulate the coating of various vitamins. The 
encapsulation of niacin by a shellac based coating inhibited in vivo an early systemic uptake 
and a precise release in the ileocolonic region as it was proposed by the in vitro release 
profile. The targeted release of nicotinic acid led to beneficial effects on the gut microbiota, 
confirming again the successful targeting of the ileocolonic region. The application of 
different subcoatings enabled to precisely modulate the release profile by affecting the 
swelling and dissolution of the shellac coating and to counteract interfering effects of the 
encapsulating substance. In vitro dissolution tests promised a robust release in the ileocolonic 
region for a broad range of gastrointestinal variations regarding pH value and residence time. 
The presented system is of high practical relevance and resulted in the following patent 
(PCT/EP2017/058733, Supplemental 11.2). The high potential of the proposed targeting 
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system is demonstrated by the following patent for dye-based chromoendoscopy 
(PCT/EP2017/058741, Supplemental 11.3). In the future, NAM cores produced by wet 
extrusion/spheronisation instead of spray granulation could lead to a less cost-intensive 
process due to higher pellet yield and lower amounts of shellac required for coating. Until 
now, pectin-zein hydrogel beads were not able to substitute shellac as colon-delivery system, 
which is related to the high water solubility and low molecular weight of niacin and not to the 
system itself.  
Nonetheless, some further questions arose during this work. The release of the encapsulated 
compound through the shellac coating was strongly depending on the compound itself and on 
the surrounding conditions. It is of interest to get further insights in direct effects on the 
shellac film properties such as the water vapor, water and acid permeability. Therefore, free 
films could be prepared and analyzed. Additionally, the investigation in different methods e.g. 
Electron Paramagnetic Resonance (EPR) may clarify the release mechanism from shellac 
coated particles with respect to different formulations and treatments.  
Further developments of pectin hydrogel beads for the encapsulation and colon delivery of 
niacin is interesting. Therefore, the influence of drying conditions, coating materials and 
addition of fillers on the bead formation and release profile could be investigated.  
As indicated in the present thesis, the upscaling of the wet extrusion/spheronisation process 
for preparing NAM cores could cause problems due to the narrow water level range. 
Therefore, it is of interest to develop an inline measurement to control the moisture content 
and moisture distribution e.g. by using near-infrared spectroscopy (NIRS) as a process 
analytical technology (PAT).  
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9 Summary 
The aim of the present thesis was to enhance the bioavailability of the water-soluble vitamin 
niacin in the ileocolonic region by microencapsulation with food-grade materials. The 
targeted release should beneficially influence the gut microbiota. Therefore, processes were 
developed to form spherical pellets (spray granulation and wet extrusion-spheronisation), 
coated pellets (fluidized bed coating) and hydrogel beads (ionotropic gelation) as carrier for 
niacin. To precisely predict the release profile and to modulate the processes an in vitro 
digestion test was designed. For the ileocolon target area, the test considered relevant pH 
values in the digestion fluids and anticipated the transit times in the gastrointestinal tract. The 
precision of the release profile of niacin from these shellac coated microcapsules was 
confirmed in a human bioavailability study with ten healthy subjects for each group examined 
by the research group of Prof. Dr. Matthias Laudes (Chapter 3 and 4). The effects of the 
encapsulated compound in interaction with an adapted intermediate subcoating was 
characterized for a targeted release in the ileocolonic region, which gave further insights in 
the pH-dependent dissolution mechanism of shellac (Chapter 5).  Two production processes 
(spray granulation and wet extrusion-spheronisation) for high NAM loaded cores were 
compared regarding their properties for the application of the functional shellac coating 
(Chapter 6). An alternative system, based on pectin-zein hydrogel beads, was evaluated 
regarding a colon-targeted delivery (Chapter 7). 
The in vitro release profile of shellac coated niacin microcapsules was precise and showed an 
efficient protection during the simulated fasted and fed gastric phase (pH 1.4 and 4.5) for at 
least 2 h. The release of NA or NAM began at a pH value of 6.8 due to an increased swelling 
of the shellac coating, which led to liberation of niacin by diffusion driven processes. 
Reaching the pH value of 7.4 of the human ileum, a complete release of encapsulated niacin 
was observed, which is related to the exceeded dissolution pH value of shellac. The designed 
in vitro dissolution test provided a targeted release of niacin in the ileocolonic region, which 
was confirmed by the pharmacokinetic curves of the human bioavailability study. In 
comparison to the free NAM, the same dose of microencapsulated NAM showed a delayed 
tmax (1 vs. 4 h), decreased Cmax and decreased AUC levels. The increase of the dose for 
microencapsulated NA and NAM resulted in no significant higher AUC levels compared to 
the reference dose. These results indicated a diffusion driven release from the microcapsules 
in the ileocolonic region with a low systemic absorption of niacin, which makes it available 
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for local action in the colon. Microencapsulated NA led to an increase in Bacteroidetes and a 
beneficial effect on systemic insulin resistance. 
The precise targeted release in the ileocolonic region was reached by adaption of the coating 
formulation on the varying properties of NA and NAM. It was shown that the combination of 
the aqueous pH value, the water solubility, and the crystallinity of the encapsulated substance 
are factors influencing the release profile. The application of an intermediate subcoating 
surrounded by an inner and an outer shellac layer was able to control these effects. The 
sodium bicarbonate subcoating enhanced the release of compounds with a relatively low 
water solubility such as NA, due to an increased intrinsic pH value and therefore a faster 
dissolution of the outer shellac coating. In contrast, citric acid reduced the swelling of shellac, 
delayed the release profile and counteracted a premature release of the alkaline and highly 
soluble NAM. Independently of the NAM core production process, both spray granulation 
and wet extrusion/spheronisation resulted in spherical NAM pellets, which were suitable for 
the coating process and an ileocolon targeted release profile. However, the resulting larger 
particles of the wet extrusion/spheronisation process reduced the requirement of shellac 
concentration, which could reduce the production process costs. 
In contrast to the modified shellac coating, pectin-zein hydrogel beads were not able to protect 
niacin during the simulated gastric residence time. The vitamins were completely liberated 
within 30 minutes. This was explained by the high solubility combined with the low 
molecular weight (≈123 Da) of niacin, which supported a high diffusion through the pores and 
cracks in the coating. The larger molecule β-lactoglobulin (≈ 18 kDa) was prevented from a 
premature release using pectin-zein hydrogel beads. Therefore, an effect of the hydrogel bead 
morphology on the release profile was only observed for β-lactoglobulin, whereby the more 
spherical beads delayed the release in the simulated small intestine.  
In conclusion, the microencapsulation of niacin using a shellac based coating lead to an 
enhanced availability of niacin in the human ileocolonic region. The designed in vitro 
dissolution test provided a precise instrument to predict the release behavior in humans. The 
usage of food-grade materials provides the potential use as nutraceutical especially with 
regard to beneficially effect on the gut microbiome and the prevention of prediabetes.  
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10 Zusammenfassung 
Ziel der vorliegenden Arbeit war es, die Bioverfügbarkeit des wasserlöslichen Vitamins 
Niacin im Bereich des Ileocolons durch den Prozess der Mikroverkaselung zu erhöhen. Die 
gezielte Freisetzung sollte die Darmmikrobiota günstig beeinflussen. Daher wurden 
verschiedene Verfahren entwickelt, um Niacin zu verkapseln. Das Vitamin wurde entweder 
als kugelförmige Pellets verkapselt, die mittels Sprühgranulation und Nassextrusion-
Sphäronisierung hergestellt und mittels Wirbelbettcoating beschichtet wurden oder es wurde 
in Hydrogelkügelchen mit Hilfe der ionotropen Gelierung eingelagert. Um das 
Freisetzungsprofil genau vorherzusagen und zu modulieren, wurde ein in vitro 
Verdauungstest entwickelt. Für den Zielbereich des Ileocolons berücksichtigte der Test 
relevante pH-Werte in den Verdauungsflüssigkeiten sowie die Transitzeiten im Magen-Darm-
Trakt. Die Präzision des Freisetzungsprofils von Niacin aus Schellack-beschichteten 
Mikrokapseln wurde in einer humanen Bioverfügbarkeitsstudie mit zehn gesunden Probanden 
pro Gruppe durch die Arbeitsgruppe von Prof. Dr. Matthias Laudes (Kapitel 3 und 4) 
bestätigt. Die Effekte der verkapselten Substanz in Wechselwirkung mit einer angepassten 
Zwischenschicht wurden für eine gezielte Freisetzung in der Region des Ileocolons 
charakterisiert, was weitere Einblicke in den pH-abhängigen Auflösungsmechanismus von 
Schellack lieferte (Kapitel 5). Zwei Produktionsverfahren (Sprühgranulation und 
Nassextrusion-Spheronisierung) mit einer hohen Beladung von NAM im Kern wurden 
hinsichtlich ihrer Eigenschaften für die Anwendung der funktionellen Schellackbeschichtung 
verglichen (Kapitel 6). Ein alternatives System, basierend auf Pektin-Zein-Hydrogel-
Kügelchen, wurde hinsichtlich einer zielgerichteten Freisetzung im Colon untersucht (Kapitel 
7). 
Das in vitro Freisetzungsprofil von Schellack-beschichteten Niacin-Mikrokapseln war präzise 
und zeigte einen wirksamen Schutz während der simulierten Magenpassage für mindestens 2 
Stunden sowohl unter nüchternen als unter nicht-nüchternen Bedingungen (pH 1,4 und 4,5). 
Die Freisetzung von NA oder NAM begann bei einem pH-Wert von 6,8, was durch erhöhtes 
Quellen der Schellackbeschichtung zu erklären ist. Die Freisetzung des Niacin scheint 
dadurch diffusionsgetrieben zu sein. Bei Erreichen eines pH-Wertes von 7,4, wie er im 
menschlichen Ileum vorliegt, wurde die gesamte Menge des verkapselten Niacin freigesetzt, 
was mit dem Erreichen des Auflösungs-pH-Wertes von Schellack zusammenhängt. Das 
entwickelte in vitro Freisetzungprofil versprach eine gezielte Freisetzung von Niacin in der 
Region des Ileocolons, was durch die pharmakokinetischen Kurven der humanen 
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Bioverfügbarkeitsstudie bestätigt wurde. Im Vergleich zum freien NAM zeigte die gleiche 
Dosis von mikroverkapseltem NAM einen verzögerte Absorptionszeitpunkt (tmax) (1 vs. 4 h), 
verringerte maximale Serumkonzentrationen (Cmax) und verringerte AUC-Spiegel. Die 
Erhöhung der Dosis für mikroverkapselte NA und NAM führte zu keinen signifikant höheren 
AUC-Werten im Vergleich zur Referenzdosis. Diese Ergebnisse verwiesen auf eine 
diffusionsgetriebene Freisetzung aus den Mikrokapseln im Bereich des Ileocolons mit einer 
geringen systemischen Absorption von Niacin, wodurch das Niacin für lokale Wirkungen im 
Dickdarm zur Verfügung steht. Mikroverkapseltes NA führte in vivo zu einem Anstieg der 
Bacteroidetes und einer positiven Wirkung auf die systemische Insulinresistenz. 
Die präzise und zielgerichtete Freisetzung im Bereich des Ileocolons wurde durch Anpassung 
der Coatingformulierung an die variierenden Eigenschaften von NA und NAM erreicht. Es 
wurde gezeigt, dass die Kombination des pH-Wertes, der Wasserlöslichkeit und der 
Kristallinität der eingekapselten Substanz Faktoren sind, die das Freisetzungsprofil 
beeinflussen. Die Anwendung einer Zwischenschicht, die von einer inneren und einer äußeren 
Schellackschicht umgeben ist, konnte diese Effekte steuern. Die Natriumbicarbonatschicht 
erhöhte die Freisetzung von Substanzen mit einer relativ geringen Wasserlöslichkeit, wie NA, 
aufgrund eines erhöhten intrinsischen pH-Wertes und daher einer schnelleren Auflösung der 
äußeren Schellackbeschichtung. Im Gegensatz dazu reduzierte Zitronensäure die Quellung 
von Schellack, verzögerte das Freisetzungsprofil und wirkte einer vorzeitigen Freisetzung der 
alkalischen und gut löslichen NAM entgegen. Unabhängig vom NAM-
Kernherstellungsverfahren ergaben sowohl die Sprühgranulation als auch die 
Nassextrusion/Sphäronisation sphärische NAM-Pellets, die für den Beschichtungsprozess 
geeignet waren, und eine Freisetzung im Ileocolon ermöglichten. Die resultierenden größeren 
Partikel des Nassextrusions-/Spheronisierungsverfahrens verringerten jedoch die benötigte 
Schellackmenge, was die Produktionsprozesskosten verringern könnte. 
Im Gegensatz zu der modifizierten Schellackbeschichtung waren Pektin-Zein-
Hydrogelpartikel nicht in der Lage Niacin während der simulierten Verweilzeit des Magens 
zu schützen. Die Vitamine wurden innerhalb von 30 Minuten vollständig freigesetzt. Dies 
wurde durch die hohe Löslichkeit in Kombination mit dem niedrigen Molekulargewicht (≈123 
Da) von Niacin erklärt, das eine hohe Diffusion durch die Poren und Risse in der 
Beschichtung induzierte. Eine frühzeitige Freisetzung des größeren Moleküls β-Lactoglobulin 
(~18 kDa) konnte hingegen mit Pektin-Zein-Hydrogelpartikeln entgegengewirkt werden. 
Daher wurde auch ein Effekt der Morphologie der Hydrogelpartikel auf das Freisetzungsprofil 
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nur für β-Lactoglobulin beobachtet, wobei die runderen Kügelchen die Freisetzung im 
simulierten Dünndarm verzögerten. 
Zusammenfassend kann gesagt werden, dass die Mikroverkapselung von Niacin unter 
Verwendung einer Schellack-basierten Beschichtung zu einer verbesserten Verfügbarkeit von 
Niacin in der menschlichen Ileocolon-Region führt. Das konzipierte in vitro 
Freisetzungsprofil erwies sich dabei als gutes Vorhersageinstrument für das 
Freisetzungsverhalten im Menschen. Die Verwendung von food-grade Materialien bieten eine 
potentielle Verwendung als Nutraceutical, insbesondere im Hinblick auf die vorteilhafte 
Wirkung auf das Darmmikrobiom und die Prävention von Prädiabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental 
214 
 
11 Supplemental  
11.1  Experimental and analytical approach for unpublished manuscripts 
11.1.1  Fluidized bed coating for production of shellac coated niacin microcapsules 
To influence the surface properties of particles with regard to aesthetic or protective purposes, 
a coating covering the surface of every single particle uniformly, can be applied. To coat 
small particles (100 µm to a few millimetres), usually the fluidized bed coater is used (Gouin, 
2004; Kumpugdee-Vollrath and Krause, 2011; Sandadi et al., 2004; Teunou and Poncelet, 
2002).  
During fluidized bed coating, the small solid particles are suspended and maintained in a 
fluidized bed through a temperature-controlled airflow (bottom-up). The dissolved coating 
material is transferred to the nozzle with a peristaltic pump and atomized with compressed air. 
The atomized coating droplets are sprayed onto the flowing particles. The solvent of the 
coating material evaporates, while a polymer film is distributed on the particles surface 
(Arshady, 1993; Desai and Jin Park, 2005; Kumpugdee-Vollrath and Krause, 2011).  In the 
present study, the nozzle was placed on the bottom of the chamber and had a diameter of 0.5 
mm. Depending on the process parameters such as inlet air temperature, inlet air velocity, 
spray rate, product temperature, atomization pressure of the coating solution and outlet air 
temperature, the fluidized bed operation and the coating efficiency is influenced. Therefore, 
similar process parameters were chosen to compare different processes and formulations. 
However, the process parameters need to be adjusted to the coating material used in order to 
avoid agglomeration (Arshady, 1993; Desai and Jin Park, 2005; Dewettinck and Huyghebaert, 
1998). The amount of the applied coating material was calculated and reported as additional 
weight gain in percent. In the present study, a Mini Glatt fluidized bed coater (Glatt 
Ingenieurtechnik GmbH, Binzen, Germany) was used to microencapsulate nicotinic acid, 
nicotinamide or riboflavin with a shellac coating to achieve a targeted release. The inlet air 
temperature, the spraying rate, the inlet and atomizing air pressure were adaptable. The 
ranges, used in the present thesis, were adjusted to the process and are shown in Table 11.1. 
After the coating process, shellac coated pellets were dried at 50 °C for 1 h in order to remove 
some of the ammonium and to strengthen the coating layer.  
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Table 11.1: Process parameter for fluidized bed coating used in present thesis 
Process parameter Applied range 
Inlet air temperature 39 – 45 °C 
Spraying rate 0.6 – 1.2 g/min 
Inlet air pressure 0.3 – 0.4 bar 
Atomizing air pressure 0.5 – 0.7 bar 
 
11.1.2  Spray granulation for production of nicotinamide cores 
Spray granulation is a drying process of liquids with simultaneous formation of granules. 
Granulation is achieved by spray drying of the dissolved or suspended substance through a 
nozzle into a temperature-controlled chamber. In the further process, the particle size 
increases by surface layering, comparable to the fluidized bed coating process. In the end, the 
formed granules consist of the dry matter of the sprayed solution. Characteristically, granules 
show a well-rounded and uniform “onion skin” layered structure, which is ideal for a further 
protecting coating step and a high particle strength (Link and Schlünder, 1997). In the present 
thesis, the spray granulation of nicotinamide was done by Glatt Ingenieurtechnik GmbH 
(Weimar, Germany). They harmonised the process parameters to achieve spherical granules 
with a narrow particle distribution and a high load of nicotinamide. This was necessary to 
meet the requirements of a higher dose in the bioavailability study and a reduced number of 
capsules the subjects would have to swallow. 
For spray granulation, a ProCell fluidized bed granulator with Vario 3 was used (Glatt 
Ingenieurtechnik, Weimar, Germany). 30 % (w/w) nicotinamide including 4 % (w/w) of 
hydroxypropyl methylcellulose (HPMC) was dissolved in tap water. The solution was sprayed 
through a nozzle. The process parameters of the spray granulation of nicotinamide are listed 
in Table 11.2. Afterwards the granules were coated in a fluidized bed coater as described 
above. 
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Table 11.2: Process parameter for spray granulation of nicotinamide used in present thesis 
process parameter applied range 
inlet air temperature 80 – 90 °C 
product temperature 50 °C 
spraying rate 5 – 24 g/min 
air rate 80 – 90 m3/h 
atomizing air pressure 2 – 2.8 bar 
 
11.1.3  Extrusion-Spheronisation process for production of nicotinamide cores 
During extrusion, a wet mass is shaped into long rods by passing an extruder screen. In the 
present thesis, a twin-screw extruder was used. Two screws mix the added powder (consisting 
of the drug and some pelletizing aids) and the granulating liquid (e.g. water), with 
simultaneous transfer of the wetted mass to the nozzle at the end of the barrel, where 
cylindrical extrudates are formed (Figure 11.1). The barrel can be tempered if necessary. 
After the extrusion process, the wet extrudates are transferred into a spheronizer. A 
spheronizer is a machine with a rotating cross-hatched friction plate, where the extrudates are 
broken up into smaller cylinders. With increasing spheronisation time, the small cylinders 
become spherical pellets, which is beneficial for further coating processes (Dukić-Ott et al., 
2009; Vervaet et al., 1995). In the present thesis, the conditions of the extrusion and 
spheronization process were varied to examine their influence on the desired product profile 
of NAM cores for coating applications (e.g. roundness and roughness). Therefore, a Quality 
by Design approach with integrated statistical Design of Experiments was used (see below).  
In general, the twin-screw extruder nano 16 from Leistritz (Nuremberg, Germany) with a 
1mm diameter die in the end was used for all experiments. The spheronizer was custom-made 
with a cross-hatched plate and a diameter of 12 cm (Figure 11.1).  
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Figure 11.1: Schematic demonstration of the (A) twin-screw extruder and (B) spheronizer 
used in the present study 
 
11.1.4 Ionotropic gelation for production of pectin-zein-niacin hydrogel beads  
Ionotropic gelation is a commonly used procedure to prepare hydrogel beads, that contain 
bioactive substances. This technique is based on the ability of some polymers to spherical 
cross-link in the presence of counter ions. Examples for natural anionic polymers are 
alginates, gellan gum and pectin. In order to form beads, an aqueous solution of the polymer 
(and the desired compound to encapsulate) is added dropwise to a solution of counter ions. In 
case of an anionic polymer a cationic cross-linking solution is used (Patil et al., 2010; Patil et 
al., 2012; Smrdel, 2008; Sriamornsak, 2011). In the present thesis, pectin was used as anionic 
polymer for the encapsulation of the vitamins nicotinic acid or nicotinamide. The mixture of 
pectin and vitamin was dropped into a cationic cross-linking solution consisting of calcium 
chloride. In some cases, zein (corn protein) was added to the calcium chloride solution in 
order to cover the formed pectin beads (Liu et al., 2006). Pectin with a low degree of 
methoxylation forms gel beads by cross-linking free carboxyl groups with calcium ions. The 
formed calcium pectinate shows a reduced solubility. For incorporation of water-soluble 
substances such as nicotinic acid and nicotinamide, however, an additional coating is 
suggested. In the present thesis, the formed pectin-niacin-hydrogel beads were added to a 
solution, that contained zein to apply a coating layer. Afterwards, the pectin-niacin-zein-beads 
were dried at room temperature for further analyses.  
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11.1.5 Dissolution tests for characterization of vitamin release rate 
In vitro dissolution tests are conducted to simulate and evaluate the dissolution and release 
behaviour of dosage forms throughout the human gastrointestinal tract. These studies are less 
labour, time and cost intensive compared to in vivo studies. Especially in early stages of 
formulation design and optimization, in vitro dissolution tests are extremely important 
(Jorgensen and Bhagwat, 1998; Shani-Levi et al., 2017; Zahirul and Khan, 1996). In vitro 
dissolution tests are performed in a dissolution test apparatus. Adapted to the formulation 
design, different dissolution specifications and the composition of the simulated 
gastrointestinal fluids are suggested by European Pharmacopeia. However, some 
specifications have to be decided case by case (Zahirul and Khan, 1996). In general, different 
stages of the gastrointestinal tract are simulated – stomach, small and large intestine. 
Depending on the simulated region, the test conditions vary regarding e.g. pH value, residence 
time, enzyme and salt concentration (Yang et al., 2002). For the coating material shellac, 
which dissolves depending on the pH value, the pH value and the residence time in the 
simulated gastrointestinal fluids were changed in the present thesis. With regard to the 
dissolution of pectin beads, microbial enzymes in the large bowel were considered (Guerra et 
al., 2012). Therefore, in the case of dissolution of pectin hydrogel beads, the enzyme 
pectinase was added to the simulated colon fluid.  
In the present thesis the dissolution tester DT 70 (Pharmatest Group GmbH, Hainburg, 
Germany) was used with a paddle apparatus for shellac-coated pellets and with a basket 
apparatus for pectin hydrogel beads. Various simulated gastric, small intestine and large 
intestine fluids were tested to evaluate the release of the encapsulated vitamin over time. To 
quantify the released vitamin in the surrounding fluids, UV-VIS spectroscopy or HPLC 
analyses were used (see below). The amount of released vitamin was related to the total 
amount of encapsulated vitamin to obtain a percentage result. 
To quantify the total amount of the encapsulated vitamin, shellac coated pellets were 
incubated for 1.5 h at pH value 7.4 (Soerensen phosphate buffer), which is above the 
dissolution pH value of shellac. Pectin-zein hydrogel beads were incubated for 5 h under 
agitation in a McIlvaine citrate-phosphate buffer (pH value 5.0) with additional pectinase to 
macerate the beads. 
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11.1.6 Light microscope/Optical microscope for characterization of particle shape 
A light microscope or optical microscope is used to magnify images of small samples by 
visible light and a system of lenses. An image can be captured by normal cameras adapted to 
the microscope system. For the present thesis, light microscope pictures of shellac coated 
particles were taken to observe their swelling properties during contact with different solvents 
and to analyze the shape of pectin-niacin-zein hydrogel beads. Depending on the size of the 
particles, the following microscopes with different magnifications were used: Motic 
Microscope (Wetzlar, Germany), which was connected to a camera (Canon Legria HF20, 
Tokyo, Japan) and from Meade Instruments Europe GmbH (Kempten, Germany) in 
combination with an electronic eyepiece (MikroOkular-II, Bresser GmbH, Rhede, Germany). 
 
11.1.7 Scanning electron microscope (SEM) for characterization of particle surface 
A SEM is an electron microscope that scans the surface of a sample using a focused beam of 
electrons. Due to the interaction of the electrons with atoms in the sample, secondary 
electrons from the sample are generated and detected by a sensor that gives information about 
the surface of the sample such as their topography and composition. The detected signals are 
converted into an image of the sample. The resolution of a SEM is more than one nanometer 
(Bozzola and Russell, 2006). In the present study, SEM images are taken to compare surface 
characteristics of different shellac coated and vitamin coated pellets, as well as of the pectin-
niacin-zein hydrogels. For SEM analyses, the samples were dried and prepared on a holder 
with carbon Leit-tabs (Plano GmbH, Wetzlar, Germany). To observe the cross-section, some 
of the beads were cut using a scalpel. Before examination in a Hitachi S-4800 SEM (Hitachi 
High Tech., Tokyo, Japan) at an accelerating voltage of 3 kV, microcapsules were sputter-
coated with a layer of 8-10 nm gold-palladium using a Leica EM SCD 500 (Leica 
Microsystems GmbH, Wetzlar, Germany) high-vacuum sputter coater.  
 
11.1.8 Differential scanning calorimetry (DSC) for characterization of physical form of 
vitamins 
DSC is a thermoanalytical technique that measures thermal transitions in a material. More 
specifically, the difference in heat flow rate between a sample and a reference as a function of 
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temperature and time is analyzed. During the analysis, both the sample and the reference are 
exposed to a similar temperature profile: the temperature increases or decreases linearly as a 
function of time. Therefore, temperature-dependent properties of materials can be analyzed by 
DSC. This includes e.g. glass transition, crystallization, melting and decomposition (Waters 
GmbH). In the present thesis, the physical form (amorphous or crystalline) of the applied 
vitamin via fluidized bed coating was investigated using DSC. Therefore, about 4 mg of 
spray-dried vitamin, either riboflavin, nicotinic acid or nicotinamide, was weighed and sealed 
in hermetic aluminum pans. The samples were measured in triplicate under nitrogen 
atmosphere with DSC (Q2000, Waters GmbH, TA Instruments, New Castle, USA). The 
initial temperature was set to 20 °C, afterwards a ramp to 200 °C (or 300 °C in case of NA) 
was programmed with an increase of 20 K/min. Glass transition temperatures, melting and 
crystallization peaks were determined by TA Instruments software Universal Analysis 2000. 
The equipment was calibrated with indium. The baseline was generated without pan.  
 
11.1.9 Viscometer for characterization of fluid characteristics (viscosity) 
A viscometer is an apparatus to measure the viscosity of a fluid. The measured fluid remains 
stationary, while an object rotates in the fluid. The required force to turn the object at a known 
speed is a function of the fluids viscosity (Barnes et al., 1989). In the present thesis, the 
viscosity of the pectin solutions for production of hydrogel beads was measured before and 
after the addition of the vitamin nicotinamide, because it was hypothesized that the viscosity 
influences the bead formation. About 15 ml of the pectin(-niacin)-solution was added to the 
viscometer (Haake Viscotester iQ, Thermo Fisher Scientific, Waltham, USA) and measured at 
20, 50, 100 and 200 rpm.  
 
11.1.10   Laser diffraction analysis for characterization of particle size 
Laser diffraction analysis gives information about the geometric dimension or size of the 
measured particles. Diffraction patterns of a laser beam pass through a sample, which consists 
of particles ranging from nanometers to millimeters. When the laser beam hits a particle, the 
light is diffracted, reflected, refracted and absorbed, which is detected by detectors. The 
particle size is inversely proportional to the angle of the scattered light: large particles scatter 
light at smaller angles while small particles scatter light through larger angles (Retsch 
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Technology GmbH, 2018). In the present thesis, uncoated and coated particles were measured 
with regard to their increase in diameter to calculate the coating thickness. Due to the use of 
dry particles, the measurements were performed using the dry feeder of the particle analyzer 
(Horiba LA-950V2, Retsch Technology GmbH, Haan, Germany) with vacuum-driven forced 
ejection, a vibration power alteration of 120 and a compressed air pressure of 0.3 MPa. The 
following refractive indices were used: cellulose: 1.63, shellac: 1.52, NA: 1.49 and NAM: 
1.47. All samples were measured in triplicate. Afterwards the increase in particle diameter 
and radius were calculated to get the total coating thickness. 
 
11.1.11   Sieve analysis for characterization of particle size distribution 
Sieve analysis is a common practice to analyze the particle size distribution of granular 
material. The added material is separated into its fractions depending on the size. Therefore, 
sieves with different meshes are required. A representative weight of the sample is poured 
into the upper sieve with the largest mesh size. Each sieve below has smaller mesh openings. 
At the bottom, a receiver pan is placed. The sieve column is shaken to separate the sample 
according to size. Afterwards, the weight of the sample retained by each sieve is taken and 
divided by the total weight to obtain the percentage size fraction.  
In the present thesis, dried pellets were analysed in a sieve shaker AS 200 control (Retsch 
GmbH, Haan, Germany) using sieve meshes of 2, 1.4, 1, 0.5 and 0.25 mm. The amplitude was 
set to 0.5 mm/”g” and the total sieve time was 3 minutes. 
 
11.1.12   Moisture content quantification 
The moisture content of solid samples can be examined in a drying oven by determining the 
weight loss. The sample is weighed into a tray and dried at 105 °C for 24 h. The sample is 
then cooled in a desiccator and weighed again. The weight loss is equated to the moisture 
content and expressed as a percentage of the total wet mass.  
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11.1.13   Ultraviolet-visible spectrophotometer (UV-VIS spectrophotometer) for vitamin 
quantification 
UV-VIS spectrophotometry is routinely used for analytical chemistry for qualitative and 
quantitative determination of different substances (mostly dissolved in a solvent). This 
method refers to the absorption spectroscopy in the UV-VIS spectral region. Some molecules 
can absorb the energy in the form of ultraviolet or visible light of a suitable frequency. Then 
the molecule is raised from its ground state to an electronically excited state. Organic 
compounds can absorb light in the UV-VIS range (Hesse et al., 2005). Niacin, as used in the 
present thesis, has a maximum UV absorbance of 260 – 263 nm in water. One of the most 
common methods for niacin determination is based on the UV absorbance of NA and NAM. 
Therefore, a UV-VIS-spectrophotometer (McLaren et al., 1973; Sheen et al., 1992) or a high 
performance liquid chromatography (HPLC) combined with a diode array detector (DAD) is 
used (Kirchmeier and Upton, 1978; Sood et al., 1977; Walker et al., 1981).  
In the present study, the UV/VIS-spectroscopy (Helios gamma, Thermo Fischer Scientific, 
Waltham, USA) was used to determine released niacin during the dissolution tests (see 
above). The wavelengths used were the absorption maxima for the measured 
substance/vitamin (niacin: 262 nm and riboflavin: 445.5 nm). Calibration curves for each of 
the fluids used were prepared for quantification of the vitamins, because the absorption is 
dependent on the pH value of the solvent, which was varied to simulate the gastrointestinal 
release (see above). If necessary, the solution was diluted to reach a measurable 
concentration.   
 
11.1.14   High-performance liquid chromatography (HPLC) for vitamin and protein 
quantification 
HPLC is an analytical technique to separate, identify and quantify components in a mixture. 
In principle, during HPLC analysis, a pressurized liquid (mobile phase) and a sample mixture 
is passed through a column, which is filled with a solid adsorbent material (stationary phase). 
Depending on the component properties, such as hydrophobicity, each compound in the 
sample interacts differently with the adsorbent material. This results in different elution times 
for the components and therefore leads to the separation of the sample mixture. The detector 
generates a signal proportional to the concentration of the eluded component, which allows 
quantification after previous calibration. For quantification, different detectors can be used. 
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The most common detector is a UV-VIS absorbance detector, also known as diode array 
detector (DAD) (Waters GmbH). The mechanism is the same as described for UV-VIS 
spectrophotometer. In the present thesis, the vitamin niacin was quantified at a wavelength of 
262 nm. The analysis of niacin by HPLC was performed for quantification of the 
encapsulation efficiency and the vitamin release during dissolution test of pectin-niacin-
hydrogel beads. The UV-VIS spectrophotometer was not applicable due to interferences of 
pectin in the absorption area.  
The niacin samples were analyzed by RP-HPLC (reversed phase high performance liquid 
chromatography; mobile phase: polar; stationary phase: non-polar) using the Agilent 1100 
Series with diode array detector (Agilent Technologies, Santa Clara, USA) and C18-Sphinx 
column (Nucleodur Sphinx RP, 5 µm, Macherey-Nagel, Düren, Germany). The injection 
volume was 10 µl at a flow rate of 1 ml/min using eluent A (0.1 % (v/v) TFA in milliQ water) 
and eluent B (0.1 % (v/v) TFA in acetonitrile) as mobile phase. The elution used gradient 
steps of 95 % A (0 – 1 min), 95 – 5 % A (1 – 10 min), 5 % A (10 – 10:50 min) and 5 – 95 % 
A (10:50 – 12 min). The column temperature was set to 20 °C and the detection wavelength 
was 262 nm.  
For the determination of β-lactoglobulin, the samples were filtered through 0.2 µm syringe 
filters (PET-30/13 membrane, Macherey-Nagel GmbH & Co. KG, Düren Germany). 
Afterwards the measurements were performed using a Thermo Scientific Dionex UltiMate 
3000 HPLC (Waltham, USA) with a diode-array detector and PLRP-S column (300 Å, 8 µm, 
150 x 4.6 mm, Agilent Technologies, Santa Clara, USA). For the analytical separation the 
injection volume was 40 µl at a flow rate of 1 ml/min and a column temperature of 40°C 
using Eluents A (0.1 % (v/v) TFA in water) and B (0.1 % (v/v) in ACN). The elution used 
gradient steps of 35-38 % B (1-8 min), 38-42 % B (8-16 min), 42-46 % B (16-22 min), 46-
100 % B (22-22.5 min) and 100-35 % B (23-23.5 min). The detection wavelength was 
205 nm.  
 
11.1.15   Encapsulation efficiency (EE) of the encapsulated compound in pectin-zein 
hydrogel beads 
As mentioned above, the HPLC analysis was conducted to calculate the encapsulation 
efficiency of nicotinic acid, nicotinamide and β-lactoglobulin in the pectin-zein hydrogel 
beads. Therefore, the relation of actual active compound content in dried beads to the 
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theoretical maximal content of the compound was calculated according to the following 
equation: 
𝐸𝐸 [%] =
(
 
 
 
 
𝑎𝑐𝑡𝑢𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 [
𝑚𝑔
𝑚𝑙 ]
𝑠𝑎𝑚𝑝𝑙𝑒 𝑤𝑒𝑖𝑔ℎ𝑡 [𝑚𝑔] ∗ (
𝑎𝑑𝑑𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 [
𝑚𝑔
𝑚𝑙 ]
𝑑𝑟𝑦 𝑚𝑎𝑠𝑠 [
𝑚𝑔
𝑚𝑙 ]
)
)
 
 
 
 
∗ 100 
 
To quantify the encapsulated vitamin, the dried hydrogel beads were incubated for 5 h under 
stirring in a McIlvaine citrate-phosphate buffer (pH value 5.0) with additional pectinase to 
macerate the beads and to get a total release of the encapsulated vitamin.  
 
11.1.16   Quality by Design approach with Design of Experiment for analysis of 
interactions of process parameters 
The Quality by Design approach is a quality assurance system and present in the 
pharmaceutical industry. It is used for pharmaceutical developments at a risk-based approach, 
where the effects of Critical Process Parameters (CPPs) and Critical Material Attributes 
(CMAs) and their interactions on the Critical Quality Attributes (CQAs) of the drug product 
are evaluated. It aims for a more flexible production process and the reduction of failure costs 
due to a design-space based production. The design space is the accepted region of the studied 
CQAs. Modifications of CPPs and CMAs within this space are not regarded as change and 
thus do not result in a different product (ICH Q8, 2009).  
In order to study the interactions of CPPs and CMAs on the CQAs a Design of Experiments 
(DoE) can be done. A DoE is an essential tool for the QbD approach. A DoE is defined as a 
systemic way to vary process parameters (input or independent variables) and to analyze their 
effect on the output or response variables (dependent variables). Furthermore, the 
relationships between all variables and the random variability of the process will be 
determined while using the minimum number of experiments, compared to the One-factor-at-
a-time method (Kleppmann, 2013).  
In the present study, a full factorial design was used for the NAM core production by 
extrusion and spheronisation (see above), where all possible factor combinations are 
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examined. For the extrusion process two 22 full factorial design with one center point in 
duplicate were evaluated by varying the screw design, screw speed and feed rate of the twin-
screw extruder. For evaluation of the spheronisation process, a 23 full factorial design by 
variations of the rotation speed, time and load was done. Therefore, the DoE software JMP 
Pro from SAS Institute (Cary, North Carolina, USA) was used.  
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11.2 Patent PCT/EP2017/058733: Shellac microcapsule formulations and compositions 
for topical intestinal delivery of vitamin B3 
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11.3 Patent PCT/EP2017/058741: Shellac microcapsule formulations and compositions 
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